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Summary 
Despite encouring preclinical advances, patients diagnosed with glioblastoma still face a dismal prognosis. 
Suicide gene therapy has shown remarkable results in preclinical research but has generated rather 
disappointing results in patients. This is believed to be at least partly contributable to suboptimal 
distribution of the suicide gene throughout the tumor area. Therefore, attention turned to therapeutic stem 
cells that can track infiltrating tumor cells to deliver the therapeutic gene more efficiently. However 
promising some stem cells might be for this purpose, a safety issue remains when using stem cells. Stem 
cells have a tremendous potential as they are capable of differentiating into several types of tissue, which is 
also a reason for concern as this might result in mass growth or other unwanted side-effects.  
Multi-modal imaging has been an increasingly important tool both clinically and preclinically to monitor 
tumor progression and therapeutic response to novel therapeutic approaches. In a clinical setting, magnetic 
resonance imaging (MRI) is mostly used for glioblastoma diagnosis and follow-up, although positron 
emission tomography (PET) can also be used for grading of tumors and assessment of tumor therapy. In our 
pre-clinical study, we aimed to follow-up not only treatment response but also guide treatment and gain 
further information on stem cell distribution prior to pro-drug initiation for the duration of treatment. 
Therefore, we used lentiviral vectors to express both a therapeutic gene, Herpes simplex virus – thymidine 
kinase (HSV-tk) and imaging reporter genes, enhanced green fluorescent protein (eGFP) and firefly luciferase 
(fLuc). Furthermore, stem cells were labeled using in house fabricated superparamagnetic iron oxide 
particles (SPIO’s) for in vivo stem cell tracking by using MRI.  
Already one day post intratumoral stem cell injection, stem cells were observed both inside and at the tumor 
border on 3D T2*-weighted MR images. Therefore, initiation of the pro-drug, ganciclovir (GCV) was 
commenced at that time. During therapy, stem cell viability was monitored by BLI using fLuc as a reporter 
gene. 
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Results showed that several stem cell lines (mouse mesenchymal stem cells (mMSC), mouse Oct4 positive 
bone marrow derived hypoblastlike stem cells (mOct4+ BM-HypoSCs), mouse Oct4 negative bone marrow 
multipotent adult progenitor cells (mOct4- BM-MAPCs) and human Multistem’s (hMultistem’s) could be 
followed non-invasively for their therapeutic potential in vivo in three different malignant glioma models 
including a syngeneic mouse model (mMSC’s, mOct4+ BM-HypoSCs and mOct4- BM-MAPCs in a GL261 
model) and two human glioma xenograft models (hMultistem’s in the U87-MG and Hs683 models).  
This strategy can now be used to further optimize and characterize the underlying mechanisms of stem cell 
based suicide gene therapy for glioblastoma by also directly and non-invasively comparing different cell lines 
in order to ameliorate treatment for not only this devastating disease but also for tracking of stem cells used 
for stem cell based therapies in other fields, such as for neurological diseases.  
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Samenvatting 
Glioblastoma patiënten worden ondanks de vele bemoedigende preklinische resultaten nog steeds met een 
zeer lage levensverwachting geconfronteerd. Experimentele therapiën zoals o.a. behandelingen die gebruik 
maken van een zelfmoordgen hebben reeds opmerkelijke resultaten gegenereerd in de preklinische setting. 
In een klinische omgeving konden deze resultaten echter zelden bevestigd worden. Bij 
zelfmoordgentherapie wordt het zelfmoordgen in kwestie, in deze studie Herpes Simplex Virus-thymidine 
kinase (HSV-tk), tot expressie gebracht in de tumorregio. Wanneer vervolgens een voor de mens 
onschadelijke prodrug, in deze studie ganciclovir, wordt toegediend zal deze vervolgens in de 
gemanipuleerde cellen worden omgezet tot een toxisch product, wat de DNA-replicatie tijdens de celdeling 
verstoord en zo aanleiding geeft celdood van delende cellen. Dit effect wordt vervolgens nog versterkt door 
het bestaan van communicatiekanalen tussen naburige cellen waardoor het toxisch product zich verder kan 
verspreiden in de tumor massa. Er werd echter vastgesteld dat er een verminderde communicatie is tussen 
cellen van kwaadaardige tumoren wat aanleiding geeft tot een suboptimale verdeling van het gen en/of 
toxisch product in de tumor, wat de vaak teleurstellende resultaten bij patiënten verklaard. Vervolgens werd 
dan ook gezocht naar een andere manier om het zelfmoordgen meer gelijkmatig te kunnen verdelen over de 
gehele tumormassa. Hiervoor werd beroep gedaan op therapeutische stamcellen die in staat zijn 
infiltrerende tumorcellen op te sporen en zo het zelfmoordgen te verspreiden. Hoewel deze stamcellen over 
veelbelovende eigenschappen beschikken voor de behandeling van glioblastoma, zijn er ook mogelijke 
veiligheidsrisico’s verbonden aan het gebruik van deze cellen. Zo zijn ze onder meer in staat te differentiëren 
naar verschillende weefseltypes, wat natuurlijk ook een risico inhoudt i.v.m. mogelijke tumorvorming of 
aanleiding kan geven tot het ontstaan van ongewenste neveneffecten.  
Multimodale beeldvorming wint in toenemende mate aan belangrijkheid in zowel de klinische als de 
preklinische omgeving voor de opvolging van tumorprogressie en therapeutische respons na behandeling. In 
de klinische setting wordt vooral magnetische resonantie beeldvorming (MRI) toegepast voor zowel 
diagnostische doeleinden als voor de opvolging van patiënten tijdens en na behandeling. 
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Verder wordt ook positron emissie tomografie (PET) op regelmatige basis toegepast om het stadium te 
bepalen waarin de kanker zich bevindt.  
In deze studie werd het effect van zelfmoordgentherapie, gebruik makend van stamcellen om het gen 
optimaal te verspreiden in de tumor, bestudeerd met verschillende beeldvormingstechnieken. Om dit 
mogelijk te maken werden lentivirale vectoren aangewend om zowel het therapeutische gen, Herpes 
simplex virus-thymidine kinase (HSV-TK) en de reportergenen, groen fluorescent proteïne (eGFP) en een 
luciferase afkomstig van de vuurvlieg (fLuc) tot expressie te brengen. Bovendien werden de stamcellen met 
superparamagnetische ijzeroxide partikels (SPIO’s) opgeladen om ze te kunnen volgen m.b.v. MRI.  
Alvorens de prodrug toe te dienen werd de verdeling van de stamcellen in en rond de tumor bepaald m.b.v. 
MRI. Reeds één dag na stamcelinjectie in de tumor werden de stamcellen zowel in de tumor als in de tumor 
rand gelokaliseerd m.b.v. 3 dimensionale T2* MR beelden. Vervolgens werd dan ook besloten met de 
prodrug, ganciclovir, te starten. Bovendien werd gebruik gemaakt van bioluminescente beeldvorming (BLI) 
met fLuc als reporter gen, om de overleving van de stamcellen op te volgen gedurende de behandeling.  
De resultaten bekomen in deze studie toonden aan dat verschillende stamcellijnen, waaronder muis 
mesenchymale stamcellen (mMSC), muis Oct4 positieve van het beenmerg geïsoleerde hypblastachtige 
stamcellen (mOct4+ BM-HypoSCs), muis Oct4 negatieve van het beenmerg geïsoleerde multipotente adulte 
progenitorcellen (mOct4- BM-MAPCs) en humane Multistem’s (hMultistem’s), niet-invasief konden worden 
opgevolgd in vivo met betrekking tot hun therapeutisch potentieel in drie verschillende hooggradige glioma 
modellen waaronder een syngeneisch muismodel (mMSC’s, mOct4+ BM-HypoSCs en mOct4- BM-MAPCs in 
het GL261 model) en twee humane gliomamodellen (hMultistem’s in het U87-MG en het Hs683 model).  
Deze werkwijze kan nu toegepast worden om zelfmoordgentherapie voor de behandeling van glioblastoma 
verder te optimaliseren en de onderliggende mechanismen te achterhalen om zo de behandeling voor niet 
uitsluitend deze ziekte met desastreuze gevolgen maar ook voor andere ziekten, zoals bijvoorbeeld 
beroertes, waarin stamcel gebaseerde behandelingen kunnen worden toegepast, te verbeteren.  
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Chapter 1: General Introduction 
Although numerous efforts have been made to develop new treatment modalities for gliomas in order to 
improve the prognosis for these patients, results have been limited so far [1]. This underlines the importance 
of well characterized preclinical glioma animal models that represent the situation in humans as close as 
possible. Animal models have the advantage that a thorough follow-up of experimental treatment 
modalities is possible. However, one always has to keep in mind that animal models in rodents do not reflect 
all aspects of the tumors in humans. Moreover, non-invasive diagnostic tests can be challenging in rodents 
and might require dedicated imaging hardware. On the other hand, imaging techniques not available or not 
feasible in humans, like some optical imaging approaches, can generate additional crucial information in 
particular when applied in a multi-modal imaging approach [2].  
1.1 Gliomas in a clinical setting 
Gliomas arise from the glial cell population (astrocytes, oligodendrogial and ependymal cells) and are the 
most common brain tumors in humans [1]. They comprise a broad range of lesions with distinct differences 
in malignancy, which is assessed according to the World Health Organization classification. Glioblastoma 
multiforme (GBM) is the most malignant tumor type (WHO grade IV) [1]. The prognosis of patients 
diagnosed with GBM is extremely poor with a five-year survival of less than 3% despite a combined 
treatment approach consisting of surgery and concomitant radio- and chemotherapy [3]. Currently, the 
golden standard for high-grade glioma treatment, such as for glioblastoma, is a combination of maximal safe 
resection, radio- (60 Gy in 30 daily fractions of 2.0 Gy fractions given 5 days a week for 6 weeks) and 
chemotherapy (Temozolomide) [4]. During surgery, 5-aminolevulinic acid [4] can be used to identify 
remaining tumor tissue thus enhancing chances of full resection. After resection, chemotherapy, usually 
temozolomide, which alkylates/methylates DNA preferably on a guanine residue and thus damages the DNA, 
triggering tumor cell death, is combined with radiotherapy. When temozolomide is administered, additional 
information on the methylation status of the promotor of MGMT, a DNA repair enzyme, which removes alkyl 
groups from guanine residues, is however required. When the promoter region is demethylated, the DNA 
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repair enzyme is active and alkylating chemotherapeutics, such as temozolomide will be ineffective. When 
methylated, the enzyme will be inactivated and the cells will therefore be unable to repair alkylated guanine 
residues. The Cancer Genome Atlas (TCGA) research network concluded that patients lacking this enzyme 
and treated with temozolomide develop mutations in the mismatch repair (MMR) genes, which results in a 
hypermutated phenotype [4]. 
The high mortality rate associated with GBM in adults is due to the several reasons. First, these tumors are 
usually diagnosed in advanced stages of the disease. At this time, tumors are generally quite large and well 
vascularized as they are capable of inducing neovascularisation when they become too large to receive 
sufficient nutrients from normal blood vessels [5]. Furthermore, their immunosuppressive properties [6] and 
their aggressive and invasive growth pattern makes them difficult to treat with standard therapy. Finally, in 
the last years, the glioma stem cell hypothesis has gained interest as these stem cells are believed to be 
capable of escaping treatment and drive tumor recurrence and progression [7]. 
Very few causal relationships have been shown for the development of brain tumors, such as therapeutic X-
ray irradiation as found in children who received prophylactic CNS irradiation for acute lymphoblastic 
leukemia (ALL) and specific hereditary symptoms such as neurofibromatosis 1 and 2 and tuberous sclerosis 
complex [8]. Furthermore, certain genetic polymorphisms increase the risk for developing certain brain 
tumors. Both important genetic (inactivation of the p53 and retinoblastoma tumor suppressor (RB) 
pathways, dysregulation of growth factor and activation of the phosphatidyl inositol 3-kinase (PI3K) 
pathway) and epigenetic (promotor methylation status of the O6-methylguanin-DNA-methyltransferase 
(MGMT)) changes have been identified. Bleeker et al. provided an extensive overview of molecular 
alterations in glioblastoma [9]. 
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1.2 Non-invasive imaging 
A multitude of non-invasive imaging techniques is available both in a preclinical and clinical setting. Some 
techniques, such as some optical imaging, are however restricted to preclinical use only. Each of these 
techniques has its own specific advantages and limitations and therefore, multi-modal imaging is often of 
advantage to elucidate specific questions, for instance: Is there a reduction in tumor volume? Are cells still 
metabolically active?,… Contrast generation in these techniques can be based on native/intrinsic contrast or 
the use of contrast agents or reporter genes to generate contrast.  
1.2.1. Ultrasound 
During an ultrasound examination, high-frequency sound (1-20 MHz) waves emitted by an ultrasound 
transducer interact with the exposed tissue. The reflected waves are subsequently received and processed 
into an image by a computer. This imaging technique has been widely used as it is readily available both in 
the preclinical and clinical setting at relatively low cost. Furthermore, ultrasound has a favorable safety 
profile and a good temporal resolution [10]. Contrast generation on the images depends on several factors 
including the applied imaging algorithm, the backscatter, the attenuation of the sound caused by reflection, 
absorption or scattering and the speed of the sound waves. Additional contrast can be generated in, for 
instance, applications such as follow-up of therapeutic cells by labeling the cells with microbubbles or gas-
filled microbubbles coated with lipids or polymers. One of the major limitations of ultrasound is however the 
severe attenuation by bone and air which makes it impossible to image the lungs or the brain [11].  
1.2.2 Photoacoustic imaging 
Photoacoustic imaging employs the same principles as ultrasound to reconstruct an image based on sound 
waves. Photoacoustic imaging however does not use high-frequency sound, like ultrasound for transmission 
but uses a nanosecond pulsed laser to irradiate a certain tissue. The resultant small and localized heating of 
the tissue subsequently generates ultrasound waves through thermo-elastic expansion. Imaging applications 
using native contrast is mainly limited to blood vessel imaging. Additional contrast can also be generated 
here for cell and specific tissue tracking purposes using for instance gold nanoparticles [10]. Due to the 
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similarities between ultrasound and photoacoustic imaging, they also share some advantages and 
limitations. As such, photoacoustic imaging also has a favorable safety profile but is more challenging for 
visualizing the lungs and the brain. Furthermore, photoacoustic imaging suffers less from artifacts compared 
to ultrasound imaging as photoacoustic imaging uses a laser light for transmission, which minimizes artifacts 
due to scattering [10].  
1.2.3 Optical imaging 
Optical imaging includes both fluorescence and bioluminescence imaging. In both cases, photons are 
captured by a charge coupled device (CCD) camera [12] and reconstructed into an image. The photon 
generation in fluorescence and bioluminescence imaging is however quite different.  
In fluorescent imaging, a fluorescent reporter gene or a contrast agent such as quantum dots are used to tag 
for instance therapeutic cells. A light source is often required to excite the fluorescent reporter. When these 
compounds absorb light, photons are emitted back which are usually characterized by longer wavelengths 
compared to the absorbed light. When placed in tissues however attenuation occurs due to scattering and 
absorption of the emitted light by hemoglobin and water, thus generating an optical imaging window from 
600-1000nm. Therefore, near infra red (NIR) fluorochromes were developed for in vivo applications due to 
its better tissue penetration. Some of these NIR fluorochromes have already been approved for clinical 
applications by the FDA [13].  
In bioluminescent imaging the expression of a reporter gene is also required. Here however, a luciferase 
gene is used to generate light when a substrate is provided. Several luciferase genes have been isolated from 
living organisms such as firefly, click beatle, sea pansy (Renilla reniformis, Gaussia princeps, etc.), which 
resulted in several different luciferases such as firefly luciferase (fLuc), Renilla luciferase (rluc) and Gaussia 
luficerase (gLuc) with slightly different characteristics. Firefly luciferase for instance requires ATP, O2 and 
Mg2+ to oxidize its substrate D-luciferin and generate light with a maximum wavelength at 560nm. As this 
reaction requires ATP, this technique is often used to assess viability of implanted cells or therapeutic 
response of fLuc expressing (tumor) cells [14, 15]. Some luciferases, such as rLuc and gLuc however require a 
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different substrate such as coelenterazin and emit light at a different maximum wavelength (rLuc: 482nm, 
gLuc: 475 nm, respectively). Thus, different cell lines can be distinguished based on the applied substrate. 
Although many improvements have been made regarding 3D reconstructions of this imaging technique, BLI 
remains however a 2D imaging modality and displays a low spatial resolution. Therefore, it is often 
combined with other imaging modalities such as MRI or CT [16]. As photons are generated exclusively by 
cells expressing the luciferase gene, background signals are low which renders BLI very sensitive as well as 
safe, easy and quick. Due to the absorption and scattering of the photons in living tissues however, its use is 
limited to preclinical imaging or superficial detection of up to 2-3 cm in depth [17].  
1.2.4. Computed tomography (CT) 
X-ray based computed tomography (CT) uses differences in X-ray attenuation by different tissues to generate 
an image. This implies a safety risk as radiation exposure is inevitable [10]. CT has an excellent resolution (1-
10µm) with a high signal to noise ratio but unfortunately displays poor soft tissue contrast, which is why in a 
clinical setting, MRI has largely replaced CT for brain imaging.  
1.2.5. Radionuclide imaging: PET/SPECT 
Prior to positron emission tomography (PET) and single photon emission computed tomography (SPECT), a 
radioactive isotope or radionuclide is administered to the patient. During SPECT, the tracer emits gamma 
radiation that is measured directly by the camera. In contrast, the radionuclides used for PET decay are 
usually β-emittors, which results in the production of a neutrino and a positron of which the latter will 
annihilate when it encounters an electron. The energy released by this annihilation is transformed into two 
gammaphotons, each 511 keV, which are emitted in opposite directions. These gammaphotons can be 
detected by a camera, comprised of a ring of hundreds of detectors. A positive signal (event) is generated 
when two photons are detected simultaneously by two detectors, placed 180° opposite to each other. This 
process is also known as coincidence detection. The point of origin is located exactly on the line between the 
two detection points. Numerous dual hits are necessary to establish the area of emission and create an 
accurate image. 
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One of the main advantages of PET imaging is that it enables the in vivo three dimensional measurements of 
metabolic and molecular processes with very high sensitivity. Several tracers have been developed 
specifically for tumor imaging. The most commonly used tracers in the diagnosis of brain tumors are 2-[18F] 
fluoro-2-deoxy-D-glucose ([18F]FDG), methyl-[11C]-L-methionine ([11C]MET) and [18F] FET (O-(2-18F-
fluoroethyl)-L-tyrosine. The accumulation of each tracer reflects the activity of its transporter via the blood 
brain barrier (BBB), as well as the activity of specific enzymes by which they are metabolized and trapped.  
Due to their excessive growth, tumors require substantial higher amounts of glucose, amino-acids and DNA 
precursors. As [18F]FDG is phosphorylated by cellular hexokinase, it represents a specific tracer for glucose 
consumption. The insulin-dependent glucose GLUT transporters, located on capillary endothelial cells, 
transport [18F]FDG over the cell membrane. The transport rate of this process depends on the glucose level 
in the blood in accordance with the Michaelis-Menten kinetics for facilitated transport. After transport into 
the cell, [18F]FDG is phosphorylated by the cellular hexokinase into [18F]FDG-monophosphate, which 
accumulates in the cell. This accumulation represents both high expression of the GLUT transporters and 
hexokinase activity within the tumor [18]. [18F]FDG-PET reveals information on intratumoral glucose 
consumption and correlates with tumor grade [19], biological aggressiveness and prognosis of patients with 
both primary and recurrent gliomas [20]. Unfortunately, [18F]FDG is also metabolized in inflammatory brain 
lesions, focal epilepsy and recent ischemic infarcts which make it unspecific for tumor growth. An additional 
drawback is the high background activity of [18F]FDG in normal cortex. These disadvantages can sometimes 
complicate a diagnosis and therefore more specific radiotracers have been developed for the diagnosis of 
brain tumors.  
[11C] MET, an amino acid radionuclide is such a molecule. Due to increased transport rates mediated by type 
L amino acid carriers, amino acids accumulate in brain tumors and this seems to be directly mediated by 
tumor growth factors [21, 22]. [11C] MET PET detects brain tumors as well as infiltrating areas with both high 
sensitivity and specificity [23]. 
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[18F] FET, another tumor specific radiotracer, which also represents a marker for amino-acid metabolism has 
furthermore been proven to be of help in distinguishing tumor recurrence from therapy related changes. 
The longer half-life of [18F] labelled radioisotopes means that a cyclotron is not required in close proximity to 
the PET imaging facility which is a major advantage compared to [11C] labelled radioisotopes  [24, 25].  
As such, PET imaging supplies valuable information on, for instance, the tumor’s extent, proliferative activity, 
metabolism and its relation to functionally relevant parts of the brain in patients diagnosed with brain 
tumors [26-28]. For tracking of cells, therapeutic cells can be labelled directly in vitro prior to injection and 
subsequently imaged. This method is however determined by the half-life of the radioisotope therefore 
limited in duration of the follow-up. An alternative method is to indirectly label therapeutic cells which 
express a reporter gene that allows radionuclide imaging such as Herpes simplex virus thymidin kinase (HSV-
tk) or the sodium iodide symporter system (NIS) [29, 30].  
In most applications of radionuclide imaging however close proximity to a cyclotron is required due to the 
short half-lives of many tracers. Furthermore, PET images are generally co-registered with MRI or CT to 
identify the anatomical localization of the tracers. For rodents, an atlas can be used to eliminate the need for 
additional imaging to some extent [31]. 
1.2.6 MRI/MRS 
1.2.6.1 Magnetic resonance imaging  
For magnetic resonance, a homogeneous magnetic field and a radio-frequency transmitter and detector are 
required. During 1H magnetic resonance imaging (MRI), the proton nucleus of the hydrogen atom (= proton), 
aligns itself parallel or anti-parallel to the strong magnetic field and reaches a thermal equilibrium. The 
proton nuclei precess about the applied field at a characteristic frequency, but with a random phase with 
respect to one another. Application of a (90°) radio frequency (RF) electromagnetic pulse flips the 
equilibrium into the transverse plane and introduces a transient phase coherence that can be detected as a 
radio signal and turned into an image. Subsequently, relaxation occurs, involving an exponential decay of the 
signal intensity and ultimately a return of the magnetization to the equilibrium. One distinguishes between 
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two different types of relaxation, T1 and T2. The transverse relaxation time T2* is a resultant of both T2 
decay (spin-spin relaxation) and inhomogeneities in the external magnetic field and local field variation due 
to particles or tissues with different magnetic susceptibilities. Due to both effects, dephasing will occur. The 
T2* signal generally fades away in a few milliseconds to tens of milliseconds. T1 relaxation also reffered to as 
spin-latice relaxation, describes the return of the magnetization to the thermal equilibrium. The observed 
radio signals from an object exposed to additional magnetic field gradients can be reconstructed into an 
image after multiple RF excitations [32]. Native contrast is generated due to differences in proton density 
and varying interactions of the protons with their environment in distinct tissues that result in T1 and T2(*) 
differences. Both the resonance frequency and the signal intensity depend on the external magnetic field 
strength. Using more specialized MRI protocols allows the generation of contrast based on properties like 
diffusion, flow, metabolism, blood oxigenation and others [33, 34].  
Due to the required higher resolution when imaging animals, higher field strengths (>7 T) on dedicated 
animal scanners and smaller RF coils are required compared to clinical imaging. Futhermore, due to the 
higher field strengths, additional safety measures, such as better shielding to reduce the stray field, are 
taken to minimize the risk of accidents. Thus, it is possible to generate high resolution anatomical 2D or 3D 
images to determine tumor location and size, vasculature, growth pattern and the presence of necrosis 
and/or bleedings which correlates with histopathology. MRI displays however a low specificity and 
limitations concerning the generation of cell function or viability information. Furthermore, distinction 
between necrosis and bleedings is impossible based solely on MR images as they both generate hypointense 
contrast on T2 weighted images [35, 36]. 
When using therapeutic cells inside the brain, native contrast is generally not sufficient to distinguish 
engrafted from host cells. Therefore, additional contrast can be generated by pre-labeling the cells with MR 
contrast agents [37]. These modify the T1, T2 and/or T2* relaxation rates. Depending on which parameter 
contrast agents exert the strongest effect, contrast agents can be distinguished in paramagnetic compounds 
which contain lanthanide chelates (Gadolinium (Gd3+)) or manganese (Mn+) and that have a stronger effect 
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on T1 than on T2 relaxation time and thus generating hyperintense contrast on T1-weighted images. 
Superparamagnetic agents like nanoparticles that are based on iron oxide mainly alter the T2/T2* relaxation 
time, thus generating hypointense contrast on T2/T2* weighted images. In addition, agents that are based 
on other MRI-active nuclei than 1H (namely 19F) and their altered spin-density have also been used for cell 
imaging [38]. 
1.2.6.2 Magnetic resonance spectroscopy (MRS) 
Magnetic resonance spectroscopy (MRS) is based on the same physical principle as MRI, but here radio-
frequency differences are mainly used for ‘ metabolic encoding’ rather than spatial encoding. This technique 
enables detection of RF differences based on chemical composition [39]. The most extensively used nuclei in 
biological systems include 1H, 31P, 13C, 23Na. To assess tumor growth and malignancy, metabolites such as 
lactate, N-acetylaspartate, creatine and choline are monitored [40-42]. Information is usually acquired on 
relative large volumes. Additional anatomical MRI scans are required to gain anatomical information on the 
location of those voxels. 
Due to the advantages and drawbacks of each individual imaging technique, multi-modal imaging is often 
applied to address certain questions in both a clinical and preclinical setting. 
  Chapter 1: General Introduction 
12 
 
1.3 Glioma imaging in a clinical setting  
Initial diagnosis and radiologic follow-up is routinely performed with serial magnetic resonance imaging 
scans (MRI) and radionuclide imaging in GBM patients [43-45]. However, routinely used MRI techniques still 
present some difficulties in clinical practice. For instance the radiological characteristics of tumor relapse and 
therapy related changes such as radiation necrosis are similar [45]. In recent years, advanced MR imaging 
techniques assessing vascularity, cell organisation and metabolism have become of increasing interest in 
therapy response assessment in neuro-oncology as they potentially provide more insights in tumoral 
pathophysiology, allowing a better distinction between progressive tumor and therapy induced reactions in 
the brain [46-48]. Positron emission tomography (PET) with radiolabeled amino acids such as [18F] FET (O-(2-
18F-fluoroethyl)-L-tyrosine) has furthermore proven to be of help in distinguishing tumor recurrence from 
therapy related changes [25]. 
Combining non-invasive imaging techniques enables clinicians to diagnose and grade tumors with increasing 
accuracy. However, for ultimate confirmation stereotactically guided biopsies and resections are needed in 
order to accurately determine the lesion grade [26].  
As the prognosis of these patients remains extremely poor with standard treatment consisting of surgery 
and combined radio- and chemotherapy, new treatment approaches are being developed. In recent years, 
clinical studies using gene therapy [49], immunotherapy [50] or anti-angiogenic approaches [51] have been 
performed with often limited results, thus underlining the importance of monitoring therapy in those 
patients closely with advanced imaging techniques but also for using well characterized preclinical animal 
models for the validation of new diagnostic techniques and thorough follow-up of experimental treatment 
modalities. Adequate and profound multi-modal imaging in those models is of vital importance before 
translating results to clinical practice.  
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1.4 Preclinical brain tumor rodent models  
Several animal models have been developed to investigate new treatment modalities. However, no 
preclinical model currently available reflects all aspects of human high-grade gliomas. Tumor models vary in 
their immunogenicity, growth patterns and invasiveness.  
An array of human glioma xenograft models exist for glioma. In these models, freshly isolated primary 
tumors, tumor stem cells [52], biopsy spheroids [53] or human brain tumor cell lines, such as Hs683 
(oligodendroglioma) or U87-MG (glioblastoma), are transplanted into immune-deficient mice. Most of these 
tumor cells can be implanted both intracranially or subcutaneously. Several rodent models have also been 
developed using orthotopic injection of rat or mouse glioma cell lines, including the C6, 9L, T9, F98, RG2, 
RT2, avian sarcoma virus induced and CNS-1 rat models[54].  
Some of these orthotopic models like the C6 rat glioma and the Avian sarcoma virus (ASV) induced gliomas 
do not have a syngeneic host or were proven immunogenic, resulting in clearance of the tumor due to an 
immune response [54]. Their usefulness as a preclinical model is therefore restricted. 
The 9L and T9 rat gliosarcoma models were also proven to be highly immunogenic but cancer stem-like cells 
(CSLCs), which grow as neurospheres, have been demonstrated in the 9L cell line [54].  
The CNS-1 rat astrocytoma model, derived from an inbred Lewis rat, proved an excellent model for 
investigation of immunological therapies and resembles human glioma cells quite well [55]. 
The F98 glioma model was generated in a CD Fisher rat and classified as an anaplastic or undifferentiated 
glioma [54]. Like human GBM, these cells overexpress PDGFβ, and Ras along with an increase in EGFR, cyclin 
D1 and cyclin D2 expression. The tumor closely resembles human gliomas as it is only weakly immunogenic, 
infiltrates normal brain parenchyma and is very aggressive [54]. Histology shows GFAP and vimentin 
expression with negligible staining for CD3 + T cells [56].  
The RG2 glioma model, also known as the D74 glioma model, displays an invasive growth pattern and is 
refractory to all therapeutic modalities. They show enhanced expression of PDGFβ, IGF-1, Ras, Erb3/HER3 
precursor mRNA and cyclin D2 [57]. It was also demonstrated that these tumors were non – immunogenic 
despite intensive immunization of syngeneic Fisher rats [58].  
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The BT4C glioma model shows high cellularity and has pleomorphic nuclei, numerous mitotic figures and 
abnormal blood vessels. BT4C cells express VEGF, tPA, uPA and MVD in the periphery of the growing tumor 
and are S100 positive by immunohistochemistry [54]. 
Murine models of malignant brain tumors were also developed [59]. The GL261 model, one of the most 
frequently used models was originally induced by intracranial injection of 3-methylcholantrene pellets into 
C57BL/6 mice and maintained by serial intracranial and subcutaneous transplantations of small tumor pieces 
on the syngeneic mouse strain [60, 61]. In vitro cell cultures were established with a population doubling 
time of 20h in log phase. GL261 cells do not express the most important glial differentiation markers but do 
display genetic anomalies such as p53 and K-ras mutations and elevated c-myc and p53 expression. 
Furthermore, these cells display an elevated MHCI expression and low levels of B7-1 and B7-2 RNA, thus 
possibly explaining the low immunogenicity of the cells in vivo [62]. When transplanted in their syngeneic 
host, the cells display a high incidence of tumor formation, where survival time is dependent on the tumor 
cell number transplanted. These tumors are invasive but do not metastatize. For an overview of frequently 
used experimental glioma rodent models we refer to table 1. 
Finally, also a number of transgenic models have been developed by introducing modifications in oncogenes 
with tissue-specific expression or deletion of tumor suppressor genes. These mice spontaneously develop 
cancer and mimic primary glioma in patients much more closely compared to tumor models that use 
engrafted tumor cells. Genetically engineered mice however also possess some disadvantages among which 
poor reproducibility, low tumor penetration, prolonged latency for tumor formation, increased 
heterogeneity and the need for advanced in vivo imaging techniques [59].  
In contrast, models using engraftment of patient biopsies or tumor stem cells recapitulate the pheno- and 
genotype of patient GBM much better compared to cell-line based models and do show single cell invasion 
into the brain [52, 53]. These models however require access to patient material and the use of 
immunodeficient animals to establish tumor growth in vivo. Therefore, the assessment of immune system 
involvement in investigational therapeutic approaches is not possible.  
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Cell-line based models lack the stepwise genetic changes occurring during tumor progression. Therefore, 
many of them remain well circumscribed in the brain architecture, lack characteristic histological 
vascularization and rarely recapitulate the phenotype of the tumor of origin. Nevertheless, based on their 
fairly good reproducibility, tumor cell engraftment models have been mostly used for evaluating new 
therapeutic concepts [63]. 
Table 1: Overview of frequently used experimental glioma rodent models. 
Model Strain/species Method Typing 
Syngeneic 
host 
Immunogenicity Invasiveness 
C6 Outbred wister rat MNU Glial tumor No +++  
9L-9T CD Fisher rat i.v. MNU Gliosarcoma Yes +++  
RT-2 Neonatal CD Fisher rat i.c. ASV suspensions 
Mostly anaplastic 
 astrocytoma 
 ++  
CNS-1 Inbred Lewis rat i.v. MNU  Yes   
F98 Pregnant CD Fisher rat i.v. ENU Anaplastic glioma Yes + Yes 
RG2 (=D74) 
Progeny of ENU  
injected Fisher rat 
  Yes 0 Yes 
BT4C Pregnant BDIX rat Transplacental ENU     
GL261 C57BL6 mice 
Intracranial 3-  
methylcholantrene pellets 
Glioblastoma Yes 0 Limited 
1.4 Innovative experimental tumor therapies 
Experimental treatment modalities under investigation include anti-angiogenic approaches, dendritic cell 
(DC) vaccination, virotherapy, gene therapy and usage of stem cells expressing a suicide gene.  
1.4.1 Anti-angiogenic treatment approaches 
In particular solid tumors depend on angiogenesis for their survival and growth, therefore anti-angiogenic 
approaches are under development for the treatment of brain tumors. Several molecules, such as 
Bevacizumab, Aflibercept, receptor tyrosine kinase inhibitors and Cediranib have already been developed 
which target vascular endothelial growth factor (VEGF) or its receptors VEGFR1, VEGFR2 and/or VEGFR3, the 
most important mediators of neovascularisation in gliomas. Despite encouraging preliminary results 
however, current anti-angiogenic therapies eventually resulted in tumor resistance and progression [51]. 
Both animal and human studies indicated that use of anti-angiogenic therapy might also result in an 
augmented infiltrative growth pattern [64, 65]. 
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1.4.2 Immunotherapy 
Dendritic cell (DC) vaccination is a promising new treatment modality. Here, autologous DC’s, exposed to 
whole tumor cell lysates are administered. Presentation of tumor antigens in MHC I and II context results in 
activation of both CD4+ and CD8+ cells, which induce a specific anti-tumor immune response. Furthermore, 
this kind of active specific immunotherapy is also capable of inducing immunological memory [66]. Following 
promising results in preclinical studies [66], clinical studies are now conducted in patients [50] but further 
intensive preclinical research remains mandatory. 
Several molecular targets, specific for brain tumors, are located in the cytoplasm or even the nucleus and are 
therefore difficult to reach. Virotherapy aims to target malignant glioma cells by use of conditionally 
replicative viruses. During virotherapy, oncolysis is achieved by intra-neoplastic cell virus replication 
mediated cell lysis [67]. Holzmüller et al. proved the feasibility of this strategy by using YB-1 dependent 
virotherapy in combination with temozolomide to treat malignant human glioma in mice [68]. The usage of 
viral particles in human patients remains however a controversial approach. 
1.4.3 Gene therapy 
Therefore, attention turned to gene therapy for delivery of therapeutic genes to the tumor site. This includes 
delivery of cytokine genes to activate and attract immune cells against the tumor, such as FMS-like tyrosine 
kinase 3 ligand (Flt3L), and interferon-β (IFN-β), delivery of tumor-suppressor genes, such as p53 to 
reprogram tumor cells into apoptosis and delivery of suicide genes such as cytosine deaminase and HSV-TK 
to convert prodrugs in the tumor and achieve tumor cell death [69]. The system most widely used in clinical 
trials however is the HSV-TK suicide gene therapy. This approach has resulted in very promising results in a 
pre-clinical setting but the therapeutic efficiency of this therapeutic approach has been rather disappointing 
however, which is generally accepted to be related to sub-optimal distribution of the gene throughout the 
tumor region [70]. Therefore, attention turned to carriers such as bacteria with a tropism for necrosis [71], 
liposomes, nanoparticles, and viral vector based carriers [69]. Unfortunately, even when employing viral 
vectors to carry the suicide gene to the tumor cells, distribution of the suicide gene remained limited. 
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Therefore, stem cells that are able to target tumor cells, thus ensuring a higher gene delivery efficiency and 
which carry these viral vectors, including the suicide gene, are also under investigation [72]. 
1.4.4 Stem cell based suicide gene therapy for gliobastoma  
1.4.4.1 Expression of suicide genes in tumor tracking stem cells 
In order to use tumor targeting stem cells to deliver a suicide gene to the tumor cells, therapeutic stem cells 
need to stably express the suicide gene. Introduction of foreign DNA into a certain cell type can be 
accomplished by two major approaches. Either through non-viral gene transfer or through virus mediated 
gene transfer.  
The first approach uses components such as plasmids, Zinc finger nucleases, DNA liposomes complexes or 
PEI (polyethyleenimine) for gaining excess to the cell. Advantages of this approach include the absence of an 
immune response and also no size constraints for the gene of interest [73].  
Viral mediated gene transfer however uses the optimized infection capabilities of viruses to deliver genetic 
material. This results in augmented transduction efficiency but as viruses are small, there is however a size 
restriction coupled to their use. Furthermore, viral vectors can also be engineered to target specific cell 
types, for instance by using a specific promoter, such as nestin, or by pseudotyping in which peptides, such 
as the RGD peptide, are added to increase specificity. Some care should be taken however in regard to 
immune responses and destruction of cells due to replication of the viruses. In order to exclude these 
threats however, viral vectors have been engineered so that they cannot replicate and should not contain 
proteins that cause immune responses. Several types of viral vectors have been developed and these can be 
subdivided into non-integrating and integrating vectors. With non-integrating vectors, the genetic material is 
present as episomal DNA and will eventually be lost due to cell division. These include adenoviral vectors 
(AV), Adeno-associated vectors (AAV), and Herpes simplex vectors (HSV). The integrating vectors result in 
stable transduction with the genetic material incorporated in the DNA of the host cell. These include 
retroviral (RV) and lentiviral vectors (LV). Retroviral vectors are however only capable of transducing dividing 
cells which makes applications in non-dividing or slowly dividing cells, such as differentiated brain cells, or 
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irregular dividing cells such as stem cells very difficult or impossible. Lentiviral vectors, which are derived 
from HIV, are however capable of transducing both dividing and non-dividing cells. An overview of the 
general characteristics of these viral vectors is given in table 2. 
Table 2: Overview of the general characteristics of viral vectors. 
 Vector Genetic 
material 
Packaging 
capacity 
Tropism Inflammatory 
potential 
Envelope 
Non-integrating 
(episomal) 
AV DsDNA 8-30kb Broad High - 
AAV SsDNA <5kb Broad Low - 
HSV-1 DsDNA 40-150kb Neurons High + 
Integrating RV RNA 8kb Dividing cells Low + 
LV RNA 8kb (non)dividing cells Low + 
 
Vector Main limitations Main advantages 
AV Risk of potential inflammatory response 
No integration  transient expression 
Extremely efficient transduction in most tissues 
High titers (10
11
 TU/ml) 
Pseudotyping renders vectors specific 
AAV Small packaging capacity 
10% integration  insertional mutagenesis 
Needs helper virus 
Pre-existing immunity 
Non-inflammatory, non-pathogenic 
Absence of gene silencing 
Very pure preps, high titers 
HSV-1 Inflammatory response 
Transient expression 
Limited to neurons 
Large packaging capacity  
Strong tropism for neurons 
RV Only dividing cells 
Insertional mutagenesis 
Stable gene expression in dividing cells 
LV Insertional mutagenesis Transduction of dividing and non-dividing cells 
Stable gene transfer in most cells 
  AV: adenoviral vector, AAV:adeno-associated vector, HSV-1: Herpes Simplex virus type 1, RV: retroviral vector, LV: lentiviral  
  vector, TU: transducing units, ds DNA: dubbel stranded DNA, ss DNA: single stranded DNA 
Incorporation of a suicide gene in these viral vectors enables tumor cell killing when the suicide gene is 
expressed [74]. As mentioned previously, viral vectors can be engineered to be specific, but for brain tumors, 
there is currently no specific promoter available. Therefore, tumor targeting stem cells are under 
investigation [72].  
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1.4.4.2 Stem cells 
An extensive overview of stem cells would be beyond the scope of this thesis but a condensed overview will 
be provided. In short, stem cells display three main characteristics: 1. Ability of self – renewal without 
senescence, 2. Ability to give rise to differentiated progeny cells and 3. Ability to reconstitute a given tissue 
in vivo [75]. Stem cells are usually classified according to their differentiation potential. Stem cells derived 
from the zygote or morula stage are totipotent, which means they can give rise to a new individual. Stem 
cells derived from the inner cell mass (ICM), such as embryonic stem cells (ESC), are pluripotent as they can 
give rise to the three somatic germ layers (ectoderm, mesoderm and endoderm), germ cells and yolk sac 
cells. When development progresses, these pluripotent cells will be restricted and will generate multipotent 
stem cells, such as neural stem cells (NSC’s) that can differentiate into all cells of a specific tissue or germ 
layer [76]. Due to the intrinsic properties of stem cells to form almost any type of tissue, stem cells have 
been investigated tremendously in regenerative medicine such as for stroke therapy [77], where 
differentiation of certain stem cells is supposed to support recovery either by cell replacement or indirectly 
by the release of neurotrophic factors to reduce detrimental effects and improve recovery [78]. 
Next to obvious ethical concerns, there are also safety issues related to working with totipotent or 
pluripotent stem cells as they can potentially form tumors. In adult tissue however, multipotent cells can 
also be found, which are responsible for tissue homeostasis and injury repair. Among these are 
mesenchymal stem cells (MSC’s) and multipotent adult progenitor cells (MAPCs). MSC’s can be isolated from 
the bone marrow, umbilical cord blood and adipose tissue and can differentiate in vitro into osteoblasts, 
adipocytes and chondrocytes. MAPCs are also isolated from bone marrow but show different characteristics 
compared to most adult stem cells. They can proliferate without senescence and can differentiate in vitro 
into cell lines of the three germ layers. Clinical trials using human MAPCs, also known as hMultistem®, are 
currently ongoing for the assessment of beneficial effect in for instance graft versus host disease due to their 
immunomodulatory characteristics [79]. 
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1.4.4.3 Stem cell based suicide gene therapy 
Stem cells that are able to target tumor cells can in principle invade the bulk tumor mass but also track 
infiltrating tumor cells. The underlying mechanism of this migration of stem cells towards tumors is still 
elusive although the chemokine receptor, CXCR4 and its ligand SDF-1 have been suggested to be involved 
[80] for hMSC’s, whereas, NSC tropism is most likely regulated by both chemo-attractant cytokines and 
extracellular maxtrix components [81].  
Due to the presence of a suicide gene like HSV-tk, the stem cells can be killed selectively, in this example 
with the pro-drug ganciclovir, as mammalian brain cells display a 1000 fold lower affinity for GCV they are 
unable to efficiently transform ganciclovir into its highly toxic metabolite, ganciclovir phosphate [82]. 
Subsequently, cellular kinases will recognize the GCV-monophosphate and will generate GCV-triphosphate 
which is highly cytotoxic as GCV is a guanosine analogue which will participate in normal DNA replication, 
causing chain termination and subsequent cell death. Normal adult brain cells do not divide and are 
therefore insensitive to this treatment. Thus, the therapeutic stem cell can be eliminated. Moreover, this 
strategy also enables killing of tumor cells by formation of gap junctions between the administered stem 
cells and their neighboring cells [83]. Via these gap junctions, the toxic ganciclovir-phosphate can be 
transferred to the tumor cells, thus also killing the latter. This phenomenon is also called the bystander 
killing effect (Figure 1). In theory this method should be sufficient to remove not only the main tumor mass, 
but also quantatively target any remaining (infiltrating) tumor cells, thus eliminating sources of possible 
recurrent tumors [82].  
The feasibility of this strategy was demonstrated by several groups in both xenograft and syngeneic animal 
models. Li et al demonstrated a potent bystander killing effect of rNSC’s on C6 rat gliomas [84], whereas 
Miletic et al [82] and Matuskova et al [85] obtained similar results for rMAPCs on 9L rat gliomas and hMSC’s 
on the human glioblastoma cell lines 8-MG-BA, 42-MG-BA and U-118 MG respectively. Migration of hMSC’s 
was furthermore optimized by Egea V [86] by preincubation with TNF-α. Treatment efficiency does, 
however, depend highly on the extent of gap junction communication between cells. As malignant gliomas 
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communicate poorly via these gap junctions, agents with the ability to augment gap junction formation 
provide a mean to optimize treatment. Paino et al demonstrated this by using Tolbutamide, a gap junction 
communication improver, which resulted in an augmented HSV-tk/GCV bystander effect in human U373 
glioma cells [87]. 
However, in vivo imaging conducted on these animals is usually limited to assessing the outcome by a single 
modality, thus limiting the information that can be obtained. As the efficiency of this approach also depends 
on the administration of the co-drug at a time point of optimal stem cell distribution, longitudinal in vivo 
information on stem cell localization can be crucial. However promising some of these treatment modalities 
may be, assessment of tumor growth and treatment should be carefully monitored by one or more non-
invasive imaging modalities such as MRI/MRS, PET, BLI, CT, or others [88].  
 Figure 1: Suicide gene therapy and bystander killing effect: mechanism. 
HSV-TK expressing stem cells generate ganciclovir monophosphate which is recognized and phosphorylated by cellular 
kinases thus generating ganciclovir triphosphate. The latter is transported into the nucleus where it will act as a chain 
terminator, resulting in cell death of the therapeutic cells. Due to the formation of gap junctions between adjacent 
cells, ganciclovir phosphate passively diffuses into neighboring tumor cells, which will also be killed. This phenomenon 
is also called the bystander killing effect. 
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1.5 Imaging in experimental glioma therapies 
As discussed previously, the most commonly used non-invasive techniques for imaging of brain tumors in 
preclinical animal models are comparable to the clinically applied methods, including MRI/MRS and PET. 
Moreover, additional imaging modalities, which are not yet available or not applicable in the clinic, can be 
used preclinically to augment information gained from preclinical rodent models and include near infrared 
(NIR) and bioluminescence imaging (BLI).  
Multi-modal imaging is applied on a daily basis for diagnosis, grading, surgery planning, treatment follow-up 
and determination of tumor recurrence in a clinical setting. In preclinical animal models dedicated systems 
have been developed and allow similar imaging in rodents. For instance, BLI can give information on cell 
viability, PET on metabolism and MRI can enhance insights regarding anatomical position, 
necrosis/bleedings, tumor size, blood supply and blood brain barrier (BBB) disruption [16]. Molecular 
changes in both cancer tissue and surrounding microenvironment can be better analyzed by MRI/MRS [40, 
89]. 
In a clinical setting, an anatomical T2 weighted MRI (T2W) image, which renders information on tumor size 
and presence of necrosis and/or bleedings, is combined with more functional information generated by 
diffusion weighted images (DWI) and diffusion tensor images (DTI) [90, 91]. During DWI, differences in 
diffusion of water molecules in different tissues are used to generate images. Tumors display an increased 
cellular density which results in a decreased apparent diffusion. Areas of necrosis however appear as regions 
with increased diffusivity as cell membranes are absent and no longer form barriers for diffusing water 
molecules. During DWI, apparent diffusion coefficient (ADC) maps can be generated which enables 
quantitative measurements [91].  
One of the most prominent features of GBM is the occurrence of the BBB disruption and their aggressive 
growth. BBB disruption can be monitored by contrast-enhanced MRI (CE-MRI) where a contrast agent, such 
as gadolinium chelates like Dotarem®, which normally does not pass the BBB, are injected intravenously 
(i.v.). In GBM, the BBB is disrupted and T1 weighted MR images (T1W) show an increased signal from areas 
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with BBB disruption. Dynamic CE-MRI can be performed to derive blood volume, cerebral blood flow, vessel 
size, contrast agent arrival and transit times [92]. In a preclinical setting, similar MRI sequences for 
anatomical information and BBB disruption assessment [35, 93] are available and an extensive 
characterization of the tumor is also possible in living rodent models. With such advanced MRI methods, 
more specific information on blood flow changes, angiogenesis and regions of ischemia can be obtained by 
perfusion weighted MRI [36] or PET using [15O] radiolabeled water as a tracer [94], and a macroscopic view 
of the tumor blood vessels can be generated with MRI angiography as shown by Doblas et al. [36], while BBB 
disruption can be analyzed with CE-MRI. Brubaker et al. compared the number of terminal branches, the 
vessel count and the average vessel radius between tumor bearing mice and healthy controls [95]. Keunen et 
al. showed a reduced blood supply and an increased tumor cell invasion in glioblastoma after anti-VEGF 
treatment [96]. Mostly, these MRI sequences are applied after anti-angiogenic therapy. Although 
longitudinal studies that monitor the animals throughout therapy would be favorable, anti-angiogenic 
treatment may result in a less aggressive phenotype with normalized and less leaky blood vessels, thus 
decreasing the contrast-enhanced region, which is therefore not always indicative for the absence of tumor 
growth [43]. Furthermore, aggressively growing tumors display a higher metabolic activity which causes an 
increased demand of oxygen and nutrients and thus an increased blood flow. The higher metabolic rate is 
characterized in the clinic by PET imaging [25] or magnetic resonance spectroscopy (MRS) [43], which are 
also available preclinically. For instance Spaeth et al. showed high tumor uptake of [18F]-fluorocholine ([18F]-
FCH), O-(2-[18F]-fluoro-ethyl-L-tyrosine ([18F]-FET) and 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]-FDG) in a rat 
glioblastoma model [97]. Furthermore, Assadian et al performed [18F]-FDG PET imaging [98], whereas Miletic 
et al used methyl-L-[11C]-Methionine ([11C]-MET) PET [82] for follow-up of anti-glioma therapies. Several 
groups have also implemented MRS in preclinical brain tumor models, such as Hekmatyar et al [99], Park et 
al [100] and Simoes et al [42] to characterize metabolic profiles of brain tumors. For an example of imaging 
approaches in glioma studies that are available both in a clinical setting and preclinically we refer to figure 2. 
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Figure 2: Comparison of imaging modalities for clinical and preclinical glioblastoma imaging. 
A. T2 weighted MR imaging and T1 weighted imaging post contrast administration in a 44-year old male patient 
diagnosed with a glioblastoma in the left frontal and temporal lobe, showed the tumor with central necrosis 
and perilesional edema. Diffusion weighted imaging (DWI) demonstrates high signal intensity (low diffusivity) 
in the solid contrast-enhancing part of the lesion (high cellularity), and low signal intensity (high diffusivity) in 
central necrotic parts. Furthermore, MRS with a spectrum obtained from tumor tissue showed an altered 
metabolism characterized by an increase in choline, NAA and lipids and a decrease in creatine. A MRS 
spectrum of normal appearing white matter is furthermore shown as a comparison. Furthermore, an [
18
F]-FET 
PET scan showed increased amino-acid metabolism within the glioblastoma. 
B. T2 weighted MRI and T1 weighted MRI post contrast administration in a mouse GL261 glioblastoma model, 
demonstrated a large tumor in the right side of the brain with central necrosis and mass effect. An MRS 
spectrum from normal and tumor tissue are furthermore demonstrated. The spectrum from tumor tissue 
showed an altered metabolism marked by an increase in choline, NAA and lipids and a creatine decrease. 
Finally, an [
18
F]-FET PET scan also demonstrated increased amino-acid metabolism in a mouse glioblastoma. 
MRS: magnetic resonance spectroscopy, [
18
F]-FET: [
18
F]Fluorethyl-L-tyrosine, PET: positron emission tomography, MRI: magnetic 
resonance imaging, ml: myo-inositol (glial marker), Cho: choline (membrane turnover), Cre: creatine (energy metabolism), Glx: 
glutamine/glutamate (neurotransmitter metabolism), NAA: N-acetyl aspartate (marker of neural density), Lipids: mobile 
lipids/lactate (necrosis/ anaerobic glycolysis) 
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Additional to the imaging modalities used in a clinical setting, several exclusively preclinical imaging 
modalities exist such as near infrared (NIR) imaging, BLI and multi-photon laser scanning microscopy 
(MPLSM). Although fairly new, gold nanoparticles are under investigation for combined imaging and therapy 
purposes. These particles display surface plasmon resonance (SPR) which make them suitable for NIR 
imaging. Furthermore, they absorb laser irradiation in the near infrared region which means they can be 
used for photothermal therapy but also for photoacoustic imaging [101]. The size and shape of these gold 
nanoparticles can vary. Spherical, nanorod and branched particles have been described. Accumulation of 
these nanoparticles can be either passive, due to BBB disruption, or active, due to functionalization of the 
particles with tumor cell receptor targeting moieties. Van de Broek et al. and Day et al. showed the feasibility 
for the detection and therapeutic usage of these gold nanoparticles in vitro by conjugating them to anti-
HER2 nanobodies in order to actively target breast cancer cells [102, 103]. Furthermore, Qian et al. and Yi et 
al. demonstrated the feasibility of detection and usage for therapy of these nanoparticles in vivo [104, 105]. 
Another preclinical multimodal imaging modality, BLI, can be used to assess cell viability and therefore 
therapeutic efficiency. As mentioned previously, cells need to be transduced with viral vectors which contain 
a reporter gene, such as the Firefly luciferase gene that enables bioluminescent imaging to assess tumor 
viability after treatment [106, 107]. Cells can also be transduced with fluorescent genes after which MPLSM 
or fluorescence imaging (FLI) can be performed on superficial tumors or animals adapted with cranial 
windows to look at glioma invasion as was shown by Winkler et al [108].  
Finally, not only tumor growth, characteristics and viability can be monitored, but also therapeutic vehicles 
themselves. Using stem cells for brain tumor therapy can be followed with several imaging modalities. 
Migration of stem cells towards a tumor can be followed in vivo by in vitro labeling of the stem cells with 
micron-sized paramagnetic iron oxide particles (MPIO), superparamagnetic iron oxide particles (SPIO) or 
ultrasmall paramagnetic iron oxide particles (USPIO) [37]. These cause negative contrast enhancement on T2 
and T2* MR images and thus darker areas in the regions of interest [109]. In mice, immunotherapy has been 
followed by labeling DC’s in vitro and performing MRI. Tavare et al were able to locate DC’s for up to 7 days 
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after injection [110]. Recently, also 19F MRI has gained importance and has been utilized for tracking DC’s in 
vivo [38]. 
When introducing a therapeutic gene, this can in some cases also be used for PET imaging. The HSV-TK gene 
can be imaged with specific radiotracers, such as [18F] FEAU (1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-
5-ethyluridine), [18F] FFEAU (1-(2’-deoxy-2’-fluoro-beta-d-arabinofuranosyl)-5-(2-fluoroethyl)uridine) [111] or 
[18F] FHBG 9-(4-[18F]-fluoro-3-butyl)guanine [112].  
Therapeutic genes can also be combined with an imaging reporter gene, such as the Firefly luciferase gene in 
multicistronic vectors or repeated cell transduction, which enables to determine the viability of therapeutic 
cells by BLI [93].  
For an overview of available imaging techniques to assess specific characteristics of gliomas in small animals 
we refer to table 3. 
Table 3: Overview of available imaging techniques to assess specific characteristics of gliomas in small animals. 
Parameter 
Imaging  
modality 
Specifications Limitations Ref 
Anatomy MRI T2 weigthed images Necrosis ↔ bleeding [113] 
Vasculature MRI 
BBB disruption: CE-MRI Limited spatial resolution [35, 96] 
MRI angiography Needs anatomical imaging [36] 
Disruption of brain tracts MRI Diffusion tensor imaging Limited info on tumor [90] 
Cellular composition MRI Diffusion weighted imaging Limited spatial resolution [91] 
Invasiveness MPLSM Dynamic in vivo MPLSM 
Cranial window requirement 
Superficial tumors 
[108] 
Metastasis MRI/MRS T2, CE-T1, DWI/
1
H MRS  [42] 
Viability BLI  
2D imaging modality 
Low spatial resolution 
[16] 
Metabolism 
PET 18F FDG/11C acetate/18F choline/18F FET 
Needs co-registration with MRI or CT 
Low spatial resolution in mice 
[98, 114] 
MRS 1H MRS/13C MRS Needs co-registration with MRI or CT [99, 100] 
Photothermal therapy NIR Golden nanoparticles Limited penetration depth 
[103, 
105] 
MRI: Magnetic resonance imaging, MPLSM: multiphoton laser scanning microscopy, MRS: magnetic resonance spectroscopy, BLI: 
Bioluminescence imaging, PET: Positron emission tomography, CT: computed tomography, CE-MRI: contrast enhanced –MRI, DTI: 
Diffusion tensor imaging, DWI: diffusion weighted imaging, [
18
F] FDG: [
18
F]-fluorodeoxyglucose, [
18
F]-FET: [
18
F]-Fluorethyl-L-tyrosine.  
  Chapter 1: General Introduction 
27 
 
Even though there is a multitude of in vivo preclinical imaging modalities available, which can be combined, 
a Pubmed search, resulted in only a few multi-modal imaging applications in preclinical GBM research, which 
involved a combination of MRI/BLI [115], MRI/PET [116, 117] or BLI/CT [118]. Other papers regarding 
glioblastoma research applied a single imaging modality like MRI e.g.[119], BLI e.g.[120] or PET e.g.[121] but 
the majority of the published papers did not use any in vivo imaging to follow-up treatment response [122]. 
Most of the latter used size measurements on xenografts, symptomatic endpoints or survival combined with 
histological validation to assess treatment efficacy. Final outcome may thus be reconstructed but no 
information is recovered about initial tumor induction efficiency in orthotopic models or morphological or 
functional changes during therapy. In order to obtain this information, additional animals must be added and 
sacrificed at certain time points, thus increasing animal use and costs. Examples of multi-modal imaging 
applications in GBM research are provided in table 4.  
Table 4: Examples of recent multi-modal imaging applications in rodents. 
Author Ref Year MRI PET BLI CT Other 
Viel et al [123] 2008 X X    
Corroyer-Dulmont et al [117] 2013 X X    
Schwartz et al [124] 2011 X X  X Ultrasound 
Jarzabek et al [115] 2012 X  X   
Baumann et al [125] 2012 X  X X  
Zhou et al [126] 2009 X  X  NIR imaging 
Dorsey et al [127] 2009  X X X Fluorescence 
Cronin et al [118] 2012   X X  
Liu-Hua Wei et al [128] 2008  X  X  
Wehrl et al [28] 2013  X   MRS 
MRI: magnetic resonance imaging, PET: positron emission tomography, BLI: Bioluminescence imaging, CT: computed tomography, 
NIR: near infrared imaging, MRS: magnetic resonance spectroscopy.  
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The most frequently used combinations of preclinical imaging methods are MRI/PET [117, 123] and MRI/BLI 
[115] although combinations of these imaging modalities with other modalities, such as ultrasound [125], 
NIR imaging [126], MRS [28] and CT (PET/CT [128], BLI/CT [118], MRI/PET/CT [124] MRI/BLI/CT [125] and 
PET/BLI/CT [127]), have also been used. For an example of a multi-modal imaging approach using MRI, BLI 
and PET in mice performed in our centre, we refer to figure 3, showing an example for a glioma model used 
in this thesis. 
Figure 3: Example of a multi-modal imaging approach in a GBM bearing mouse injected with fLuc expressing stem cells. 
A. T2 weighted MR imaging on a GL261 glioblastoma bearing C57BL6/J mouse was used to confirm the striatal 
location of the tumor and to determine the tumor size. Furthermore, T1 weighted imaging post contrast 
administration was performed in the same animal to confirm BBB disruption. 
B. Subsequently, a dynamic [
18
F] FET PET scan was performed for 80 min which showed an increased amino-acid 
metabolism in the tumor. 
C. Finally, BLI was performed on the same animal to assess the viability of fLuc positive mMAPCs injected 
intratumorally 2 weeks prior to imaging. BLI confirmed that these stem cells were viable for at least 2 weeks in 
a glioblastoma environment. 
MRI: Magnetic resonance imaging, [
18
F ]FET PET: [
18
F] Fluorethyl-L-tyrosine positron emission tomography, BLI: Bioluminescence 
imaging, T1W: T1 weighted image, fLuc: Firefly luciferase. 
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1.6 Conclusion 
The dismal prognosis faced by patients suffering from glioblastoma, has multiple causes. First, the aggressive 
nature and the presence of resistant stem cells and infiltrating tumor cells complicate treatment. 
Furthermore, early detection is usually impossible as symptoms are vague and MRI and / or PET scans are 
not routinely performed for screening. After treatment, it is difficult to discriminate tumor (re)growth from 
therapy induced edema and necrosis which complicates distinction between progression and 
pseudoprogression [129]. As a consequence, it becomes more difficult to distinguish responders from non-
responders by using only conventional imaging techniques. Consistent combination of PET/BLI and MR 
spectroscopy [130] aids clinicians to identify true progression at an earlier time point and enable adaptations 
of treatment schedules when necessary. Current standard treatment remains however inefficient as 
indicated by the high mortality rate still experienced by patients suffering from high grade gliomas. 
Therefore, research should focus on the development and assessment of new treatment approaches. 
Extrapolation of the acquired data remains however difficult as no existing animal model recapitulates all 
aspects of a human brain tumor. Special efforts should therefore also be made to characterize models 
carefully before investigating new treatment modalities, which should be thoroughly followed by non-
invasive imaging to assess treatment efficiency before proceeding to clinical settings. New treatment 
approaches not only have to focus on the main tumor mass but also on erasing tumor cells that infiltrate 
normal brain tissue as these cells are mainly responsible for relapse after therapy. Several imaging 
modalities are available to investigate different characteristics, each with their own strengths and 
limitations. Often, multi-modal imaging is required to answer specific research questions. Thus, imaging can 
aid researchers to guide therapy, better evaluate experimental treatment modalities, investigating factors 
such as treatment efficiency, progression free survival and possible side-effects more thoroughly before 
implementing experimental therapies in patients. 
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Chapter 2: Objectives and outline of this work 
2.1 Outline of this work 
During the last decades, new therapeutic approaches have resulted in decreased mortality rates for various 
tumor types. For glioblastoma patients, the prognosis remains however poor as innovative approaches 
derived from preclinical research models show unsatisfactory results when translated in a clinical setting. It 
is therefore crucial to thoroughly evaluate both preclinical models and the experimental therapy in order to 
maximize insights in treatment mechanisms and possible reasons for treatment failure. Unlike clinical 
practice where multi-modal imaging is applied frequently, preclinical research uses the abilities of in vivo 
multi-modal imaging, including magnetic resonance imaging (MRI), positron emission tomography (PET) and 
bioluminescence imaging (BLI), less extensively. These imaging modalities can however help researchers in 
assessing therapy mechanisms while reducing the number of animals, time and costs and increase statistical 
power of preclinical studies. In this study, preclinical in vivo multi-modal imaging techniques were used to 
study suicide gene therapy and the associated bystander killing effect in preclinical glioma models. 
Although, the proof-of-principle for suicide gene therapy has been demonstrated before [82], imaging 
played a minor role in guiding therapy in this first study on the bystander-killing effect of tumor infiltrating, 
HSV-TK expressing stem cells.  
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2.2 Objectives 
The first objective of this study was to label and transduce both stem cells and glioma cells to obtain cells 
with a therapeutic potential and that are traceable with non-invasive multi-modal imaging methods. For this 
purpose, several lentiviral vectors were designed. These vectors were designed to image both therapeutic 
and tumor cells and contained different fluorescent proteins (enhanced green fluorescent protein (eGFP) for 
stem cells, mCherry for glioma cells), and different luciferases (fLuc for stem cells, rLuc for glioma cells). 
Furthermore, stem cells were labeled with superparamagnetic iron oxide particles (SPIO’s) for MR tracking 
(Figure 4).  
The second objective was to characterize and optimize different glioma models, both using mouse and 
human cell lines. The presence of BBB disruption and reproducibility were key indicators to select a model.  
The third aim of this study was to conduct in vivo multi-modal imaging proof-of-principle experiments in 
order to generate a model for screening of stem cell mediated suicide gene therapy in different preclinical 
glioblastoma models. Therefore, eGFP-fLuc-HSV-TK positive cells were labeled with iron oxide particles and 
stereotactically injected into the brain of mice to optimize imaging protocols and define limits of the used 
methods. Repeated MRI provided detailed information on the biodistribution of the cells relative to the 
tumor. Thus, decisions could be made in regard to timing of ganciclovir administration. BLI (fLuc) or PET 
([18F]-FHBG) were assessed for their informative potential. Tumor formation and therapy assessment was 
performed by MRI (lesion size), PET ([18F]-FET) and BLI (rLuc). In vivo findings were correlated to histology. 
The final objective for this study was to assess stem cell mediated suicide gene therapy in different 
preclinical glioblastoma models using multi-modal small animal imaging, including MRI/BLI for follow-up of 
stem cell distribution and treatment response.  
 Chapter 2: Objectives and outline of this work  
35 
 
Figure 4: Overview of the developed lentiviral vectors for multi-modal imaging follow-up of suicide gene therapy.  
For glioma cells, a lentiviral vector was produced carrying the mCherry and rLuc controlled by a cytomegalovirus 
promotor (CMV). For the stem cells, a control vector carrying the eGFP and fLuc genes was produced. Furthermore, two 
lentiviral vectors were designed to transduce cells with the eGFP, Fluc and HSV-TK genes. Stem cell lentiviral vectors 
were controlled by the elongationfactor 1α (EF-1 α). Furthermore, blasticidine- or puromycine resistance genes were 
added for selection of the transduced cells. Following transduction, cell viability was assessed by BLI, using either fLuc 
(Stem cells(SC)) or rLuc (Glioma) and PET (HSV-tk / [116] FHBG). Finally, stem cells were labeled with SPIO’s for MRI cell 
tracking. Glioma cells
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Chapter 3: Generation and validation of cell lines for non-invasive imaging of 
 suicide gene therapy 
3.1 Introduction 
Over the past years, stem cells have gained interest as a mean for potential tumor treatment, where they 
can be used as cellular vehicles to deliver suicide genes to the malignant tissue [131]. Stem cells are also 
being considered in the broad field of regenerative medicine, such as in stroke [77], where differentiation of 
certain stem cells is supposed to support recovery either by cell replacement or indirectly by the release of 
neurotrophic factors [78]. Several types of stem cells are available and the selection of the most suitable 
stem cell type depends on the intrinsic stem cell characteristics and the anticipated results of the treatment. 
One type of stem cells that is currently being tested in a number of clinical trials are multipotent adult 
progenitor stem cells (MAPCs), which can be isolated from adult human bone marrow [132, 133] and display 
some unique features including the ability for self-renewal, which is shown by the observation that they can 
be cultivated for up to 70 passages [134].  
In this study, we have assessed the transduction efficiency of a CMV promoter driven lentiviral vector 
encoding for either, eGFP and fLuc or eGFP, fLuc and HSV-TK on HEK293T cells and rOct4+ BM-HypoSCs. An 
EF1α promoter driven lentiviral vector encoding for eGFP was assessed in order to increase the transduction 
stability and efficiency. In addition to the previously mentioned cell lines this vector was furthermore 
assessed in two additional, related mouse cell lines namely mOct4+ BM-HypoSCs and mMSC’s. Subsequently, 
EF1α promoter driven lentiviral vectors were produced which encoded for eGFP and fLuc (pCH-EF1a-3flag-
fLuc-T2A-eGFP-Ires-Bsd) or eGFP, fLuc and HSV-TK (pCH-EF1a-eGFP-Ires-puro and pCH-EF1a-3flag-fLuc-T2A-
HSVTK-Ires-Bsd).  
After simultaneous preliminary in vivo experiments (see also chapter 4, 5), three different mouse cell lines 
(mOct4+ BM-HypoSCs, mOct4- BM-MAPCs and mMSC’s) and one human cell line (hMultistem) were 
transduced with these lentiviral vectors and labeled using in house fabricated SPIO’s for MRI tracking. 
Subsequently, transduction efficiency was assessed using fluorescence activated cell sorting (FACS), BLI and a 
Chapter 3: 
Generation & validation of cell lines for non-invasive imaging of suicide gene therapy 
40 
 
GCV killing experiment. Furthermore, the effect of SPIO labeling (sensitivity, adverse effects, label stability, 
etc.) was assessed using, MRI, BLI, ICP and an MRI phantom.  
Finally, a mouse (GL261-Glioblastoma) and human glioma xenograft (Hs683-oligodendroglioma and U87-MG 
-glioblastoma) models were selected for assessment of the bystander killing effect. Subsequently, these 
tumor cells were transduced using a CMV promoter driven lentiviral vector encoding for mCherry and rLuc. 
The expression of the rLuc gene was assessed by BLI using Coelenterazin-h as a substrate for rLuc.  
3.2 Materials & methods 
Cell lines 
eGFP-fLuc + and eGFP-fLuc-HSVTK+ HEK 293T cells were acquired from the Laboratory of Molecular Virology and Gene 
Therapy, KU Leuven (also known as the Leuven Viral Vector Core) and were cultured using medium containing 
Dulbecco’s Modified Eagle Media (DMEM) + Glutamax (Gibco®Invitrogen®Invitrogen, ThermoFisher Scientific, Waltham, 
MA USA) supplemented with 10% FCS and Gentamycin (50µg/ml, Gibco®Invitrogen).  
Mouse and rat m/rOct4
+
 BM-HypoSCs and mOct4
-
 BM-MAPCs were obtained from the laboratory of Stem Cell Biology 
and Embryology at KU Leuven. Cells were cultured as described previously [135]. In short, culture dishes, coated with 
fibronectin were used to passage cells every 48 hours. Rat stem cell medium contained 60% low glucose DMEM 
(Gibco®Invitrogen BRL), 40% MCDB-201 (Sigma), 1 x insulin-transferrin-selenium (ITS) (Sigma), 1 x linoleic acid bovine 
serum albumin (LA-BSA) (Sigma), 10
-9
 M dexamethasone (Sigma), 10
-4
 M ascorbic acid 3-phosphate (Sigma), 100 units of 
penicillin, 1000 units of streptomycin (Cellgro), 2% fetal bovine serum (FBS; HyClone), 10 ng/mL human platelet-derived 
growth factor (R&D systems), 10 ng/mL mouse epidermal growth factor (Sigma), and 1000 units/mL mouse leukemia 
inhibitory factor (Esgro ESG, Chemicon). Mouse stem cell medium was similar with some modifications: 1 x selenium-
insulin-transferrin-ethanolamine (SITE) (Sigma) was used instead of ITS, a combination of 0.2 mg/mL LA-BSA and 0.8 
mg/mL powdered bovine serum albumin (BSA; Sigma) was added instead of using only LA-BSA, 1 x chemically defined 
lipid concentrate (Gibco®Invitrogen) was included, and dexamethasone was not included. Finally, b-mercaptoethanol (1 
x; Gibco®Invitrogen) was added freshly to both types of media. Media was sterilized using a 22-mm filter (Millipore, 
USA).  
mMSC’s were also obtained from the laboratory of Stem Cell Biology and Embryology at KU Leuven and were cultured 
using medium containing Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco®Invitrogen) supplemented with 10% FBS 
(Hyclone), 10% horse serum (Biochrom, Berlin, Germany), 1% L-glutamine (Gibco®Invitrogen) and 100 units of penicillin 
and 100µg of streptomycin (Cellgro). Cells were split every 60-72 hrs at 70-80% confluency. 
hMultistem’s and the U87-MG cell line were acquired from Regenesys (Leuven, Belgium) and the American Type 
Culture Collection (ATCC code HTB-14-Manassas, VA, USA) respectively and were cultured according to the 
manufacturer’s guidelines.  
The GL261 cell line, used as a mouse model for glioblastoma, and the Hs683 cell line, used as a human glioma xenograft 
model for oligodendroglioma, was obtained from the Laboratory of Clinical Immunology, at KU Leuven and the 
Laboratory for Toxicology at the Free University Brussels (ULB). Both cells were cultured as described previously [106]. 
The Hs683 cell line was obtained from the toxicology laboratory at the ULB and was cultured as described previously 
[136].  
Genetic modification 
CMV promoter driven lentiviral vectors encoding for eGFP-fLuc or eGFP-fLuc-HSVTK 
eGFP-fLuc + and eGFP-fLuc-HSVTK + HEK 293T cells were obtained from the Laboratory of Molecular Virology and Gene 
Therapy, KU Leuven (Leuven Viral Vector Core) [137]. rOct4
+
 BM-HypoSCs were transduced using a CMV promoter 
driven lentiviral vector encoding for eGFP and fLuc or eGFP, fLuc and HSV-TK (20pg p24/cell). Subsequently, transduced 
cells were selected using puromycin (2-4 µg/ml) as the lentiviral vectors contained a puromycin resistance cassette. 
Samples for flow cytometric analysis were prepared using a final concentration of 2% paraformaldehyde and the 
percentage eGFP positive cells and the total eGFP expression (mean fluorescence intensity x %eGFP+ cells) were 
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measured using a FACSCanto system (BD Biosciences, Erembodegem, Flanders, Belgium) and analyzed with the 
FACSDiva software package provided with the instrument.  
Evaluation of EF1α promoter driven lentiviral vector encoding for eGFP for stem cell transduction 
HEK293T cells and rOct4
+
 BM-HypoSCs were transduced with an EF1α promoter driven lentiviral vector encoding for the 
eGFP gene and a puromycin resistance cassette (HEK 293T: 8pg p24/cell, rOct4
+
 BM-HypoSCs 20pg p24/cell). 
Furthermore, mOct4
+
 BM-HypoSCs (p24 = 20pg p24/cell), mOct4
-
 BM-MAPCs (p24 = 20pg p24/cell) and mMSC’s (p24 = 
8pg p24/cell) were transduced with the same lentiviral vector. Cells were subsequently selected with increasing 
puromycin concentration ranging from 2-4 µg/ml (HEK293T, rOct4
+
 BM-HypoSCs, mOct4
+
 BM-HypoSCs,  
mOct4
-
 BM-MAPCs) or 4-6 µg/ml (mMSC). Samples for flow cytometric analysis were prepared as described previously 
and the % of eGFP positive cells and the total eGFP expression (mean fluorescence intensity x %eGFP+ cells) were 
measured using a FACSCanto system (BD Biosciences) and analyzed with the FACSDiva software package provided with 
the instrument.  
Viral vector construction, production and transduction 
A control and two multicistronic HIV-based lentiviral vector transfer plasmids [137] were provided by the Molecular 
Virology and Gene Therapy, KU Leuven (Leuven Viral Vector Core) driving reporter gene expression from an EF1 alpha 
promoter. The first transfer plasmid was engineered to express a 3xflag tagged firefly luciferase (3flag-fLuc) together 
with Herpes simplex virus thymidine kinase (HSV-TK) and a blasticidin resistance cassette (BsdR) linked by a peptide2A 
sequence (T2A) and an internal ribosomal entry site (IRES), respectively (pCH-EF1a-3flag-fLuc-T2A-HSVTK-IRES-BsdR), 
whereas the second encoded enhanced green fluorescent protein (eGFP) and a puromycin resistance cassette (PuroR), 
linked by an IRES (pCH-EF1a-eGFP-IRES-PuroR). The control transfer plasmid was engineered to express 3xflag tagged 
derived firefly luciferase (3Flag-fLuc) together with eGFP and a blasticidin resistance cassette (BsdR) linked by a peptide 
2Asequence (T2A) and a internal ribosomal entry site (IRES), respectively (pCH-EF1a-3flag-fLuc-T2A-eGFP-IRES-BsdR). LV 
vectors were produced by Molecular Virology and Gene Therapy, KU Leuven (Leuven Viral Vector Core) as previously 
described [137]. Filtered vector particles were concentrated with Vivaspin 15 columns (Vivascience, Han- nover, 
Germany), aliquoted and stored at −80°C and are referred to as LV_ EF1a-3flag-fLuc-T2A-HSVTK-IRES-BsdR, LV_EF1a-
eGFP-IRES-PuroR and LV_EF1a-3flag-fLuc-T2A-eGFP-IRES-BsdR, respectively.  
mOct4
+
 BM-HypoSCs (p24 = 20pg p24/cell), mOct4
-
 BM-MAPCs (p24 = 20pg p24/cell), hMultistem (p24 = 20pg p24/cell) 
and mMSC’s (p24 = 8pg p24/cell) were consecutively transduced with the mentioned lentiviral vectors driven by an 
EF1α promoter. First, LV_EF1a-eGFP-IRES-PuroR was used for transduction and cells were subsequently selected with 
puromycin (Invivogen, San Diego, USA) (2-4 µg/ml, Sigma-Aldrich). Following selection, LV_ EF1a-3flag-fLuc-T2A-HSVTK-
IRES-BsdR was used to transduce the cells, which were subsequently selected with blasticidin (20-80 µg/ml, Invivogen). 
Control cells were generated by adopting a similar strategy using the LV_EF1a-3flag-fLuc-T2A-eGFP-IRES-BsdR. 
Evaluation of EF1α promoter driven lentiviral vectors encoding for eGFP, fLuc (and HSV-TK) for stem cell transduction 
eGFP expression was used for visual confirmation of transduction after which fLuc and HSV-tk expression were 
assessed. For fLuc expression, 1 x 10
5
 cells were seeded in triplicate in a 24 well plate and allowed to attach prior to 
fLuc BLI measurements. 75µg of D - luciferine (Promega, Madison, WI, USA) was added per well prior to placing the 
plates in the IVIS® 100 system (Perkin Elmer, Waltham, MA, USA) at 37°C. A scan was taken (medium binning, f stop = 1, 
time= 10s or 1 min) and acquired data were analyzed by the living image® 2.50.1 software.  
Subsequently, HSV-tk expression was confirmed with a GCV killing experiment. Hereby, 2 x 10
4
 cells were seeded in a 24 
well plate and allowed to grow. The following day, ganciclovir (GCV, Cymevene®, Roche, Basel, Switzerland) was added 
in different concentrations, 100µM, 1µM and 0.01µM, for 4 consecutive days after which BLI was performed as 
described previously using the IVIS® 100 system (Perkin Elmer). Cells were subsequently collected and a BCA protein 
assay (ThermoScientific, Rockford, USA) was performed. 
Stem cell characterization 
Cell surface phenotype 
The mOct4
+
 BM-HypoSCs and mOct4
-
 BM-MAPCs cells were trypsinized, washed with PBS and incubated for 15 min at 
room temperature with antibodies dissolved in staining buffer. Cells were washed once, resuspended in PBS and 
analyzed by flow cytometry. 
Antibodies for mouse cell-surface markers were: CD140a-APC, CD31-APC, CD44-APC (eBioscience, San Diego, CA), c-Kit-
APC (BDPharmingen, San Diego, CA), Sca1-APC (Abcam, Cambridge, UK). 
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Karyotyping 
Two days after seeding mouse and rat Oct4
+
 BM-HypoSCs and mouse and rat Oct4
-
 BM-MAPCs were exposed to 0.1 
μg/ml colcemid (Sigma) for 3 h, harvested, washed, and incubated with 75 mM KCl hypotonic solution for 9 min at 37°C. 
Cells were centrifuged and the pellet fixed for 10 min using 15 ml methanol/acetic acid (3:1). Subsequently, cells were 
again centrifuged and the pellet was resuspended in 0.15 ml methanol/acetic acid (3:1). Cells were put onto a hot glass 
slide. Chromosomes were stained using Wright's stain and seventeen chromosomal spreads were counted per 
population [138]. 
 
RNA isolation and qRT-PCR 
Total RNA from (non-)transduced cells was extracted using the RNeasy microkit (Qiagen, Valencia, CA). mRNA was 
reverse transcribed using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) and cDNA underwent 40 rounds 
of amplification (ABI PRISM 7700, Perkin Elmer/Applied Biosystems, Foster City, CA) as follows: 40 cycles of a two-step 
PCR (95°C for 15 sec, 60°C for 60 sec) after initial denaturation (95°C for 10 min) with 1 μl DNA solution, 1 × TaqMan 
SYBR Green Universal Mix PCR reaction buffer (Applied Biosystems). Primers used for amplification are shown in 
Supplementary Table 1. The mRNA levels were normalized using the housekeeping gene GAPDH and compared to the 
expression in embryonic stem cells. 
SPIO labeling of stem cells 
eGFP-fLuc-HSVTK expressing stem cells were seeded (1.2 x 10
3
 cells/cm
2
: mOct4
+
 BM-HypoSCs, mOct4
-
 BM-MAPCs / 2 x 
10
3
 cells/cm
2
: hMultistem’s / 2.1 x 10
4
 cells/cm
2
: mMSC’s) and labeled for 24 hours using in house fabricated SPIO’s 
[139, 140] (20 µg Fe/ml: mOct4
+
 BM-HypoSCs, mOct4
-
 BM-MAPCs , hMultistem’s or 10 µg Fe/ml: mMSC’s) combined 
with 1.5µg/ml poly-L-Lysin (PLL). Subsequently, cells were washed three times with PBS and incubated overnight in iron 
free medium. Afterwards, cells were trypsinized and counted prior to sample preparation for BLI to assess cell viability 
following labeling, MRI of phantoms and inductively coupled plasma optical emission spectrometry (ICP-OES) for the 
assessment of contrast generation and cellular iron content, respectively. For BLI, 1 x 10
5
 cells were seeded in triplicates 
in 24 well plates and allowed to attach. The following day, BLI was performed. For MRI Phantom scanning, 1 x 10
5
 cells 
were resuspended in 100 µl PBS (concentration: 1000cells/µl) and mixed with 1.5% agarose (Sigma-Aldrich) in a 1.1 
ratio (final concentration: 500 cells/µl). All samples were subsequently transferred to a pre-made matrix made of 1.5% 
agarose [141]. Upon solidifying, the phantoms were scanned using a 9.4T Bruker Biospin MR scanner. For ICP-OES, 
triplicate samples of 5 x 10
4
 cells were lysed with concentrated 37% HCL (Vel Labs, Leuven, Belgium). Samples were 
further homogenized with distilled water and the iron content per cell was determined using ICP-OES (Varian, 720ES, 
Santa Clara, USA). 
Glioma cell transduction using a CMV promoter driven lentiviral vector encoding for mCherry and rLuc 
1.25 x 10
4
/cm
2
 tumor cells (GL261, Hs683, U87-MG) were seeded and allowed to attach prior to transduction. Cells 
were incubated (108 pg p24 /cell) for 24 hours with a CMV promoter driven lentiviral vector encoding for mCherry, rLuc 
and a blasticidin resistance cassette. Subsequently, cells were washed and expanded. Approximately one week post 
transduction, when mCherry expression became apparent, blasticidin selection was commenced and maintained for 
one week (40-60 µg/ml). 2.5 x 10
4
 cells were seeded per well and allowed to attach after which rLuc BLI (IVIS® 100 
system (Perkin Elmer)) was performed using Coelenterazin-h (Rediject Coelenterazin-h, Perkin Elmer, 0.25 µg / well) as 
a substrate.  
Imaging: 
Magnetic resonance imaging (MRI) 
For scanning of agar phantoms containing labeled cells, a 9.4T Bruker Biospec small animal MR scanner (Bruker Biospin, 
Ettlingen, Germany; horizontal bore 20cm) equipped with actively shielded gradients (600mT m
-1
) was used. A 
quadrature radio-frequency (rf) resonator (transmit/receive; inner diameter 7cm, Bruker Biospin) was used for image 
acquisition. Two dimensional multi-slice-multi-echo (MSME) scans were acquired for the calculation of T2 values 
(TR=2000ms, TE increments: 10.1ms, 16 echo’s, number of slices: 8, slice thickness: 0.4mm, interslice distance: 0.6mm, 
matrix size: 200x200, in plane resolution: 100µm
2
). Furthermore, three dimensional, high resolution T2* weighted MR 
images were acquired using a gradient echo sequence (TR = 1500ms, first TE = 4.44ms with 8 increments of 6.75ms, 
matrix size 400 x 400, in plane resolution: 78µm
2
, slice thickness: 0.35mm, number of slices: 12). Images were 
processed using the Paravision 5.0/5.1 software (Bruker Biospin). 
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Bioluminescence imaging (BLI) 
For BLI, cells were seeded and allowed to attach. The following day, the substrate (D-luciferine (75µg/well, Promega) or 
Coelenterazin-h (0.25µg/well, Perkin Elmer) was added to each well, prior to imaging using an IVIS® 100 system (Perkin 
Elmer). A scan was taken (medium binning, f stop = 1, time= 10s or 1 min) and acquired data were analyzed by the living 
image® 2.50.1 software (Perkin Elmer). 
3.3 Results 
3.3.1 Evaluation of transduction efficiency using a CMV promoter driven lentiviral vector  
rOct4+ BM-HypoSCs transduced with a CMV promoter driven lentiviral vector encoding for eGFP-fLuc or 
eGFP-fLuc-HSVTK (20pg p24/cell) were compared to puromycin selected eGFP-fLuc + and eGFP-fLuc-HSVTK + 
HEK 293T cells (positive control). Transduction efficiency was assessed by FACS analysis (Figure 5). HEK 293T 
cells contained both, high percentages of positive cells (eGFP-fLuc: 96.3 ± 0.4%, eGFP-fLuc-HSVTK: 86.8 ± 
1.9%) and high levels of fluorescence (eGFP-fLuc: 2.5 x 106 ±1.4 x105, eGFP-fLuc-HSVTK: 1.8 x106 ± 1.8 x105), 
for at least 30 days when keeping them in culture for both eGFP-fLuc and eGFP-fLuc-HSVTK + cell lines 
(Figure 5A). In rOct(+) BM-HypoSCs, the transduction efficiency was much lower (eGFP-fLuc: 22.1%, eGFP-
fLuc-HSVTK: 23.9%). Although puromycin selection increased the percentage of eGFP positive cells (eGFP-
fLuc-puro: 82.3%), expression levels were not stable and both the number of eGFP+ cells and the total 
fluorescence decreased over time even when applying another puromycin selection regimen(Figure 5B).  
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Figure 5: HEK 293T and rOct4
+
 BM-HypoSCs transduction assessment using a CMV promoter driven lentiviral vector. 
A. eGFP expression analysis using FACS of HEK 293T cells showed efficient cell transduction that remained stable 
over time for both lentiviral vectors. Both the % eGFP+ cells and the total fluorescence remained high for at least 
30 days when keeping them in culture. 
B. ROct4
+
 BM-HypoSCs displayed a less efficient gene transduction with approximately 20% eGFP+ cells, which 
increased up to 80% following puromycin selection. Unfortunately, this gene expression proved unstable and 
both the % of eGFP+ cells and the total fluorescence decreased over time even when applying another 
puromycin selection. 
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As transgene expression in rOct4+ BM-HypoSCs proved to be unstable using a CMV promoter, the EF1α 
promoter was subsequently investigated in order to reach stable gene expression. As the insert size 
combined with the length of the EF1α promoter would greatly diminish the packaging capacity of a lentiviral 
vector, one control vector (eGFP-fLuc-Blasticidin) and two treatment vectors (eGFP-Puromycin / fLuc-HSVTK-
blasticidin) were produced. As an EF1α promoter driven lentiviral vector encoding for eGFP and a puromycin 
selection cassette was available, proof of principle experiments were first conducted in order to assess the 
transduction efficiency of an EF1α promoter driven lentiviral vector.  
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3.3.2 Evaluation of transduction efficiency using an EF1α promoter driven lentiviral vector 
First, HEK293T cells and rOct4+ BM-HypoSCs were transduced using the EF1α promoter driven lentiviral 
vector encoding for eGFP and a puromycin selection cassette after which eGFP expression was assessed by 
FACS. HEK 293T transduction was stable and following puromycin selection similar expression levels were 
obtained with the EF1α promoter driven lentiviral vector as with the CMV promoter driven lentiviral vector. 
Both the percentage of eGFP+ cells and the total fluorescence remained stable in these cells over time 
(Figure 6A). In rOct4+ BM-HypoSCs higher expression levels were obtained using the EF1α promoter driven 
lentiviral vector compared to transduction with the CMV promoter driven lentiviral vector. Furthermore, the 
percentage of eGFP+ cells and the total fluorescence remained more stable over time. FACS based cell 
sorting further increased the amount of eGFP+ cells (Figure 6B).  
In addition to these cells, transduction of mOct4+ BM-HypoSCs was assessed in order to develop a syngeneic 
mouse model when combined with the GL261 glioblastoma mouse model. The transduction efficiency of 
these cells was acceptable and further increased by either puromycin selection or FACS based cell sorting. In 
both cases, expression levels remained stable for up to 25 days post transduction (Figure 6C). Finally, 
transduction of mMSC’s was also assessed as Wolfs et al have shown that CMV promoter driven lentiviral 
vectors are unable to reach efficient transgene expression (personal communication). With the newly 
designed lentiviral vectors, the percentage of eGFP+ cells was initially rather low but increased significantly 
after puromycin selection. It remained stable for up to 40 days (Figure 6D).For an overview of the obtained 
FACS data we refer to table 5. 
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Figure 6: Transduction assessment using an EF1α promoter driven lentiviral vector. 
A. FACS data of HEK 293T cells showed efficient transduction of the cells after selection using puromycin.  
B. FACS data of rOct4
+
 BM-HypoSCs showed increased transduction efficiency of the EF1α promoter driven 
lentiviral vector compared to the CMV promoter driven lentiviral vector. The % of eGFP+ cells was further 
increased by puromycin selection 
C. FACS data of mOct4
+
 BM-HypoSCs showed similar transduction efficiency following puromycin selection and 
FACS based cell sorting.  
D. FACS data of mMSC’s showed limited number of eGFP+ cells which increased substantially after puromycin 
selection. 
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Table 5: FACS data after transduction of several cell lines using an EF1α promoter driven lentiviral vector.  
 
3.3.3 Evaluation of the transduction using lentiviral vectors encoding for eGFP, fLuc and HSV-TK 
After simultaneous in vivo experiments (see chapter 4, 5), we chose to work with one mouse and two human 
glioma xenograft models. Therefore, three different mouse cell lines (mOct4+ BM-HypoSCs, mOct4- BM-
MAPCs and mMSC’s) and one human cell line (hMultistem) were selected for assessment of suicide gene 
therapy in a mouse (GL261-Glioblastoma) and in two human glioma xenograft (Hs683-oligodendroglioma / 
U87-MG -glioblastoma) models. 
For the mentioned stem cells, full transductions were subsequently performed, thus generating eGFP-fLuc or 
eGFP-fLuc-HSVTK positive cells, which were assessed for functional transgene (fLuc and HSV-TK) expression. 
First, fLuc expression was assessed by BLI (Figure 7) which confirmed sufficient expression for in vivo 
validation of both the control vector (eGFP, fLuc) and the treatment vectors (eGFP, fLuc, HSV-TK). 
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Figure 7: Functional transgene expression: fLuc expression assessment using BLI. 
For all cell lines, fLuc expression was significantly different compared to WT cells for both eGFP-fLuc and eGFP-fLuc-
HSVTK expressing cells although small differences were observed between eGFP-fLuc and eGFP-fLuc-HSVTK expressing 
cells. (A. mOct4
+
 BM-HypoSC, B. mOct4
-
 BM-MAPC, C. mMSC, D. hMultistem) 
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Subsequently, HSV-tk activity was assessed by a ganciclovir killing experiment, in which cells were subjected 
to different concentrations of GCV for four consecutive days after which BLI and a BCA protein assay were 
performed (Figure 8). BLI data showed that for all cell lines expressing eGFP and fLuc, a reduction in cell 
viability was only seen for the highest ganciclovir concentration which is probably due to cytotoxicity caused 
by GCV itself. Cells expressing eGFP, fLuc and HSV-TK however showed a dose-dependent cell killing even at 
concentrations as low as 0.01µM of GCV. The BCA protein assay confirmed these results.  
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Figure 8: Functional transgene expression: HSV-TK expression assessment by using a GCV killing experiment. 
BLI data (left) showed that for all cell lines expressing eGFP and fLuc, only a reduction in cell viability was seen for the 
highest ganciclovir concentration which is due to cell toxicity. Cells expressing eGFP, fLuc and HSV-TK however showed 
a dose-dependent cell killing with cell killing at concentrations as low as 0.01µM of GCV. The BCA protein assay (right) 
confirmed these results. (A. mOct4
+
 BM-HypoSC, B. mOct4
-
 BM-MAPC, C. mMSC, D. hMultistem) 
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3.3.4 Stem cell characterization and transduction related effects 
Stem cell characterization by flow cytometry showed that mOct4+ BM-HypoSCs were CD31, Sca-1 negative 
and CD140a, cKit, CD44 positive, whereas mOct4- BM-MAPCs were CD31, cKit negative and CD140a, Sca-1, 
CD44 positive (Figure 9). For characterization of the rOct4+ BM-HypoSCs and rOct4- BM-MAPCs, we refer to 
the work of Ulloa-Montoya et al.[132].  
Figure 9: Cell-surface phenotype evaluated by flow cytometry 
Left panel: Flow cytometry results for mOct4
+
 BM-HypoSCs. 
Right panel: Flow cytometry results for mOct4
-
 BM-MAPCs. 
From left to right are shown wt, eGFP-fLuc and eGFP-fLuc-HSVtk expressing cells. The histogram in each panel plots the 
number of cells (as a percentage of the maximum) on the vertical axis against the fluorescence intensity of the labeled 
antibody bound to the indicated protein (horizontal axis). 
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qRT-PCR (Figure 10) further showed a primitive endoderm gene expression pattern including high expression 
of Gata4, Gata6, Sox7 and Sox17 for mOct4+ BM-HypoSCs whereas mOct4- BM-MAPCs showed very low 
expression of Gata4, Gata6, Sox7 and Sox17. Both cell lines were positive for c-Myc and Klf4. Oct4 and Sall4 
were however expressed in mOct4+ BM-HypoSCs but not in mOct4- BM-MAPCs. For rat cells, a similar 
pattern was observed with primitive endoderm gene expression in rOct4+ BM-HypoSCs but not in rOct4- BM-
MAPCs. Both cell lines expressed c-Myc and Klf4 but rOct4+ BM-HypoSCs expressed Oct4 and Sall4 whereas 
rOct4- BM-MAPCs did not. Subsequently, the effect of transduction on stem cell characteristics, such as gene 
and cell surface marker expression was assessed using qRT-PCR and flow cytometry. Results indicate no 
pronounced differences in gene or cell surface marker expression between transduced and untransduced 
cells, neither for mOct4+ BM-HypoSCs nor for mOct4- BM-MAPCs. Karyotyping revealed cytogenetic 
abnormalities in both rat and mouse cell lines, but this was not related to tumor growth or transduction 
status as wild-type lines also showed abnormalities. It is a well known phenomenon that long-term culture of 
bone marrow-derived stem cells (especially murine cells) induces chromosomal instability [142]. 
Supplementary Table 1: Overview of qRT-PCR primers.  
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Figure 10: q-RT-PCR analysis 
A. qRT-PCR analysis for the expression of Sox7, Sox17, Gata 4, Gata6, Oct4, Sall4, Klf4 and c-Myc in  
  mOct4
+
 BM-HypoSCs and mOct4
-
 BM-MAPCs showed a primitive endoderm gene expression pattern for  
 mOct4
+
 BM-HypoSCs, including Gata4, Gata6, Sox7 and Sox 17 expression whereas mOct4
-
 BM-MAPCs  
 showed very low expression of Gata4, Gata6, Sox7 and Sox17. Both cell lines were positive for c-Myc and Klf4.  
 Oct4 and Sall4 were however expressed in mOct4
+
 BM-HypoSCs but not in mOct4
-
 BM-MAPCs. No profound  
  alterations in gene expression could be detected following transduction for both mOct4
+
 BM-HypoSCs and  
 mOct4
-
 BM-MAPCs. Relative mRNA expression compared to the housekeeping gene GAPDH is shown. 
B. qRT-PCR analysis for the expression of Sox7, Sox17, Gata 4, Gata6, Oct4, Sall4, Klf4 and c-Myc in rOct4
+
 BM- 
 HypoSCs and rOct4
- 
BM-MAPCs showed also a primitive endoderm gene expression pattern for rOct4
+
 BM- 
 HypoSCs, but not for rOct4
- 
BM-MAPCs. Both cell lines expressed c-Myc and Klf4 but rOct4
+
 BM-HypoSCs  
 expressed Oct4 and Sall4 whereas rOct4
-
 BM-MAPCs did not. No profound alterations in gene expression  
 could be detected following transduction for both mOct4
+
 BM-HypoSCs and mOct4
-
 BM-MAPCs. Relative  
 mRNA expression compared to the housekeeping gene GAPDH is shown.  
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3.3.5 Labeling stem cells with SPIO’s 
As the previous results indicated that the stem cells are adequately transduced for in vivo validation, stem 
cells were subsequently labeled using in house fabricated superparamagnetic iron oxide particles  
(SMG2-mPEGSi) [143] for in vitro assessement of cell tracking by MRI.  
eGFP-fLuc-HSVTK expressing stem cells (mMSC’s, mOct4- BM-MAPCs, mOct4+ BM-HypoSCs, and 
hMultistem’s) were labeled with SMG2-mPEGSi particles after which ICP-OES (left), an MRI of a cell 
containing phantom (middle) and BLI (right) were performed to assess labeling efficiency and stem cell 
viability (Figure 11). For mMSC’s (Figure 11A), ICP-OES showed an iron uptake of 5.4 ± 0.6 pg iron/cell for 
SMG2-mPEGSi and 1.4 ± 0.2 pg iron/cell for Endorem® labeled cells. An MRI phantom showed contrast 
generation of SMG2-mPEGSi labeled cells while no marked differences in cell viability were observed 
between labeled and unlabeled cells as assessed by BLI. Similar results were obtained for mOct4- BM-
MAPCs, mOct4+ BM-HypoSCs, and hMultistem’s, although the amount of iron / cell varied between different 
cell types. mOct4- BM-MAPCs, mOct4+ BM-HypoSCs, and hMultistem’s contained 15.9 ± 1.5 pg iron/cell, 9.3 
± 0.6 pg iron/cell and 27.0 ± 0.7 pg iron/cell, respectively, without significant differences in cell viability as 
assessed by BLI. Differences in the amount of iron / cell were represented in the contrast generation in the 
corresponding MRI phantoms, with higher amounts of iron generating a rapid and more profound 
hypointense contrast.  
In conclusion, an adequate cell labeling was confirmed by ICP-OES and MRI of phantoms with no or very little 
effect on stem cell viability for all cell lines. Furthermore, mMSC’s and mOct4- BM-MAPCs were also labeled 
with Endorem® as a reference compound. These experiments indicate that the SMG2-mPEGSi particles 
displayed superior labeling characteristics. 
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Figure 11: In vitro assessment of stem cells labeling using SMG
2
-mPEGSi. 
Left column contains ICP-OES acquired iron content per cell, middle column contains MRI acquired relaxation 
information and right column contains BLI acquired stem cell viability information.  
ICP-OES (left) and MRI phantoms (middle) showed efficient stem cell labeling using SMG
2
-mPEGSi particles 
without significant effects on stem cell viability for mMSC’s (A), mOct4
-
 BM-MAPCs (B), mOct4
+
 BM-HypoSCs 
(C) and hMultistem’s (D). For mMSC’s and mOct4
-
 BM-MAPCs Endorem® labeled stem cells were used as a 
reference. 
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3.3.6 Transduction of glioma cells using a CMV promoter driven lentiviral vector encoding for mCherry and 
rLuc 
Finally, also tumor cells were transduced with a lentiviral vector encoding for mCherry, rLuc and a blasticidin 
selection cassette of which the expression was driven by a CMV promoter in order to follow tumor viability 
in vivo. As mentioned earlier, one mouse (GL261-glioblastoma) and two human glioma xenograft (Hs683-
oligodendroglioma / U87-MG -glioblastoma) models were selected. mCherry expression was used in order to 
visually confirm transduction by fluorescence microscopy. All three models showed rLuc expression in vitro 
when assessed by BLI using coelenterazin-h as a substrate (Figure 12).  
Figure 12: rLuc expression evaluation using BLI.  
All tumor cell lines (GL261, Hs683, U87-MG) showed rLuc expression when Coelenterazin-h was provided as a substrate.  
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3.4 Discussion 
Due to their self-renewal, migration and differentiation capacity, stem cells are increasingly regarded as 
candidates in regenerative medicine or as cellular vehicles to deliver therapeutic molecules. Although 
pluripotent stem cells hold the greatest potential, their ability to form teratomas also hampers their clinical 
use [144]. Multipotent stem cells are more restricted in their differentiation potential and therefore less 
likely to form teratomas, although mass formation has been reported [145]. It is therefore crucial that the 
fate of stem cells is followed longitudinally in vivo to assess possible safety issues but also to monitor the 
therapeutic response. For this purpose, we have developed eGFP-fLuc and eGFP-fLuc-HSVTK+ stem cells, 
which were subsequently labeled with SPIO’s in order to track them longitudinally in vivo with MRI and BLI 
while using them as cellular vehicles to carry the suicide gene (HSV-TK), to the tumor site. These cells were 
subsequently used to investigate suicide gene therapy for malignant gliomas. Transduction and labeling of 
cells has been applied previously in order to follow-up on cell behavior [146-148]. For instance Wolfs et al. 
showed that expression of the human sodium iodide symporter (hNIS) can be used to assess stem cells in 
vivo by using PET [148]. The low spatial resolution and the hardware (e.g. a cyclotron) required for 
production of radioactive tracers however means that application of PET is more cost and labor intensive 
compared to BLI. 
Lentiviral vectors were used to obtain stable gene expression in stem cells. Lentiviral vectors driven by the 
most commonly used promoter, namely the cytomegalovirus (CMV) promoter resulted in stable gene 
expression levels in 293T cells but not in rOct4+ BM-HypoSCs which is concurrent with the observation that 
the CMV promoter is less suitable for stable stem cell transduction [149]. Wang et al showed that the human 
elongation factor 1 alpha (EF1α) is better suited for stable gene transduction in stem cells [149]. Therefore, a 
lentiviral vector encoding for eGFP and a puromycin resistance cassette was used to transduce not only HEK 
293T cells and rOct4+ BM-HypoSCs but also mOct4+ BM-HypoSCs and mMSC’s. All cell lines showed efficient 
gene expression following puromycin selection when using the EF1α promoter driven lentiviral vector. 
Furthermore, qRT-PCR and flow cytometry showed that transduction of mOct4+ BM-HypoSCs and for mOct4- 
BM-MAPCs, did not result in genetic (Sox7, Sox17, Gata6, Gata4, Oct4, Sall4, Klf4 and c-myc) or cell surface 
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marker (CD31, CD140a, Sca-1, cKit and CD44) aberrations compared to WT cells. EF1α promoter driven 
lentiviral vectors encoding for eGFP and fLuc or eGFP, fLuc and HSV-TK were assessed for functional gene 
expression in mOct4+ BM-HypoSCs, mOct4- BM-MAPCs and mMSC’s for glioma models in mice and in 
hMultistem’s for human glioma xenograft models. In all cell lines expressing eGFP, fLuc and HSV-TK a dose 
dependant stem cell killing was observed both in BLI signal (cell viability) and a BCA protein assay (protein 
content) after GCV administration. This was not the case for cells that only expressed eGFP and fLuc, 
although some cell toxicity was observed with high concentrations of GCV which is concurrent with data 
published by Li et al [84]. Subsequently, eGFP-fLuc-HSVTK + mOct4+ BM-HypoSCs, mOct4- BM-MAPCs, 
mMSC’s and hMultistem’s were labeled for MR imaging using in house fabricated SPIO’s. Efficient cell 
labeling was confirmed using MRI phantoms and ICP-OES. Furthermore, stem cell viability was checked with 
BLI using D-luciferine as a substrate.  
As such, we have shown that several different stem cells can be detected in vitro by MRI and BLI and 
therefore, in vivo assessment of stem cell localization prior to treatment initiation and stem cell viability 
follow-up can be commenced. In regard to suicide gene therapy, it is however also useful to investigate 
tumor viability following suicide gene therapy as tumor size alone might not be the most efficient readout 
for rapid validation of therapy. Therefore, three different tumor cell lines, namely GL261, Hs683 and U87-
MG were also transduced using a CMV promoter driven lentiviral vector encoding for mCherry and rLuc in 
order to follow-up tumor cell viability. All three cell lines showed in vitro rLuc expression when BLI was 
performed using coelenterazin-h as a substrate.  
These results indicate that subsequent in vivo assessment of both stem cells and tumor cell lines can be 
commenced. 
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Chapter 4:  
In vivo validation of cell lines for non-invasive imaging of suicide gene therapy 
This chapter has been compiled based on the following publications:  
Leten C., et al., In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma  
  animal models. J Neurooncol, 2014. 
Leten C., et al. Controlling and monitoring stem cell safety in vivo in an experimental rodent model.  
  Stem cell, 2014. 
Leten C., et al., Assessment of bystander killing mediated therapy of malignant brain tumors using a multi- 
  modal imaging approach. (Submitted to Stem cell research & therapy) 
4.1 Introduction 
Gliomas arise from the glial cells (astrocytes, oligodendrogial and ependymal cells) and are the most 
common brain tumors in humans. They comprise a broad range of lesions with distinct differences in 
malignancy, which is assessed according to the World Health Organization classification. Glioblastoma 
multiforme (GBM) is the most malignant glioma of the spectrum (WHO grade IV) [1]. The prognosis of 
patients diagnosed with GBM is still extremely poor with a 5-year survival of less than 3% despite a 
multimodal treatment approach consisting of surgery and concomitant radio- and chemotherapy[3]. 
Therefore, new treatment modalities are under investigation, among which therapy based on the bystander 
killing effect following suicide gene therapy [84, 150-152]. 
This therapeutic approach relies on administration of cells carrying a suicide gene, such as the gene encoding 
for the Herpes Simplex virus-thymidine kinase (HSV-TK). When the substrate for this enzyme, for instance 
ganciclovir (GCV) is provided, it enters the cell and is converted by HSV-TK into GCV-monophosphate. The 
HSV-tk displays a 1000 fold higher affinity for GCV than the mammalian thymidine kinase [152] and 
therefore this targeting approach limits systemic toxicity while the increased affinity boosts tumor therapy 
capabilities [152]. Subsequently, cellular kinases recognize the GCV-monophosphate and will create GCV-
triphosphate, a guanine nucleoside analogue which causes DNA chain termination and subsequent cell 
death. Due to the formation of gap junctions between adjacent cells, ganciclovir monophosphate can 
passively diffuse into neighboring cells which will result in mostly tumor and therapeutic cell killing as normal 
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adult brain cells usually do not replicate. Thus, both tumor and therapeutic cells can be killed. This is also 
known as ‘the bystander killing effect 
When using stem cells that can track infiltrating tumor cells, this method can in theory be applied to remove 
not only the main tumor, but also destroy any remaining tumor cells, thus eliminating sources of possible 
recurrent tumors [152]. The feasibility of this strategy was demonstrated by several groups in both xenograft 
and syngeneic animal models. Miletic et al. [152] and Matuskova et al. [85] demonstrated a potent 
bystander killing effect of rMAPCs on 9L rat gliomas and hMSC’s on the human glioblastoma cell lines 8-MG-
BA, 42-MG-BA and U-118 MG respectively.  
However suitable some stem cells might be, there is also a potential safety risk associated with stem cell 
therapies as the transplanted cells have the ability to proliferate longitudinally and can differentiate into 
several cell types of which some can result in unwanted side effects. Well known examples of this are 
embryonic stem cells (ESC) [153] and induced pluripotent stem cells (iPSC) which can form teratomas [125], 
hampering applications of those cells in vivo [90]. Lo Nigro et al recently demonstrated that rat bone marrow 
(BM) derived cells, expressing high levels of Oct4, generated in vitro, so called Hypoblast-like stem cells (BM-
HypoSC) [145], share characteristics with blastocyst derived HypoSC including high levels of Oct4 expression 
as well as a compliment of primitive endoderm genes [133]. Other rodent cell lines [132] isolated under the 
identical condition as the Oct4+ cells (MAPC conditions), however do not express high levels of Oct4 and do 
not have the primitive endoderm gene signature (Oct4- BM-MAPCs). To better illustrate this difference, the 
cells with high Oct4 expression are called BM-HypoSCs and the ones with no Oct4 expression MAPCs 
throughout the manuscript. Likewise, human Oct4low/no MAPCs, currently used for clinical trials under the 
name Multistem, also do not express high levels of Oct4 nor do they display the endodermal gene signature. 
High levels of Oct4 in rat rOct4+ BM-HypoSCs [145] and mouse mOct4+ BM-HypoSCs (unpublished data) 
appear to be responsible for the formation of yolk-sac tumors when injected in animals while none of the 
low/no level Oct4 rodent or human MAPCs have generated yolk sac like tumors [154] as shown by 
transplantation of the cells under the kidney capsule or as xenografts.  
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Unfavorable safety profiles can hamper the application of stem cells, which might be otherwise very well 
suited for particular applications in vivo, for example the ability of stem cells to track infiltrating tumor cells 
and erase them by the expression of suicide genes [84, 150, 151]. Therefore, safety studies were performed 
using r and mOct4+ BM-HypoSCs, r and mOct4- BM-MAPCs and mMSC’s to assess possible tumor formation 
in the brain of syngeneic C57BL6/J mice. 
In a clinical setting, patients are routinely followed up by non-invasive imaging such as magnetic resonance 
imaging (MRI). In a preclinical setting, these non-invasive imaging techniques are also available and should 
therefore, when possible, also be used to evaluate stem cell viability and treatment response. Therefore, 
stem cells expressing eGFP and fLuc or eGFP, fLuc and the HSV-TK suicide gene and labeled using in house 
fabricated SPIO’s that were assessed previously in vitro (Chapter 3) were validated in vivo for multi-modal 
imaging follow-up. Thus, the HSV-TK gene can be used as a suicide gene for bystander mediated cell killing in 
tumor treatment but also as a safety switch for tumor forming stem cells.  
Furthermore, animal models for glioblastoma were developed. These included one mouse glioblastoma 
model (GL261) in syngeneic C57BL6/j mice and two malignant glioma models (Hs683: oligodendroglioma / 
U87-MG: glioblastoma) in an immunodeficient Hsd:athymic Nude-Foxn1nu mice. The GL261 model, a 
syngeneic model in a syngeneic (immunocompetent) host, has been characterized extensively [106, 155, 
156] and is widely considered as the gold standard in glioblastoma research. The U87-MG and Hs683 models 
have been well described also and are often used as human glioma xenograft models [157, 158]. 
Subsequently, multi-modal imaging of suicide gene therapy for glioblastoma using stem cells as cellular 
vehicles was assessed using MRI, BLI and PET.  
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4.2 Materials & methods 
Cell lines 
Cells were cultured as described previously (Chapter 3).  
Animals 
All animal experiments were conducted according to the European Union Community Council guidelines and were 
approved by the local ethics committee of KU Leuven. C57BL6/j mice and Fisher 344 rats were used for experiments 
which required a syngeneic host whereas Hsd:athymic Nude-Foxn1
nu
 mice were used for the optimization of the human 
glioma xenograft models. 
Stereotactic injection  
For surgery, animals were anaesthetized by an i.p. injection with a mixture of Ketamine (Ceva, Pompidou, France) 
(mice: 4.5mg/kg; rats: 30 mg/kg) / medetomidin (Domitor®, Pfizer, New York, USA) (mice: 0.6 mg/kg, rats: 0.2 mg/kg). 
Local analgesia (2% xylocain, AstraZeneca, London, UK) and antibiotics (6mg/mouse, Ampiveto-20 (200mg/ml), VMD, 
New Haw, Surrey, UK) were administered prior to surgery. After fixation of the animals in a stereotactic frame adapted 
with a Quintessential stereotaxic injector (All from Stoelting, Wood Dale USA), cells were injected with a 10 µl Hamilton 
(total volume 5µl, infusion rate: 0.5 µl/min) syringe, equipped with a 22 G needle, into the right striatum of C57Bl6/j 
mice or Fisher rats respectively. Coordinates for mice were 0.5 mm anterior and 2.0 mm lateral to bregma and 3.0 mm 
from the dura for mice. For rats, injection coordinates were 2.8 mm lateral to bregma and 5.5 mm from the dura. 
2.5x10
5
 or 5x10
5
 stem cells were injected for in vivo proliferation experiments or ganciclovir killing experiments, 
respectively. Cell numbers were chosen based on previous experiments for stem cell therapy in the rat brain [152] and 
considerations regarding the cell yield. 
In vivo proliferation experiment 
2.5 x 10
5
 m/rOct4
+
 BM-HypoSCs, m/rOct4
- 
BM-MAPCs, mMSC’s or hMultistem’s suspended in 5 µl PBS were injected 
stereotactically into the striatum, using the same device and coordinates as previously described, of C57BL6/J mice or 
Fisher rats. Animals were followed using MRI to assess possible tumor development.  
In vivo ganciclovir treatment experiment 
A total of 5 x 10 
5
 eGFP-fLuc-HSV-tk positive mOct4
+
 BM-HypoSCs, mOct4
-
 BM-MAPCs, mMSC’s or hMultistem’s 
suspended in 5µl PBS were injected stereotactically in the striatum of C57BL6/j mice, using the same device and 
coordinates as previously described,. The following day, MRI and BLI were performed to ascertain the site of injection 
and the cell viability after which, PBS or GCV (50mg / kg, intraperitoneally) was administered for 14 consecutive days. 
mOct4
-
 BM-MAPC (PBS: N = 2, GCV: N = 2), mMSC (PBS: N = 2, GCV: N = 2) and hMultistem (PBS: N = 3, GCV: N = 3) 
injected animals were sacrificed following MRI and BLI at the end of treatment (d15). Of the mOct4
+
 BM-HypoSC 
injected animals (PBS: N = 5, GCV: N = 5), three animals from the GCV treated group were followed up for 12 weeks by 
MRI and BLI to check for tumor regrowth.  
In vivo validation of SPIO labeling of stem cells for MRI tracking 
For each cell line (mMSC, mOct4
-
 BM-MAPCs), a similar approach was used. Four C57BL6/j mice were stereotactically 
injected with the following in opposing hemispheres: mouse 1: PBS and 3x10
5
 unlabeled stem cells, mouse 2: 1x10
5
 and 
3x10
5
 Endorem® labeled stem cells, mouse 3: 1x10
5
 SMG
2
-mPEGSi labeled stem cells, mouse 4: 3x10
5
 SMG
2
-mPEGSi 
labeled stem cells such that for each condition N = 2).  
In vivo validation of mCherry rLuc transduction of malignant glioma cells 
2.5 x 10
5
 GL261, 5 x 10
4
 Hs683 or 3 x 10
5
 U87-MG cells (mCherry-rLuc +) were injected stereotactically into the striatum 
of C57BL6/j or Hsd:athymic Nude-Foxn1
nu
 mice brain as described previously and followed up once a week using MRI 
and BLI using coelenterazin-h (Rediject Coelenterazin-h, Perkin-Elmer, 15µg / animal, i.v.) as a substrate for rLuc. 
Subsequently, animals were sacrificed, 1 mm brain slices were cut and ex vivo BLI scans were taken for one 
representative mCherry-rLuc + GL261 and one Hs683 tumor bearing animal (one drop of Rediject Coelenterazin-h/slice, 
Perkin-Elmer).  
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Imaging: 
Magnetic resonance imaging (MRI) 
All MR images were acquired with a 9.4T Biospec small animal MR scanner (Bruker Biospin, Ettlingen, Germany) 
equipped with a horizontal bore magnet and an actively shielded gradient set of 600mT m
-1
 (117 mm inner diameter) 
using a 7 cm linearly polarized resonator for transmission and an actively decoupled dedicated mouse or rat surface coil 
for receiving (Rapid Biomedical, Rimpar, Germany). MRI was performed once per week to assess the proliferation 
potential in vivo. Prior to scanning, mice and rats were anaesthetized with 2% or 4% isoflurane for induction and 1.5% 
or 2% isoflurane for maintenance, respectively. Temperature and respiration were monitored throughout the 
experiment and maintained at 37°C and 100-120 breaths / minute for mice and 70-90 breaths / minute for rats, 
respectively.  
T2 weighted (rapid acquisition with refocused echoes (RARE) sequence, repetition time (TR):3157.6 ms; echo time 
(TE):48.8 ms; matrix size: 256 x 256, FOV: 2.5 x 2.5 cm, in plane resolution: 78 µm
2
, number of continuous slices 24 / 12 
in mouse/rat, slice thickness 0.5mm, slice orientation: axial) and T2 weighted (RARE sequence, TR: 3000ms, TE: 50.2ms, 
matrix size: 256 x 256, FOV: 2 x 2 cm, number of slices: 16 / 9 in mouse/rat, slice thickness: 0.5mm, interslice distance: 
0.5mm in rat, slice orientation: coronal, in plane resolution: 78 µm
2
) MRI scans were acquired to establish graft sizes. 
The area of the graft was determined by delineating it manually on all slices of the T2 weighted coronal MR images 
using the 5.1 Paravision software (Bruker, Biospin). The mean of the cross sectional area was used to determine the 
total graft volume. An ANOVA test (GraphPad PRISM, GraphPad Software, La Jolla, CA, USA) was used to determine 
significant differences with p < 0.05. In case of tumor formation, further characterizations were performed using T2 
maps (multi slice multi echo (MSME) experiments, TR: 2000ms, TE increments: 10.1ms, 16 echo’s, number of slices: 8, 
slice thickness: 0.4mm, slice thickness: 0.6 mm, matrix size: 200x200, in plane resolution: 100µm
2
) and diffusion 
weighted MRI (echo planar imaging (EPI) with spin echo read out, TR: 300ms, TE: 25.4ms, B-values: 250, 500, 1000, 
1400 s/mm
2
, matrix size: 96, FOV: 2 x 2 cm, number of slices: 8, in plane resolution: 208µm
2
. For quantification, regions 
of interest (ROIs) were defined by placing a ROI over the tumor area followed by placing a ROI of identical size on the 
striatum (the site of cell engraftment) of the contralateral hemisphere. Subsequently, T2- and ADC maps were 
generated and T2 and ADC values were extrapolated for analysis using the Paravision 5.1. software. To validate the 
integrity of the blood brain barrier, pre- and post-contrast (gadolinium (Dotarem®), Guerbet, Villepinte, France, dosage: 
100µl / mouse of 0.05 mmol/ml, i.v.) T1 weighted MR images were acquired (RARE sequence, RARE factor: 4, TR: 
819ms, TE: 7.6ms, matrix size: 256 x 256, FOV: 2 x 2 cm, number of continuous slices: 20, slice thickness: 0.5mm, slice 
orientation: axial, in plane resolution: 78 µm
2
). The relative signal intensity of the tumor region showing the strongest 
contrast enhancement (relative to surrounding brain tissue) was determined by placing ROI over the tumor and normal 
brain tissue areas using the Paravision 5.1. software. For statistical analysis of the BBB integrity, pre-contrast scans 
were subtracted from post-contrast scans after which the percent increase following gadolinium injection was 
calculated for the contralateral hemisphere (negative control set to 100%), tumor tissue and extracranial muscle tissue 
(positive control) for each animal.  
Significance of relative differences was determined by using ANOVA test (GraphPad PRISM, GraphPad Software, La 
Jolla, CA, USA) with p < 0.05. 
For in vivo tracking of the SPIO labeled stem cells 3D T2* (FLASH sequence, TR: 100ms, TE: 12 ms, flip angle: 20°, 
resolution: 78 µm
2
, field of view: 2.0 x 1.5 x 0.75 cm) MR images were acquired and analyzed with the Image J software 
(National institute of health, Bethesda, Maryland, USA) to calculate the hypointense voxel volume. 
Bioluminescence imaging (BLI) 
Mice were anesthetized with isoflurane (2% induction, 1.5% maintenance) and placed in the IVIS® 100 system (Perkin 
Elmer, Waltham, MA, USA), maintaining the body temperature at 37°C. Subsequently, D-Luciferin (126mg/kg) 
(Promega, Madison, WI, USA) was injected intravenously and bioluminescent images were acquired for 1 minute with 
medium binning and f stop = 1. Data were analyzed for maximum intensity of the photon flux by the living image® 
2.50.1 software (Perkin Elmer). Animals were imaged before and after GCV treatment, after which 3 GCV treated 
mOct4+ BM-HypoSC bearing animals were imaged every other week for another 12 weeks. 
Positron emission tomography (PET) 
For xenograft experiments, 5 x 10
5
 or 1 x 10
6 
HEK293T cells were injected. The following day, BLI and an 80 min dynamic 
[
18
F] FHBG scan were performed. Mice were anesthetized with isoflurane (2% induction, 1.5% maintenance) and placed 
in a Focus 220 microPET system (Siemens Medical Solutions USA) after which 300µCi activity was injected i.v. Images 
were reconstructed using an iterative maximum a posteriori probability algorithm with ordered subsets (MAP; 18 
iterations, 9 subsets, fixed resolution: 1.5 mm) and analyzed in PMODv.3.1 (PMOD Inc, Zurich, Switzerland). Summed 
images of the 80-min acquisition time were used for the analysis. 
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Statistical analysis 
Values are represented as the mean ± SEM. Analysis were perfomed using GraphPad PRISM 5 software (GraphPad, 
California, USA). The degree of significance is indicated where necessary (*: p < 0.05, **: p < 0.01, ***: p < 0.001,  
****: p < 0.0001). 
In vivo proliferation experiment 
2.5 x 105 m/rOct4
+
 BM-HypoSCs or m/rOct4
-
 BM-MAPCs suspended in 5 µl PBS were injected stereotactically into the 
striatum, using the same device and coordinates as previously described, of C57BL6/J mice or Fisher rats. Animals were 
followed using MRI to assess possible tumor development. 
Ganciclovir treatment experiment 
A total of 5 x 10 
5
 eGFP-fLuc-HSV-tk positive mOct4
+
 BM-HypoSCs or mOct4
-
 BM-MAPCs suspended in 5µl PBS were 
injected stereotactically in the striatum, using the same device and coordinates as previously described, of C57BL6/j 
mice. The following day (day 1 post injection), MRI and BLI were performed to ascertain the site of injection and the cell 
viability after which, PBS or GCV (50mg / kg, intraperitoneally) was administered for 14 consecutive days. mOct4
-
 BM-
MAPC injected animals (PBS: N = 6, GCV: N = 6) were sacrificed following MRI and BLI at the end of treatment (d15 post 
injection). Of the mOct4
+
 BM-HypoSC injected animals (PBS: N = 5, GCV: N = 5), three animals from the GCV treated 
group were followed up for 12 weeks by MRI and BLI to check for tumor regrowth. Anova tests were used to perform 
statistical analysis. 
Furthermore, C57BL6/j mice were stereotactically injected in the brain with eGFP-fLuc expressing mOct4
+
 BM-HypoSCs 
and treated with PBS or GCV (N = 3 for each group). Significant differences in tumor growth and cell viability were 
determined using a Kruskal-Wallis test using Dunn’s correction using GraphPad PRISM. 
Endpoints 
For mass forming experiments, rats stereotactically injected with rOct4
+
 BM-HypoSCs were sacrificed when symptoms 
reached grade 3 out of 4 (grade 0 for healthy rats, grade 1 for slight unilateral paralysis, grade 2 for moderate unilateral 
paralysis and/or beginning hunchback, grade 3 for severe unilateral or bilateral paralysis and pronounced hunchback, 
and grade 4 for moribund rats) [66].  
In mice, mOct4
+
 BM-HypoSCs mass formation reached an equilibrium after approximately 25 days, after which one 
mouse was sacrificed at 53 days (n = 1) post injection and the remaining mouse at 104 days (n = 1) post injection. 
For the m/rOct4
-
 BM-MAPCs, animals were followed for 110 days, mMSC’s for 63 days and hMultistem’s for 14 days, 
after which they were sacrificed. 
For the GCV treatment experiment, two animals stereotactically injected with mOct4
+
 BM-HypoSCs of each group (PBS-
GCV) were sacrificed on the last day of GCV treatment (= day 15 post injection) whereas three animals were followed 
up by MRI and BLI every other week for up to 12 weeks to validate tumor regrowth. 
Histology 
Animals were sacrificed by an i.p. overdose of Nembutal (300µl; Ceva) and subsequently perfused with 4% ice-cold 
paraformaldehyde (PFA) solution (Sigma-Aldrich). After overnight post fixation in 4% PFA, the brain tissue was stored in 
a 0.1% sodium azide solution (Fluka, Sigma-Aldrich) at 4°C. Brains were embedded in paraffin and 50 µm vibratome or 5 
µm paraffin sections were sliced and a Masson’s trichrome staining was performed. Sections were deparaffinized in 
xylol, followed by rehydration through ethanol. Subsequently, sections were stained with hematoxylinen 
ponceau/fuchine and aniline blue. Finally, sections were dehydrated and mounted with di-n-butylPhthalate in xylene 
(Sigma-Aldrich). Furthermore, brain slices of animals injected with m/rOct4
+
 BM-HypoSCs were stained for H&E, 
Periodic acid Schiff (PAS), and laminine [145]. Finally, brain slices of mOct4+ BM-HypoSCs or mOct4- BM-MAPC bearing 
animals were stained using an anti-FLAG antibody (Sigma F1804). 
For confirmation of MRI obtained results from SPIO labeled stem cells a prussian blue staining was performed to stain 
for iron present in the brain by combining a 20% aqueous solution of hydrochloric acid and a 10% aqueous solution of 
potassium ferrocyanide and counterstained with nuclear fast red staining. Slices were scanned with a Mirax desk (Carl 
Zeiss, Oberkochen, Germany) and microscopic images were taken with the Mirax viewer software. 
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4.3 Results 
4.3.1 Safety studies m and rOct4+ BM-HypoSCs, m and rOct4- BM-HypoSCs, mMSC’s and hMultistem’s 
4.3.1.1 m and rOct4+ BM-HypoSCs 
Intracranial engraftment of m/rOct4+ BM-HypoSCs was performed on C57Bl6/J mice and Fisher rats 
respectively. Mass formation was monitored by weekly MR imaging.  
In mice (N = 5), masses developed without obvious symptoms reaching a relative plateau at 26 days post 
injection (21 ± 4 mm3) after which, three animals were sacrificed. One more animal was sacrificed at 53 days 
post injection when the average mass size was 25 ± 8 mm3. The final animal was sacrificed at 104 days post 
injection and showed a mass of 37 mm3 (Figure 13A). 
Rats (N = 6) also developed masses reaching an average size of 286 ± 52 mm3 at 43 days post injection as 
shown in Figure 13B after which they were sacrificed as grade 3 symptoms emerged. In vivo MRI data 
suggest that after an initial formation of some solid tumor parts, heterogeneous, cyst like (fluid filled) 
structures formed. Hereby, masses were more heterogeneous in rats when compared to mice (see also 
Figure 13C).  
After sacrificing the animals, trichrome stainings were performed on vibratome sections of the brain and 
compared to the MRI scans of the last time point. Histology on mouse brain sections confirmed intracerebral 
mass formation and showed a solid pattern for the mice injected with mOct4+ BM-HypoSCs (Figure 13C).  
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Figure 13: Mass formation of m/rOct4
+
 BM-HypoSCs in mouse and rat brain monitored by in vivo MRI.  
A. Mass formation in the mouse brain (N = 5) following intracranial cell engraftment. After 26 days, three mice  
  were sacrificed. Another mouse was sacrificed 53 days post injection. The final mouse was monitored until day  
 104 post injection. 
B. Mass formation in the rat brain following intracranial cell engraftment. Rats (n = 6) developed large masses  
 reaching an average size of 286 ± 52 mm
3
 at 43 days post injection.  
C-D.  Masson’s trichrome stained brain slices of mice (C) and rats (D) were concurrent with the obtained MRI data.  
 (scale bar: 2000µm) 
E-G. Histology of rOct4
+
 BM-HypoSC masses showed a microcystic pattern with wisps of myxoid material in cystic  
spaces (e. 10x scale bare: 100µm) ), fluid filled cyste formation (f. 5x *, scale bar: 500µm) and immune cell  
 infiltration caused by necrosis (characterized by a loss of cell membrane integrity and an uncontrolled release  
of cell death products into the intracellular space) (f. 40x). g: 40x magnification image of fluid filled cyst with 
immune cell infiltration including 1. Lymphocyte (small, round cell with a very large nucleus and barely any 
cytoplasm), 2. Macrophage (very large, irregularly shaped cells with a small nucleus in comparison to the 
amount of cytoplasm) (scale bar: 50µm) 
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Histological analysis showed yolk sac tumor characteristics, like Periodic acid Schiff (PAS) and laminin 
positive staining (Figure 14) [145]. Histology on rat brain sections also showed mass formation but with a 
microcystic pattern (Figure 13D-G) with wisps of myxoid material in cystic spaces, fluid filled cyst formation 
and immune cell infiltration caused by necrosis. The histological data were therefore concluded to be 
concurrent with the MRI images obtained before sacrificing the animals. 
Figure 14: Histological analysis of mOct4+ BM-HypoSC tumors.  
Histological analysis of mOct4
+
 BM-HypoSC tumors revealed yolk sac tumor characteristics like Periodic Acid Schiff (PAS) 
and laminine positive staining (scale bar overview: 2000µm, 40x: 50µm).  
 
Mass formation following mOct4+ BM-HypoSC engraftment was subsequently further characterized by MR 
imaging (Figure 15). MRI analyses on mOct4+ BM-HypoSC masses on day 15 and day 27 post injection 
showed elevated T2 relaxation times (N = 6, 39.3 ± 4.1 ms) (Figure 15A) and increased diffusion (N = 3, 0.002 
± 0.00009 mm2/s) (Figure 15B) compared to the contralateral hemisphere (T2 relaxation time: 29.4 ± 0.55 ms 
/ ADC values: 0.001 ± 0.000055 mm2/s). Furthermore, BBB integrity loss was apparent on day 15 and 27 (N = 
6, see Figure 15C). Hereby, larger tumors displayed a more heterogeneous BBB disruption pattern.  
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Figure 15: MRI analysis of mass formation after engraftment of mOct4+ BM-HypoSCs.  
A. T2 relaxation time of masses formed by mOct4
+
 BM-HypoSCs increased compared to the contralateral  
  hemisphere on day 15 (p < 0.05) and day 27 (p < 0.0001) post injection, indicating an increased fluid content in  
 the masses. (N = 6) 
B. The apparent diffusion coefficient (ADC) of masses formed by mOct4
+
 BM-HypoSCs was also elevated  
 compared to the contralateral hemisphere on day 15 (p < 0.0001) and day 27 (p < 0.0001) post injection,  
 indicating an increase of the intercellular space [26]. (N = 3) 
C. BBB disruption was shown by an increased signal intensity at the mass site after Dotarem injection. (N = 6) 
 For each graph, one representative analysis is shown (ROI = yellow circle).  
  Graft sites of mOct4
-
 BM-MAPCs were characterized by decreased signal intensities, T2 and ADC values in  
 comparison to the contralateral hemisphere which is concurrent with damage caused by cell injection (data  
  not shown). 
The significance for all graphs refers to *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.3.1.2 m and rOct4- BM-MAPCs 
As Oct 4 is a marker for pluripotency [159], we wanted to assess the hypothesis that stem cells, not 
expressing Oct4 might not give rise to mass formation. Therefore, m/rOct4- BM-MAPCs, were injected in the 
striatum of C57BL6/j mice (N=6) and Fisher rats (N=6), respectively. MRI of the remaining animals (N=3) did 
not indicate mass formation even after 110 days. The absence of mass growth was subsequent confirmed by 
histology, which neither revealed intracerebral mass formation in mice (Figure 16A) nor in rats (Figure 16B). 
In rats, grafts were rather difficult to locate as graft sizes seemed to be limited to the needle tract made by 
the initial injection. In mice, grafts were more easily detected as cells seemed to have persisted at the graft 
location without causing tumor formation. Hypointense contrast was obvious from the first MRI post cell 
engraftment, indicating minor injury/bleeding. This contrast did not change over time, resulting in volumes 
of 0.8518 mm3 ± 0.0684 for mOct4- BM-MAPCs injected in mice and 0.7217 mm3 ± 0.1323 for rOct4- BM-
MAPCs injected in rats, respectively (Figure 16C).  
Figure 16: Histology and MRI data obtained for animals injected intracranially with m/rOct4
-
 BM-MAPCs. 
A-B. MRI scans and subsequent histology showed a minor injury due to the engraftment of stem cells but did not  
  reveal mass development neither in mice (A) nor in rats (B).  
C. Statistical analysis of the data obtained by MRI resulted in hypointense volumes of 1.2 ± 0.2 mm
3
 and 2.0 ± 0.2  
  mm
3
 for mouse and rat stem cells respectively at 110 days post injection. These volumes did not significantly  
  change in size over the course of the experiment (day 1 tot 110) 
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4.3.1.3 mMSC’s 
Subsequently, mMSC’s were injected stereotactically in the striatum of syngeneic C57BL6/j mice. MRI of 
these animals did not indicate mass formation even after 63 days as lesion sizes remained small at 1.81 mm3 
± 0.32 mm3 over the entire duration of follow-up(Figure 17A) as assessed by T2 weighted MR images (Figure 
17B). Subsequent histology did also not reveal intracerebral mass formation (Figure 17C). 
Figure 17: Histology and MRI data obtained from animals injected intracranially with mMSC’s 
A. Lesion size in the brain (N = 4) following intracranial mMSC engraftment. Mice were followed for 63 days after 
which they were sacrificed for Masson’s trichrome staining. 
B. Example of T2 weighted coronal images on day 1 and day 63 post injection of a representative animal.  
C. Masson’s trichrome staining of a representative animal showing a lesion in the right hemisphere. 
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4.3.1.4 hMultistem’s  
Finally, also human Multistem’s were stereotactically injected in the healthy brain of Hsd:athymic Nude-
Foxn1nu mice. MRI showed no mass formation (Figure 18A) but rather a decrease of the graft, indicative of 
cell death at 14 days post injection. Lesion sizes were assessed by T2 weighted MR images (Figure 18B). 
Subsequent histology did also not reveal intracerebral mass formation (Figure 18C). 
Figure 18: Histology and MRI data obtained from animals injected intracranially with hMultistem’s 
A. Lesion size in the brain (N = 4) following intracranial hMultistem engraftment. Mice were followed for 63 days 
after which they were sacrificed for Masson’s trichrome staining. 
B. Example of T2 weighted coronal images on day 1 and day 63 post injection of a representative animal.  
C. Masson’s trichrome staining of a representative animal showing a lesion in the right hemisphere. 
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4.3.2 In vivo validation of fLuc and HSV-TK expression in eGFP-fLuc-HSVTK transduced stem cells 
4.3.2.1 mOct4+ BM-HypoSCs and mOct4- BM-MAPCs 
The data above suggest that using Oct4- stem cells would greatly improve the safety profile of these stem 
cells. However, as some ‘therapeutic’ properties of those cells might be different to cells expressing higher 
Oct4 levels, we investigated an additional safety measure for the mouse stem cells, namely transducing both 
mOct4+ BM-HypoSCs and mOct4- BM-MAPCs with a lentiviral vector containing the HSV-TK gene, which 
makes these cells susceptible for ganciclovir treatment and subsequent formation of cytotoxic 
phosphorylated ganciclovir.  
mOct4- BM-MAPC graft volumes of PBS and GCV treated animals were not significantly different on MRI 
although BLI signal intensity of GCV treated animals injected with transduced cells did show a significant 
decrease over time indicating a cytotoxic effect (Figure 19A). Injection of 5 x 105 cells generates a rather 
small graft which explains the lack of difference on MRI.  
Masses formed in mice implanted with eGFP-fLuc-HSVtk expressing mOct4+ BM-HypoSCs and treated with 
GCV (N = 5) showed a significant difference in both graft size (MRI) and cell viability (BLI) when compared to 
PBS control animals (N = 5, day 15, see Figure 19B). Observations made by in vivo imaging were confirmed 
with histology (Figure 19C) and the more specific anti-FLAG staining, in order to specifically stain for fLuc 
expression (Figure 20). This specific staining showed eGFP-fLuc-HSVtk expressing cells at the graft site for 
mOct4- BM-MAPC (Figure 20A) and mOct4+ BM-HypoSC (Figure 20B) bearing animals treated with PBS for 14 
days (=15days post injection). In GCV treated animals, only few fLuc positive cells were detected in both 
mOct4- BM-MAPC (Figure 20C) and mOct4+ BM-HypoSC (Figure 20D) bearing animals, which is concurrent 
with the results obtained by MRI, BLI and Masson’s trichrome staining.  
Three GCV treated animals implanted with eGFP-fLuc-HSVtk expressing mOct4+ BM-HypoSCs were 
maintained to assess delayed cell growth but both MRI and BLI confirmed that there was no mass formation 
or increased BLI signal intensity for up to 12 weeks post GCV treatment. For an overview of both MRI and BLI 
measurements see Table 6. In contrast, animals implanted with eGFP-fLuc expressing mOct4+ BM-HypoSCs 
and treated with GCV (N=3) did not show significant differences to PBS treated animals (N=3, Figure 21). 
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Figure 19: In vivo transgene expression assessment of eGFP-fLuc-HSV-TK + mOct4
-
 BM-mMAPCs and mOct4
+
 BM-
HypoSCs.  
A. For mice injected with mOct4
-
 BM-mMAPCs, no significant change in mass volume could be detected by MRI. 
However, a decrease in BLI signal intensity and hereby of cell viability was detected after GCV treatment but 
not in PBS control animals. 
B. GCV treatment resulted in significant differences of both mass volume (MRI) and viability (BLI) after GCV 
treatment between PBS and GCV treated mice injected with mOct4
+
 BM-HypoSCs.  
C. Histology: Masson’s trichrome staining on animals killed at the end of GCV treatment confirmed MRI and BLI 
data (scale var overview: 200µm, 20x:100µm). 
The significance for all graphs refers to *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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Figure 20: Anti-FLAG staining on eGFP-fLuc-HSVtk expressing stem cells after treatment. 
A. mOct4
-
 BM-MAPC bearing mice showed a high abundance of fLuc expression at the graft site following PBS 
treatment (day 15 post injection). 
B. mOct4
+
 BM-HypoSC bearing mice also showed fLuc expression at the graft site following PBS treatment (day 15 
post injection). Here however, masses developed as described previously.  
C. mOct4
-
 BM-MAPC bearing mice treated with GCV showed less fLuc expression compared to the PBS treated 
group (A) at the end of treatment, which is consistent with the decreased viability observed by BLI. 
D. mOct4
+
 BM-HypoSC bearing mice treated with GCV also showed a decrease in fLuc expression at the graft site 
(black circle) following treatment (day 15 post injection) in comparison to the PBS treated group. Furthermore, 
mass development was absent which is concurrent with the results obtained by MRI and BLI.  
(images: magnification: 10x, scale bar: 200µm 
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Table 6: Quantitatification of mass volumes (MRI) and cell viability (BLI) of mOct4
+
 BM-HypoSCs in vivo. 
 
Figure 21: Suicide gene therapy in eGFP-fLuc expressing mOct4
+
 BM-HypoSCs 
A. MRI data showed no statistically significant difference in tumor growth between mOct4
+
 BM-HypoSC bearing 
mice treated with PBS (day 1: 1.8 ± 0.5mm
3
-day 15: 15.3 ±3.3mm
3
) or GCV (day1: 1.5 ± 0.4mm
3 
-day 15: 12.2 ± 
4.3mm
3
).  
B. BLI data also did not show a statistical significant difference between PBS (day 1: 4.1x10
7
 ± 1.2x10
7
 P/s – day 
15: 3.2x10
8
 ±9.0x10
7 
P/s) and GCV treated (day1: 4.2x10
7
 ± 9.7x10
6
 P/s - day 15: 2.1x10
8
 ± 2.4x10
7
 P/s) mOct4
+
 
BM-HypoSCs in cell viability.  
 
Finally, mice injected with eGFP-fLuc-HSVtk expressing mOct4+ BM-HypoSCs (N = 3) were treated with GCV 
starting 8 days after injection. At the end of GCV treatment, BLI showed a reduced viability of the stem cells 
(Figure 22). However, this did not result in complete removal of the tumor. 
Figure 22: Suicide gene therapy in eGFP-fLuc expressing mOct4
+
 BM-HypoSCs 
BLI data obtained from mice in which eGFP-fLuc-HSVtk expressing mOct4+ BM-HypoSC were allowed to grow for 8 days 
prior to commencing GCV treatment showed a reduction in cell viability at the end of treatment. 
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4.3.2.2 mMSC’s 
Subsequently, eGFP-fLuc-HSVTK expressing mMSC’s were evaluated in vivo for stem cell detectability and 
HSV-tk killing potential. On MRI, eGFP-fLuc-HSVTK expressing mMSC lesion volumes of both PBS control and 
GCV treated animals decreased over time (Figure 23A). On day 8 post stem cell injection, a significant 
decrease in viability was seen between PBS control (N = 2) and GCV treated (N = 2) animals indicating cell 
killing after 7 days of GCV treatment. This difference could not be demonstrated at the end of the GCV 
treatment as the viability of the stem cells in animals treated with PBS also decreased indicating a poor 
survival of the stem cells in vivo. (Figure 23B). An overview of MRI and BLI images generated on prior to (day 
1) and at the end of GCV treatment (day 15) are depicted in Figure 23C. Furthermore, histology confirmed 
the obtained data although the graft proved difficult to locate in some mice (Figure 23C). 
Figure 23: In vivo transgene expression evaluation of eGFP-fLuc-HSVTK + mMSC’s.  
A. For mice injected with mMSC’s, lesion volumes decreased over time. 
B. Stem cell viability assessment using BLI (fLuc) showed a statistically significant difference between PBS control 
and GCV treated animals at day 8. However, PBS control animals also showed a decrease in stem cell viability 
indicating poor survival of the stem cells in the brain of healthy mice. *** p < 0.001 
C. Overview of MRI and BLI images generated before (day 1) and after (day 15) treatment. Furthermore, a 
Masson’s trichrome staining confirmed the results obtained by MRI and BLI although in one animal the graft 
could not be localized (PBS control animal 2).  
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4.3.2.3 hMultistem’s 
Finally, also eGFP-fLuc-HSVTK expressing human Multistem’s were assessed in vivo for their transgene 
expression. On MRI, eGFP-fLuc-HSVTK expressing hMultistem lesion volumes of PBS control and GCV treated 
animals were not significantly different due to the small lesion sizes caused by the injection of 5x105 cells 
(Figure 24A).  
At the end of treatment (day 15), a significant decrease in stem cell viability was observed between PBS 
control (N = 3) and GCV treated (N = 3) animals. Stem cell viability in the GCV treated group remained high, 
indicating no significant toxicity of the GCV on the stem cells (Figure 24B), which might be related to 
insufficient levels of GCV in the brain, with limited BBB disruption. An overview of MRI and BLI images 
generated prior to (day 1) and at the end of GCV treatment (day 15) are depicted in Figure 24C. 
Furthermore, histology confirmed the obtained data (Figure 24C). 
Figure 24: In vivo transgene expression evaluation of eGFP-fLuc-HSVTK + hMultistem’s.  
A. For mice injected with hMultistem, lesion volumes were not statistically significantly different between PBS 
control (N = 3) and GCV treated animals (N = 3). 
B. Stem cell viability assessment using BLI (fLuc) showed significantly less viable hMultistem’s in the PBS control 
group compared to the GCV treated group at the end of treatment (day 15). However, GCV treated animals did 
not show a decrease in stem cell viability at the end of GCV treatment. * p < 0.05 
C. Overview of MRI and BLI images generated before (day 1) and after (day 15) treatment. Furthermore, a 
Masson’s trichrome staining confirmed the results obtained by MRI and BLI.  
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In conclusion, we were able to detect all eGFP-fLuc-HSVTK expressing stem cells by BLI (fLuc) in vivo one day 
after stereotactical injection into the healthy mouse brain. mOct4+ BM-HypoSCs and mOct4- BM-MAPCs 
survived well in vivo for at least two weeks, whereas the majority of the mMSC’s and hMultistem’s showed 
signs of profound cell death after two weeks, which was irrespective to assignment of the animals to the PBS 
control or GCV treated group.  
Furthermore, we attempted to detect eGFP-fLuc-HSVTK expressing cells by using [18F] FHBG PET imaging. 
Therefore, eGFP-fLuc-HSVTK expressing HEK 293T cells were assessed in vitro (Figure 25A) and in vivo (Figure 
25B) for BLI expression (in vitro: Figure 25A, in vivo: Figure 25C) and [18F] FHBG tracer uptake (in vitro: Figure 
25B, in vivo: Figure 25D). BLI showed sufficient fLuc expression both in vitro and in vivo for detection. [18F] 
FHBG tracer uptake was proven to be significant elevated in vitro at two hours and three hours post tracer 
injection compared to eGFP-fLuc transduced HEK 293T cells. Unfortunately, 5 x 105 eGFP-fLuc-HSVTK 
expressing HEK293 T cells could not be detected in a xenograft. A plausible explanation for this is the partial 
volume effect which makes it impossible to distinguish the signal from the background. Subseqently, eGFP-
fLuc-HSVTK expressing mMSC’s, mOct4- BM-MAPCs and mOct4+ BM-HypoSCs cells were assessed in a 
syngeneic mouse glioblastoma (GL261) model for cell viability (fLuc) and HSV-tk driven [18F] FHBG tracer 
uptake. BLI and MRI showed the presence and viability of the stem cells inside the tumor area (Figure 25E), 
whereas stem cells could be detected with some difficulty by an [18F] FHBG PET scan (Figure 25 F).  
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Figure 25: In vivo HSV-tk imaging assessment using [
18
F] FHBG PET imaging.  
A. HEK 293T fLuc expression assessment using BLI showed no statistically significant differences in vitro between 
eGFP-fLuc and eGFP-fLuc-HSVTK expressing cells. 
B. Gamma counter measurements on HEK 293T cells showed significantly more [
18
F] FHBG tracer uptake in eGFP-
fLuc-HSVTK expressing cells compared to eGFP-fLuc expressing cells. 
C. In vivo BLI on HEK293T xenografts in Hsd:athymic Nude-Foxn1
nu
 mice showed sufficient expression of fLuc for 
in vivo detection of the cells. 
D. [
18
F] FHBG PET scan of the same animal mentioned in C could not show presence of the stem cells in vivo. The 
partial volume effect explains is believed to be responsible for this result as it makes it impossible to 
distinguish the signal from the background. 
E. MRI and BLI measurements on GL261 tumor bearing animals injected with 5 x 10
5
 mMSC’s, mOct4
+
 BM-
HypoSCs or mOct4
-
 BM-MAPCs showed that stem cells could be easily detected by MRI (SMG
2
-mPEGSi) and 
BLI (fLuc). 
F. [
18
F] FHBG PET scan on the same animals mentioned in E showed that HSV-TK expressing stem cells could also 
be detected using PET although this proved more challenging. 293T BLI in vitro
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4.3.3 In vivo assessment of stem cells labeled with SPIO’s using MRI 
Subsequently, stem cells labeled with in house fabricated SPIO’s (see Chapter 3) were compared to 
Endorem® labeled cells for in vivo MR tracking. Therefore, a set number (1x105 or 3x105) of labeled mMSC’s 
(Figure 26A) and mOct4- BM-MAPCs (Figure 26B) were stereotactically injected into the right striatum of 
C57BL6/j mice and followed by MR imaging. Places that contained labeled stem cells created a signal void on 
3D T2* MR images, which were quantified by using the software program Image J. Only slight differences 
were observed when imaging two or eight days post injection. Animals were sacrificed and trichrome and 
Prussian blue staining were performed to confirm the data obtained by MR imaging.  
Figure 26: In vivo SPIO labeling evaluation of mMSC’s and mOct4
-
 BM-MAPCs.  
A. Hypointense voxel volume analysis coused by stereotactical injection of SPIO labeled mMSC’s (left) on 3D T2* 
MR images (middle). MRI results were confirmed with histology (Masson’s Trichrome and Prussian blue 
(right)). 
B. Hypointense voxel volume analysis coused by stereotactical injection of SPIO labeled mOct4
-
 BM-MAPCs (left) 
on 3D T2* MR images (middle). MRI results were confirmed with histology (Masson’s Trichrome and Prussian 
blue (right). 
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4.3.4 In vivo assessment of mCherry-rLuc transduction of malignant glioma cells using MRI and BLI 
Finally, in vivo expression of mCherry and rLuc in all three tumor cell lines was investigated using BLI. 2.5 x 
105 GL261, 5 x 104 Hs683 or 3 x 105 U87-MG cells (mCherry-rLuc +) were injected stereotactically into the 
brain and followed up using MRI and BLI. For the GL261 cell line, MR images showed a slight growth 
difference between WT cells and mCherry rLuc + cells (Figure 27A1). Although tumors grew exponentially, 
this was not reflected in the BLI signal originating from the tumor cells (Figure 27 A2). BLI and MR images for 
one representative mCherry-rLuc+ GL261 tumor bearing animal are shown in figure 27A3.  
mCherry-rLuc + Hs683 tumors also showed a marked growth delay compared to WT Hs683 tumors on week 
4; 5 and 6 post injection (Figure 27B1). Although a BLI signal could be observed from the mCherry-rLuc+ 
Hs683 tumors, it was very small and not proportional to the actual tumor size (Figure 27B2). BLI and MR 
images for one representative mCherry-rLuc+ Hs683 tumor bearing animal are shown in figure 27B3. 
Finally, mCherry-rLuc + U87-MG tumors were assessed for in vivo rLuc expression. These tumors did not 
show a growth delayed on MRI compared to WT tumors (Figure 27C1). As tumors grew larger, BLI signal 
became apparent which was significantly different compared to the first timepoint (Figure 27C2). BLI and MR 
images for one representative mCherry-rLuc+ U87-MG tumor bearing animal are shown in figure 27C3. 
Since mCherry-rLuc expressing GL261 and Hs683 cells showed a detectable in vitro but not in vivo rLuc 
expression ex vivo BLI scans from brain slices were also taken (Figure 28). These ex vivo measurements 
showed that although rLuc expression is present in both cell lines, very little signal can be detected in vivo. 
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Figure 27: In vivo validation of mCherry-rLuc transduction of malignant glioma cell lines.  
A. mCherry-rLuc expression in the GL261 model  
1. MRI showed a slight difference in growth delay of transduced GL261 cells in vivo.  
2. BLI using Coelenterazin-h as a substrate for rLuc did not show significant rLuc signal originating from the 
tumor cells.  
3. Example of BLI and MR images of one representative mCherry-rLuc + GL261 tumor bearing animal.  
B. mCherry-rLuc expression in the Hs683 model 
1. MRI showed a significant growth delay of transduced Hs683 cells in vivo.  
2. BLI using Coelenterazin-h as a substrate for rLuc showed a slight but insignificantly different from WT cells 
rLuc signal originating from the tumor cells.  
3. Example of BLI and MR images of one representative mCherry-rLuc + Hs683 tumor bearing animal. 
C. mCherry-rLuc expression in the U87-MG model 
1. No difference could be shown in growth characteristics between WT and mCherry-rLuc transduced cells in 
vivo.  
2. BLI using Coelenterazin-h as a substrate for rLuc showed an increasing BLI signal originating from the 
tumor.  
3. Example of BLI and MR images of one representative mCherry-rLuc + U87-MG tumor bearing animal. 
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Figure 28: Ex vivo validation of mCherry-rLuc expression in GL261 and Hs683 tumors.  
A. In vivo BLI of a mCherry-rLuc + GL261 tumor bearing animal showing very little signal originating from the 
tumor site.  
B. Ex vivo BLI of the animal in A did however show that there is rLuc expression present in the GL261 cells. 
C. In vivo BLI of a mCherry-rLuc + Hs683 tumor bearing animal showing some signal originating from the tumor 
site. 
D. Ex vivo BLI of the animal in C confirmed rLuc expression in Hs683 cells. 
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4.4 Discussion 
In this study we have evaluated the cells generated in Chapter 3 in vivo by MRI, BLI and PET. Due to their self 
renewal, migration and differentiation capacity, stem cells are increasingly regarded as candidates in 
regenerative medicine or as cellular vehicles to deliver therapeutic molecules. Although pluripotent stem 
cells hold the greatest potential, their ability to form teratomas also hampers their clinical use [144]. 
Multipotent stem cells are more restricted and therefore safer to work with but some may still give rise to 
mass formation [145]. Before considering stem cells as possible therapeutic agents, it is therefore crucial to 
investigate the safety of the therapeutic cells. 
In this study, we have shown that m/rOct4+ BM-HypoSCs are characterized in vivo by the formation of 
masses that show a disrupted BBB integrity, an elevated diffusivity and T2 relaxation times, when engrafted 
into the healthy rodent brain which is concurrent with data obtained by Lo Nigro et al [145] and Burns et al 
(unpublished data) in xenograft and stroke models. These tumors were characterized as yolk sac tumors by 
H&E staining combined with positive laminin, periodic acid Schiff (PAS), α-fetoprotein (AFP) and cytokeratin 
staining [145]. Furthermore, it has been shown in our laboratory that even 5x104 engrafted cells can give rise 
to yolk sac tumor formation whereas systemic, intracardiac injection did not result in mass formation 
(unpublished data). In rats, Oct4+ BM-HypoSCs gave rise to large masses characterized by the formation of 
large fluid filled cysts, wisps of myxoid material in these cystic spaces, necrosis and the consequential 
immune cell infiltration, characterized mostly by macrophages and lymphocytes. In mice, solid masses 
developed more slowly over time. 
As Oct 4 is a marker of pluripotency [159] we hypothesized that the absence of Oct 4 would reduce the mass 
forming capacity in the brain as was shown for m/rOct4- BM-MAPCs. We have shown that at least some 
mOct4- BM-MAPCs survive well in vivo without causing masses even when followed for several weeks. Even 
110 days after engraftment into healthy rodent brains, no mass formation could be detected, indicating that 
m/rOct4- BM-MAPCs, like human MAPCs are safe for in vivo use confirming the results obtained previously in 
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a stroke model in our laboratory (unpublished data). Furthermore, mMSC’s and hMultistem’s do not show 
tumor formation.  
Although one should aim to select stem cells that are safe, stem cells with the required characteristics for 
stem cell therapy do not always have a favorable safety profile. One novel experimental cancer therapy 
approach is based on suicide gene expression, where stem cells expressing a suicide gene, such as HSV-TK, 
are used to kill cancer cells after administration of the substrate ganciclovir. This therapy has been 
investigated for the treatment of several cancers including glioblastoma [152]. First, we applied the suicide 
gene therapy approach to HSV-tk positive, mOct4- BM-MAPCs. Ganciclovir treated animals bearing these 
cells did not show a significant difference in graft volume (MRI) after ganciclovir treatment compared to PBS 
treated animals as the graft size caused by minor injury related to the injection of 5 x 105 cells is relatively 
small. The cells did however show a decrease in viability after ganciclovir treatment compared to PBS control 
animals, proving that the stem cells could be killed selectively.  
Next, the yolk-sac tumor forming mOct4+ BM-HypoSCs were investigated in order to augment their safety 
profile. Mice injected with HSV-tk positive mOct4+ BM-HypoSCs and treated with PBS grew masses over time 
as measured by MRI. In contrast, ganciclovir treated animals did not display mass development and even 
more, the stem cell viability (BLI) decreased until the cells could no longer be detected. Even 12 weeks after 
the end of the ganciclovir treatment, mass growth could not be detected neither by MRI nor BLI, indicating 
that GCV concentrations in the brain were sufficiently high for efficient killing of the stem cells.  
When allowing masses to form, for 8 days prior to GCV administration cell viability decreased after GCV 
treatment as assessed by BLI. However, treatment did not result in complete removal of the tumor mass. 
This is possibly due to the fact that GCV does not reach all tumor cells in a larger mass after a single 
administration. Further studies concerning repeated GCV administration are required.  
Furthermore, animals injected with eGFP-fLuc expressing mOct4+ BM-HypoSCs, treated with GCV did not 
show a reduction in tumor growth or stem cell viability indicating that the cell death described here for GCV 
 Chapter 4:  
In vivo validation of cell lines for non-invasive imaging of suicide gene therapy  
87 
 
treated animals injected with eGFP-fLuc-HSV-tk positive mOct4+ BM-HypoSCs is due to expression of HSV-tk 
and not by cytotoxic effects of GCV alone. 
mMSC’s failed to survive for the duration of the treatment (two weeks) in the healthy brain whereas 
hMultistem’s did not seem to respond to GCV treatment in vivo. This however might be due to incomplete 
BBB disruption, which might cause suboptimal GCV concentrations in the healthy brain. Furthermore, in vitro 
data suggested that hMultistem’s might be slightly more resistant to GCV treatment compared to mOct4+ 
BM-HypoSCs. 
The mechanism of cell killing is still under investigation but the following hypothesis is generally accepted. 
When the substrate for the suicide gene, e.g. ganciclovir (GCV) / HSV-tk, is provided, GCV enters the cell and 
is converted by HSV-TK into GCV-monophosphate [82]. The HSV-tk displays a 1000 fold higher affinity for 
GCV than the mammalian thymidine kinase and therefore, limited side effects are expected. Subsequently, 
cellular kinases recognize the GCV-monophosphate and will create GCV-triphosphate, a highly toxic guanine 
nucleoside analogue which causes DNA chain termination and subsequent cell death, which can occur 
through both apoptotic and non-apoptotic mechanisms [160]. Due to the formation of gap junctions 
between adjacent cells, ganciclovir monophosphate can passively diffuse into neighboring cells. This 
phenomenon is also called the bystander killing effect and has already been used for stem cell mediated 
glioma therapy [82]. Furthermore, results from the suicide gene therapy field suggest that besides this 
bystander killing effect, a Th1 response might also be generated by necrotic cell death which releases 
immunostimulatory molecules [161-163]. Thus, a more efficient cell killing can be achieved. 
Furthermore, we would also like to point out that although selection of HSV-tk positive cells is very 
important in order to maximize the suicide gene therapy, non-transduced cells should also be killed as the 
bystander killing effect, which is well described for suicide gene therapy, also kills neighboring fast growing 
cells [84, 150-152]. These HSV-tk positive cells therefore have a dual potential purpose. They can be used as 
vehicles to deliver suicide gene therapy for anti-neoplastic therapy but the system can also be used as a 
‘safety switch’ in case of unwanted and uncontrolled growth of therapeutic cells opening the way for use of 
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stem cells with an unfavorable safety profile. For the latter application, further research regarding safety and 
applicability is however mandatory. 
Finally, also the mCherry-rLuc+ malignant glioma cells were evaluated in vivo. Although all cell lines 
generated a BLI signal in vitro, GL261 and Hs683 tumors could only be detected when tumors grew very 
large and even then, detection was not always straightforward. Therefore, ex vivo scans were performed 
which showed that both tumor cells still expressed the rLuc. In contrast, U87-MG tumors were already 
detectable at 1 week post injection by using BLI for rLuc.  
Several factors may be responsible for the unexpected GL261 and Hs683 results. First, rLuc emits light at 
480nm (blue light). At this wavelength, much more absorption occurs by the animals’ skin, skull, brain tissue 
and blood (albumin) compared to eGFP which emits at 560nm (green light). Therefore, less light is available 
for in vivo detection. Furthermore, in Hs683 tumors, BBB disruption is incomplete (see Chapter 5), which 
might cause insufficient high levels of Coelenterazin-h to enter the brain as it does not pass the BBB easily. 
GL261 tumors do however display a BBB integrity loss (Chapter 3), so it does not explain the discrepancy 
between the in vitro and in vivo data for this cell line. Another reason could be the presence of efflux pumps, 
which are present on tumor cells [164]. Also, the human glioma xenograft tumor models that we used are 
generated in Hsd:athymic Nude-Foxn1nu mice. These mice do not synthetize melanin, which also absorbs 
light. The GL261 model however has a syngeneic host, namely C57BL6/j mice, which do produce melanin 
that can therefore further absorb the signal coming from the brain. We would like to stress that it is possibly 
a combination of all these factors which results in the unexpected failure to detect GL261 and Hs683 tumor 
cells in vivo. 
As a final remark, we would like to point out that increasing the rLuc expression could possibly overcome the 
issues with the detection of these tumors. This is however not recommendable as both the GL261 and Hs683 
cell lines transduced with mCherry and rLuc already displayed a growth delay in vivo.  
 Chapter 4:  
In vivo validation of cell lines for non-invasive imaging of suicide gene therapy  
89 
 
In conclusion, we have shown that at least a fraction of the mOct4- BM-MAPCs remains in vivo without 
causing unwanted side-effects, even when followed for several weeks. This hypothesis is supported by BLI 
and histological findings where a small but apparent cell graft is still present.  
In contrast, mOct4+ BM-HypoSCs formed yolk sac tumors. Both stem cell types can however be selectively 
killed after suicide gene expression making them safer for in vivo applications. This approach can also be 
applied to other, very promising but tumor forming stem cells to augment their safety profile and increase 
their applicability in vivo. 
Furthermore, we have validated both tumor transduction and stem cell transduction and labeling in vivo. All 
stem cells were easily detectable by MRI and BLI (fLuc – D-luciferin) but not PET ([18F] FHBG) whereas for the 
tumor cells, only the U87-MG could be followed using BLI (rLuc – coelenterazin-h) for the hU87-MG from 
week 1 post injection. 
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Chapter 5: Malignant glioma model development 
This chapter has been compiled based on the following publication:  
Leten, C., et al., In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma 
animal models. J Neurooncol, 2014. 
5.1 Introduction 
One of the characteristics of high grade gliomas is angiogenesis as tumors rely on both co-option of existing 
blood vessels and neovascularization to meet their oxygen and nutrient requirements [165]. Only specific, 
carrier mediated transport is possible in the normal brain. Under pathological conditions, both transcellular 
and paracellular transport increase, thus allowing passage of substances into the brain that normally do not 
cross an intact blood brain barrier (BBB) [166, 167].  
In humans, neovascularization is correlated with tumor grade and malignancy. Therefore, T1 weighted (T1W) 
magnetic resonance imaging (MRI) after injection of contrast agents like gadolinium chelates, such as 
Dotarem® (MW 562Da) is performed on a regular basis to assess the BBB integrity and diagnose high-grade 
gliomas [168]. Accumulation of these chelates in the brain indicates loss of BBB integrity as they normally do 
not cross the BBB. Contrast enhanced MRI (CE-MRI) has mostly replaced CT for non-invasive BBB integrity 
assessment as MRI shows higher soft tissue contrast compared to CT [169, 170]. 
In a preclinical setting, several low and high molecular weight vascular permeability markers are available to 
assess the BBB integrity [167]. Both radiolabeled markers including alpha-aminoisobutyric acid, sucrose and 
inulin [171, 172] and non-radioactive low molecular markers such as sodium fluorescein were developed for 
ex vivo assessment of the BBB integrity. Radiolabeled markers can be used for PET/SPECT imaging. 
Furthermore, high molecular weight markers were developed including horseradish peroxidase, dextran and 
Evans blue [167]. The non-toxic Evans blue (MW 961) binds to albumin (Evans blue-Albumin: MW 69kDa) 
directly after intravenous injection and is therefore contained to the blood stream. When sites of BBB 
disruption are present, Evans blue crosses the BBB, thus resulting in site-specific accumulation [167]. 
Unfortunately, to assess the BBB disruption with such low or high molecular weight dyes, animals need to be 
sacrificed and brain sections analyzed, which is labor intensive and requires large number of animals as 
longitudinal studies on individual animals are impossible. In addition to histological methods, non-invasive 
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CE-MR imaging protocols using injection of gadolinium chelates, similar to the protocols used in humans 
have been developed for dedicated small animal MR imaging [35, 168, 173] hereby, facilitating longitudinal 
studies on a small number of animals. 
The loss of the BBB integrity is both in humans and experimental glioma models one of the characteristics 
used to assess and follow-up therapeutic response of glioblastoma. Furthermore, the effectiveness of some 
experimental treatments, such as systemic delivery of cells [174, 175] or administration of large or 
hydrophilic compounds [176] usually depends on the disruption of the BBB. It is therefore crucial to 
characterize the vascular integrity of tumor models very carefully before assessing novel treatment 
approaches. 
In this study we compared two brain tumor models for the disruption of the BBB. The most frequently used 
glioblastoma mouse model is the GL261 model, which has been well described [155] with a documented BBB 
disruption [35]. Furthermore, two human malignant glioma xenograft models, namely the Hs683 
oligodendroglioma model [136] and the U87-MG glioblastoma were selected to validate to what extent they 
meet the hallmarks of glioblastoma models like the disruption of the BBB integrity and for in vivo 
characterization.  
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5.2 Materials and methods 
Cell lines 
The GL261 cell line, a mouse glioblastoma model, was obtained from Dr S. Van Gool, University of Leuven, Belgium and 
cultured as described previously [106]. The Hs683 cell line, derived from a human oligodendroglioma, was obtained 
from Dr R. Kiss, University of Bruxelles, Belgium and cultured as described previously [136]. U87-MG cells were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to the 
manufacturer’s instructions. 
Stereotactical injections 
All animal experiments were conducted according to the European Union Community Council guidelines and were 
approved by the local ethics committee of KU Leuven. Animals were anaesthetized by an i.p. injection of a Ketamine 
(Ceva, Pompidou, France, 4.5mg/kg)/medetomidin (Domitor®, Pfizer, New York, USA, 0.6 mg/kg) mixture. Local 
analgesia (2% xylocain, AstraZeneca, Londen, UK) and antibiotics (6mg/mouse, Ampiveto-20 (200 mg/ml), VMD, New 
Haw, Surrey, UK) were administered prior to surgery. After fixation of the animals in a stereotactic frame adapted with 
a Quintessential stereotaxic injector (both from Stoelting, Wood Dale USA), cells were injected (speed: 0.5 µl/min) into 
the right striatum of C57Bl6/j mice at the following coordinates: 0.5 mm anterior and 2.0 mm lateral to bregma and 3.0 
mm from the dura using a 10 µl Hamilton syringe, equipped with a 22 G needle. 2.5x10
5
 GL261 cells, 5 x 10
4
 Hs683 cells 
or 3 x 10
5
 U87-MG cells were injected in C57Bl6/j or Hsd:athymic Nude-Foxn1
nu
 mice (Harlan Laboratories, Indianapolis, 
Indiana, USA) respectively.  
Imaging: 
Magnetic resonance imaging (MRI) 
All MR images were acquired with a 9.4T Biospec small animal MR scanner (Bruker Biospin, Ettlingen, Germany) 
equipped with a horizontal bore magnet and an actively shielded gradient set of 600mT m
-1
 (117 mm inner diameter) 
using a 7cm linearly polarized resonator for transmission and an actively decoupled dedicated mouse surface coil for 
receiving (Rapid Biomedical, Rimpar, Germany). MRI was performed once per week to follow-up tumor growth and BBB 
integrity. Prior to scanning, mice were anaesthetized with 2% isoflurane for induction and 1.5% isoflurane for 
maintenance, respectively. Temperature and respiration were monitored throughout the experiment and maintained 
at 37°C and 100-120 breaths min
-1
. T2 weighted MRI scans (RARE sequence, TR:3000 ms; TE:50.2 ms, RARE factor: 9, 
matrix size 256 x 256, FOV: 2 x 2 cm, number of continuous slices:16, slice orientation: coronal, in plane resolution: 78 
µm
2
) were used to monitor tumor growth. The area of the tumor was determined by outlining it manually on all slices 
of the T2 weighted MR images with coronal orientation using the 5.1 Paravision software (Bruker, Biospin). The sum of 
the cross sectional discs was used to determine total tumor volume. To validate the integrity of the blood brain barrier, 
pre- and post-contrast (gadolinium (Dotarem®, Guerbet, Villepinte, France, dosage: 100µl / mouse of 0.05 mmol/ml, 
i.v.) T1 weighted MR images were acquired (RARE sequence, RARE factor: 4, TR: 819ms, TE: 7.6ms, matrix size: 256 x 
256, FOV: 2 x 2 cm, number of slices: 20, slice thickness, 0.5mm, orientation: axial, in plane resolution: 78 µm
2
). The 
relative signal intensity of the tumor region showing the strongest contrast enhancement (relative to surrounding brain 
tissue) was determined by placing a region of interest (ROI) over the area using the Paravision 5.1 software. To avoid 
influences from strong tumor heterogeneity (necrosis), we only analyzed tumor regions with strong contrast 
enhancements by manual delineation. For statistical analysis of the BBB integrity, pre-contrast scans were subtracted 
from post-contrast scans after which the procentual increase following gadolinium injection was calculated for the 
contralateral hemisphere (negative control set to 100%), tumor tissue and extracranial muscle tissue (positive control) 
for each animal. Significant differences were determined by ANOVA testing (GraphPad PRISM, GraphPad Software, La 
Jolla, CA, USA) with p<0.05. 
Evans Blue Staining 
A phototrombotic stroke was induced as described previously [177] as a positive control for Evans blue uptake and the 
disruption of the BBB. In short, the animal was sedated with isoflurane (2% induction-1.5%maintenance). After 
exposing the skull, the photosensitizer rose bengal (20 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) was injected 
intravenously followed by photo-illumination of the right motor cortex with green light (wave length, 540 nm; 
bandwidth 80nm) from a xenon light (model L-4887; Hamamatsu Photonics, Hamamatsu City, Japan) for 20 min with an 
irradiation intensity of 0.68 W/cm
2
. Focal activation of the photosensitive dye results in local endothelial cell injury 
leading to microvascular thrombosis and circumscribed cortical infarctions. Afterwards, the mouse was allowed to 
recover. Within 24 hours, Evans blue (4µl / g of body weight of a 2% Evans blue solution [167]) was administered i.v. 
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and the mouse was perfused approximately 25 minutes post injection. At several time points, one animal from the 
GL261 tumor bearing group (week 2 and 4) and one animal from the Hs683 tumor bearing group (week 2, 4 and 5) was 
sacrificed similarly. 
Endpoints 
Animals were sacrificed when symptoms reached grade 3 out of 4 (grade 0 for healthy mice, grade 1 for slight unilateral 
paralysis, grade 2 for moderate unilateral paralysis and/or beginning hunchback, grade 3 for severe unilateral or 
bilateral paralysis and pronounced hunchback, and grade 4 for moribund mice) [66]. 
Histology 
Animals were sacrificed by an overdose of Nembutal (250µl, i.p., Ceva, Libourne, France) and subsequently perfused 
with 4% ice-cold paraformaldehyde (PFA) solution (Sigma-Aldrich). After overnight post-fixation in 4% PFA, the brain 
tissue was kept in a 0.1% sodium azide solution (Fluka, Sigma-Aldrich, Belgium) at 4°C. Paraffin sections (5µm thickness) 
were sliced and a Masson’s trichrome staining and a GFAP staining were performed. In short, for the Masson’s staining, 
sections were deparaffinized and rehydrated prior to hematoxylin, ponceau / fuchsine and aniline blue staining after 
which they were dehydrated and mounted with DPX (Sigma-Aldrich). For the GFAP staining, which was kindly provided 
by Professor Verfaillie from the Stem cell Institute, KU Leuven, sections were also deparaffinized and rehydrated prior 
to staining. Subsequently, antigen retrieval was performed and sections were incubated overnight at 4°C with the 
primary polyclonal rabbit anti-glial fibrillary acidic protein (GFAP) antibody (1/250, Dako – Z0334), followed by staining 
with the secondary Alexa Fluor® 488 goat anti-rabbit IgG antibody (1/500, Invitrogen, A11034) for 30 min at room 
temperature and Hoechst (1/1000, Sigma-Aldrich, 33258) after which they were also dehydrated and mounted with 
Prolong ® Gold antifade reagent(Invitrogen, P36930). 
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5.3 Results 
5.3.1 Mouse glioblastoma model (GL261) 
Injection of 2.5 x 105 GL261 cells in the striatum of C57BL6/J mice resulted in tumors with an average size of 
76 ± 14 mm3 at 5 weeks post injection Figure 29A. MR images of a representative GL261 tumor bearing 
animal are shown in Figure 29B. Weekly MRI sessions showed an increased BBB disruption over time (Figure 
29C, D), starting already from week 2 post glioma injection. The relative signal intensity increased over time 
indicating progressing BBB disruption with tumor growth.  
Figure 29: BBB integrity assessment by contrast enhancement in T1W MRI for GL261 tumors.  
A. Tumors grow gradually over time until they reach an average size of 76 ± 14 mm
3 
at 5 weeks post injection  
(N = 12). 
B. Example of tumor growth in a representative animal (T2W MR image, coronal orientation).  
C. Intravenous injections of gadolinium showed a loss of BBB integrity, which deteriorates over time (N = 11). 
D.  Example of contrast enhancement on T1W MR images in the same animal mentioned in C over time. 
   * p<0.05, ** p<0.01, ***p<0.001, **** p<0.0001 
 
Furthermore, histological analysis (Figure 30) was performed to evaluate the characteristics of the 
developing tumor more elaborately. Masson’s trichrome staining revealed tumor infiltration of small tumors 
into the normal brain parenchyma (Figure 30A) whereas this was less apparent in larger tumors. Also nuclear 
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atypia (Figure 30B1), mitosis (Figure 30B2) and the presence of extensive vascularization (Figure 30B3), all 
characteristics of glioblastoma were detected. Furthermore, histology showed both necrosis and apoptosis 
as tumors grew larger (Figure 30C), which correlated with non-enhancing regions on MRI after gadolinium 
injection (Figure 30D). Also a midline shift caused by the aggressive growth of the tumor was observed both 
on MRI and histology. Finally, GFAP staining proved negative (Figure 30E). 
Figure 30: Histological analysis of the GL261 tumors.  
A. Infiltration of the tumor cells into normal brain parenchyma was observed mainly for smaller tumors, whereas 
this was less apparent in larger tumors. 
B. Several typical characteristics of glioblastoma were detected, such as nuclear atypia (1), mitosis (2) and the 
presence of extensive vascularization (3). 
C. In very large tumors, necrosis (1) and apoptosis (2) became apparent in the centre of the tumors. 
D. Central necrosis correlated with non-enhancing regions on MRI after gadolinium injections. Both on MRI and 
histology, a midline shift became apparent as tumors grew larger. 
E. GFAP staining showed that the tumor is negative for the glial fibrillary acidic protein as no GFAP staining 
(green) could be detected in the tumor whereas it was stained with Hoechst (blue). 
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Subsequently, one animal was sacrificed on week 2 and 4 post tumor cell injection after Evans blue injection 
to confirm loss of BBB integrity (Figure 31). Infiltration of the Evans blue solution into the tumor confirmed 
the BBB disruption observed on MR images as early as week 2 post glioma initiation. 
Figure 31: BBB integrity assessment using Evans blue staining.  
A. Contrast enhancement in T1w MRI before and after gadolinium injection showed a loss of the BBB integrity. 
B. Sliced brains of Evans blue perfused animals confirmed BBB disruption on both week 2 and week 4 post tumor 
cell injection. A phototrombotic stroked animal was used as a positive control for BBB disruption. 
 
5.3.2 Human malignant glioma xenograft models 
5.3.2.1 Human glioma xenograft (oligodendroglioma) model (Hs683) 
Injection of 5 x 104 Hs683 cells in the striatum of Hsd:athymic Nude-Foxn1nu mice resulted in tumor 
formation with an average tumor volume of 244 ± 0.3 mm3 at 8 weeks post injection (Figure 32A) with 
animals developing symptoms between week 6 and 8. MR images of a representative Hs683 tumor bearing 
animal are shown in Figure 32B. T1 weighted MR imaging following i.v. injection of gadolinium showed loss 
of the BBB integrity compared to the contralateral hemisphere (Figure 32C), However, the relative changes 
in signal intensity compared to the contralateral hemisphere and extracranial muscle tissue were much 
smaller than those observed for the GL261 tumors.  
In contrast to the GL261 glioblastoma model, extensive heterogeneity was evident on T1 weighted post-
contrast MR images in large Hs683 model (Figure 32D), which was confirmed by T2 weighted MR images 
(Figure 33A) and histological analysis (Figure 33B and C) of Hs683 tumors. Masson’s trichrome staining of 
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paraffin embedded brains revealed large fluid filled cysts but no regions of pronounced necrosis or 
apoptosis. Many of the large fluid filled cysts also contained blood. Finally, GFAP staining was also negative 
for Hs683 tumors (Figure 33D). 
Figure 32: BBB integrity assessment by MRI for the Hs683 tumor model.  
A. Tumors grew gradually over time until they reached an average size of 244 ± 0.3 mm
3
 at 8 weeks post injection 
(N = 22). 
B. Example of Hs683 tumor growth in a representative animal (T2W MR images, coronal orientation).  
C. Intravenous injections of gadolinium showed a loss of BBB integrity starting from week 2 post tumor initiation 
(N = 22). 
D. Intratumoral heterogeneity of the integrity of the BBB causes differences in maximal signal intensity on later 
time points. Areas with high (red arrows) and low signal intensities can be seen within a single tumor. 
   * p<0.05, ** p<0.01, ***p<0.001, **** p<0.0001 
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Figure 33: Histological analysis of the human glioma xenograft (oligodendroglioma - Hs683) model.  
A. T2W MR images (coronal orientation) of Hs683 tumor bearing animals at week 6 post tumor initiation. 
B. Corresponding 5 µm thick paraffin embedded brain sections stained with a Masson’s trichrome staining 
showed large fluid filled cyst formation and blood vessels which corresponded to respectively hyper-and 
hypointense areas on T2W MR images shown in A. 
C. Examination of the tumors did not show pronounced necrosis/apoptosis (10x). 
D. GFAP staining was negative for Hs683 tumors (5x). (Hoechst = blue) 
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Subsequently, animals was sacrificed following Evans blue injections on weeks 2, 4 and 5 post tumor 
initiation to confirm the observations made by T1 weighted post-contrast MR images (Figure 34). Loss of BBB 
integrity in the Hs683 model could however not be shown at any of the mentioned time points by Evans 
blue, which is in line with the relatively small changes in the T1 weighted post-contrast MR images. 
Figure 34: Assessment of the BBB integrity using Evans blue staining in the Hs683 tumor model.  
A. Contrast enhancement on T1W MRI before and after gadolinium injection showed BBB disruption.. 
B. Sliced brains of animals receiving Evans blue prior to perfusion did not show BBB integrity loss for any of the 
animals on weeks 2, 3, 4 or 5 post tumor cell injection. 
A phototrombotic stroked animal was used as a positive control for BBB disruption. 
              
5.3.2 Human glioma xenograft (glioblastoma) model (U87-MG) 
The second human malignant glioma model that was selected was the U87-MG cell line which is classified as 
a human glioblastoma by the supplier. Injection of 3 x 105 U87-MG cells in the striatum of Hsd:athymic Nude-
Foxn1nu mice resulted in tumors with an average size of 65 ± 10 mm3 at 4 weeks post injection (Figure 35A) 
with animals developing symptoms at a very late stage. T1 weighted MR imaging following i.v. dotarem 
injections showed BBB integrity loss (Figure 35B). T2 weighted anatomical MR images of a representative 
U87-MG tumor bearing animal are shown in Figure 35C. These tumors seemed rather homogeneous on 
anatomical scans, which was confirmed by T1 weighted pre- and post-contrast MR images (Figure 35D) 
showing a homogenous BBB integrity loss.  
Histological analysis (Figure 36) was performed which confirmed the results obtained by MRI. A general 
overview showed a homogeneous tumor environment with some bleedings at the tumor border (Figure 
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36A). Further analysis revealed several characteristics of glioblastoma including mitosis and nuclear atypia 
(Figure 36B: 1, 2). Also striking in this tumor model was the presence of connective tissue in the tumor 
region which was predominantly present in the central part of the tumor but not so much in the tumor 
border (Figure 36C: 3). Finally, microbleedings were also apparent on histological sections (Figure 36C: 4). 
Figure 35: Human glioma xenograft (glioblastoma - U87-MG) model characterization.  
A. Tumors grew gradually over time until they reached an average size of 65 ± 10 mm
3
 at 4 weeks post tumor cell 
injection (N = 3). 
B. Example of U87-MG tumor growth in a representative animal (T2 weighted MR images, coronal orientation)  
C. Intravenous injections of gadolinium showed a loss of the BBB integrity starting from week 2 post tumor 
initiation (N = 3). 
D. Contrast enhancement on T1 weighted post-contrast MR images showed a rather homogeneous tumor 
environment. 
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Figure 36: Histological analysis of the human glioma xenograft (glioblastoma - U87-MG) model.  
A. General overview of a paraffin section stained using a Masson’s trichrome staining from the brain of a 
representative U87-MG tumor bearing animal, sacrificed at week 4 post injection when symptoms became 
apparent. Tumors appeared rather homogenous which corresponded with the obtained MR images. 
B. Analysis of the tumors revealed glioblastoma characteristics such as mitosis (1) and nuclear atypia (2). 
Furthermore, the presence of connective tissue was observed (blue lines). (40x) 
C. The connective tissue seemed to be mainly present in the tumor bulk (3) but not so much in the tumor border. 
(10x). Microbleedings (4) were observed both in the tumor itself and at the tumor border (10x). 
1
1
2
3
4
A. B. C.
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5.4 Discussion 
In this study, the BBB integrity was assessed in one mouse glioblastoma model (GL261) and two high grade 
human glioma xenograft mouse models (Hs683 and U87-MG). One of the hallmarks of high grade gliomas is 
neovascularization [178], characterized by severe leakiness [179], which is correlated with tumor grade and 
malignancy [168]. Furthermore, some experimental brain tumor treatments, using for instance systemically 
injected stem cells [174, 175] or administration of large or hydrophilic therapeutic molecules [176], could be 
hampered by incomplete BBB disruption, which might decrease treatment efficacy. It is therefore crucial to 
characterize tumors models very carefully before considering the assessment of possible treatment regimes.  
Here, we compared the assessment of the BBB disruption by using CE-T1W MRI and the high molecular 
weight marker, Evans blue. While CE-T1W MRI is common practice in the clinic, we have used MRI and Evans 
blue staining for the comparison of a frequently used experimental model (GL261) with the less frequently 
used, human glioma xenograft models (Hs683, hU87).  
One of the most used glioblastoma models in preclinical research is the GL261 model as it is a syngeneic and 
well characterized model with a very reproducible growth. In this model, BBB disruption was shown as soon 
as 2 weeks post tumor cell injection (2.5 x 105). Hereby, we confirmed the results obtained previously by Cha 
et al [35] and proved that the applied methodology can be used to assess BBB disruption. Furthermore, we 
showed infiltration, mitosis, nuclear atypia and the presence of blood vessels in these tumors. Extensive 
central necrosis was however only observed in the GL261 model but not the U87-MG nor the Hs683 model. 
Also a midline shift due to the aggressive growth of the tumor, causing elevated intracerebral pressure, was 
apparent both on MRI and histological analysis. GFAP staining was negative, which is consistent with 
previously published reports [155]. 
Translation of the results obtained in preclinical animal research is however not straight forward [70]. We 
have used human glioma xenograft animal models, (transplantation of human tumor cells (Hs683) in an 
immune-suppressed animal), which is less extensively characterized.  
The BBB integrity of the GL261 model was compared with the Hs683 model. These tumors grew very large 
before resulting in grade 3 symptoms. Furthermore, large fluid filled cysts appeared both on MRI and BLI. 
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These tumors were also GFAP negative which is consistent with previous reports from Belot et al, who 
observed very low levels of GFAP mRNA [180]. Lamoral-Theys et al proposed that this oligodendroglioma 
model could represent a glioblastoma with an oligodendroglial origin [181].To our knowledge there are 
however no reports on the BBB status in this model. CE-T1W MRI showed a heterogeneous contrast 
enhancement of lower relative signal intensity changes in the tumor region when compared to the GL261 
model. In contrast, Evans blue did not give evidence for BBB disruption at any time point. Although loss of 
BBB integrity is a general characteristic of glioblastoma, little is known about the actual mechanisms 
involved in the BBB disruption. One hypothesis is however that increased MMP3 activity, followed by agrin 
degradation results in loss of astrocyte polarity causing BBB integrity loss [182]. BBB disruption on MRI but 
not after Evans blue injection could be explained by an incomplete BBB disruption as gadolinium chelates 
(Dotarem®) and Evans blue bound to albumin have different molecular weights of 562 Da and 69 kDa, 
respectively. If the BBB is not fully disrupted, larger molecules would have more difficulty passing the BBB, 
which would explain the negative Evans blue staining.  
These results might aid researchers to assess mechanisms of novel therapeutic approaches where the 
breakdown of the BBB might be of importance. For example, Mathieu et al. studied the combination of 
chemotherapeutics (Temozolomide) and anti-angiogenic compounds (Bevacuzimab) where Temozolomide is 
able to cross the BBB (MW Temozolomide:149 Da, MW Dotarem: 562Da) but Bevacuzimab would not be 
able to cross the BBB (MW Bevacuzimab: 149 kDa, MW albumin-bound Evans blue: 69 kDa) but may still 
exert its anti-angiogenic effect from within the tumor vessels [183]. In conclusion, the Hs683 model should 
be used with caution when using therapeutic products that normally do not pass the BBB easily.  
The third model that was characterized was the U87-MG model. MRI showed a homogenous loss of BBB 
integrity as early as one week post injection which remained present until grade 3 symptoms occurred. 
Further histological analysis confirmed the homogenous nature of these tumors and several glioblastoma 
characteristics such as mitosis, nuclear atypia and the presence of blood vessels were observed. The 
formation of connective tissue in the U87-MG tumors was also very striking on Masson’s trichrome staining.  
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Finally, a difference in heterogeneity of the BBB disruption was observed by CE-T1W MR imaging of these 
glioblastoma models. Glioblastomas are known for their inter- and intratumoral heterogeneous nature [184, 
185], which logically results in regional differences in contrast enhancement. Therefore, we have analyzed 
only enhancing regions for our semi-quantitative assessment of the BBB disruption, which are also the 
regions selected in the clinic for histopathological evaluation [186]. The GL261 and U87-MG tumors 
appeared relatively homogenous on CE-T1W MR imaging, even as tumors grew very large. Only very few 
regions did not enhance on T1W MRI, representing necrotic regions, which was also confirmed on 
histological sections. The Hs683 tumors became however increasingly heterogeneous over time, with the 
presence of very large fluid filled cysts and microbleedings shown both on T2 weighted images and 
histological sections, which also explains their heterogeneous contrast enhancement on CE-T1W MR images.  
Recently, macromolecular Gadolinium-chelates, such as albumin bound chelates, have been investigated as 
contrast agents for BBB disruption [187]. Although promising results have been reported, further feasibility 
studies are required as preliminart results show that longer delay times of up to 4 hours are required prior to 
imaging for obtaining reliable results [187].  
In conclusion, in this study the BBB integrity was assessed by means of CE-T1W MR imaging and Evans blue 
assessment. The BBB integrity data from both methods was concurrent for the GL261 glioblastoma model, 
clearly indicating BBB integrity loss as soon as 2 weeks post tumor cell injection. In contrast, the data 
obtained for the Hs683 oligodendroglioma model showed a limited BBB disruption based on the high 
molecular weight Evans blue staining and a reduced uptake of low molecular weight gadolinium chelates as 
indicated by CE-T1W MRI. These results clearly indicate the importance of checking the BBB integrity status 
using different methods. This is in particular of importance for the assessment of therapeutic molecules and 
the selection of appropriate animal models. Care should be taken with the appropriate assessment of the 
BBB disruption prior to commencing therapeutic investigations. 
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Chapter 6:  
Multi-modal imaging of the bystander killing effect in malignant brain tumors 
This chapter has been compiled based on the following publication:  
Leten C., et al., Assessment of bystander killing mediated therapy of malignant brain tumors using a multi- 
  modal imaging approach. (Submitted to Stem cell research & therapy) 
6.1 Introduction 
Gliomas arise from glial cells (astrocytes, oligodendrogial and ependymal cells) and are the most common 
brain tumors in humans. They comprise a broad range of lesions with distinct differences in malignancy, 
which is classified according to the World Health Organization [5]. Glioblastoma multiforme (GBM) is the 
most malignant tumor (WHO grade IV) in the spectrum of brain tumors [1]. The prognosis of patients 
diagnosed with GBM is still extremely poor with a 5-year survival of less than 3% of patients despite 
multimodal treatment approaches consisting of surgery and concomitant radio- and chemotherapy [188]. 
Therefore, new treatment modalities are under investigation, among which therapy based on the bystander 
killing effect following suicide gene therapy [84, 150-152]. 
Previously, several clinical trials have attempted to treat glioblastoma patients using viral vectors encoding 
for HSV-TK to directly introduce the suicide gene within the tumor cells, with usually poor results [70]. This is 
generally believed to be caused by insufficient distribution of the viral vectors throughout the tumor [189]. 
Therefore, attention turned to carriers such as bacteria [71, 190] and tumor tracking stem cells [191] to 
enhance delivery of the suicide gene. Stem cells that are capable of forming gap junctions with infiltrating 
tumor cells will allow transfer of the GCV-phosphate into neighboring cells, which results in bystander 
mediated tumor cell killing [192, 193]. This approach can in theory eliminate both the primary tumor and the 
infiltrating tumor cells, thus eliminating sources of possible recurrent tumors [82]. 
The feasibility of this strategy was demonstrated by several groups in both xenograft and syngeneic animal 
models [82, 84, 93, 151, 174, 194]. Miletic et al. [82, 152] and Matuskova et al. [85] demonstrated a potent 
bystander killing effect of HSV-TK expressing rat bone marrow-derived tumor-infiltrating progenitor cells on 
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9L rat gliomas and human mesenchymal stem cells (hMSC’s) on the human glioblastoma cell lines 8-MG-BA, 
42-MG-BA and U-118 MG respectively.  
In previous reports, different imaging modalities have been used mainly for the assessment of the treatment 
rather than for guidance of the therapy [194]. In a clinical setting, patients are routinely followed up by non-
invasive imaging such as magnetic resonance imaging (MRI) and positron emission tomography (PET) [195, 
196]. In a preclinical setting, these non-invasive imaging techniques are also available and should therefore, 
when possible, also be used to guide therapy and evaluate treatment response. Furthermore, additional 
preclinical imaging modalities such as bioluminescence imaging (BLI) are available to further optimize the 
acquired information prior to treatment initiation and follow-up of therapeutic efficacy [197]. In addition, 
molecular imaging methods could also be used to monitor the location of therapeutic cells [198]. 
In this chapter, the therapeutic potential of these mOct4- BM-MAPCs was assessed in a mouse glioma model 
and in particular, the guidance of this therapy by In vivo multi-modal imaging methods (MRI, BLI and PET) for 
optimization of the therapeutic response and for identification of therapeutic windows. In short, therapeutic 
eGFP, fLuc and HSV-tk expressing mMSC’s, mOct4+ BM-HypoSCs and mOct4- BM-MAPCs were assessed in 
GL261 tumor bearing C57BL6/j mice while therapeutic hMultistem’s were assessed in human malignant 
glioma xenograft models (Hs683/U87-MG) for cell tracking properties and their tumor killing capabilities.  
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6.2 Materials and Methods 
Cell culture 
All cell lines (mMSC’s, mOct4
-
 BM-MAPCs and mOct4
+
 BM-HypoSCs, GL261, U87-MG, Hs683) were cultured as described 
previously (Chapter 3). 
Stereotactical tumor and/or stem cell injections 
All animal experiments were conducted according to the European Union Community Council guidelines and were 
approved by the local ethics committee of the KU Leuven. Before surgery, animals were anaesthetized by an i.p. 
injection with a mixture of ketamine (Ketamine1000, 4.5mg/kg, Ceva, Pompidou, France)/medetomidin (0.6 mg/kg, 
Domitor®, Pfizer, New York, USA). Local analgesia (2% xylocain, AstraZeneca, London, UK) and antibiotics (6mg/mouse, 
Ampiveto-20, 200mg/ml, VMD, New Haw, Surrey, UK) were administered prior to surgery. After fixation of the animals 
in a stereotactic frame adapted with a stereotaxic injector (both from Stoelting, Wood Dale USA), cells were suspended 
in 5µl PBS and injected (0.5 µl/min) with a 10 µl Hamilton syringe, equipped with a 22 G needle, into the right striatum 
of C57Bl6/j mice at the following coordinates 0.5 mm anterior and 2.0 mm lateral to bregma at 3.0 mm from the dura.  
Glioblastoma mouse model (GL261): Suicide gene therapy 
2.5 x10
5
 GL261 were stereotactically injected in the striatum of C57BL6/j mice and allowed to grow for two weeks prior 
to intratumoral stereotactical injection of 5 x 10
5
 labeled and transduced mOct4
-
 BM-MAPCs. [155] All animals received 
tumor induction followed by the generation of three treatment groups two weeks after tumor cell injection. As such, 
SHAM operated animals, which received a PBS injection, PBS treated animals which received 5 x 10
5 
mOct4
-
 BM-MAPCs 
and that were treated with PBS and GCV treated animals, which also received 5 x 10
5
mOct4
-
 BM-MAPCs but were 
treated with GCV, were distinguished. To reduce the blooming effect and the possible negative effects on stem cell 
behavior, only a limited % of cells were labeled prior to injection. (mMSC’s and mOct4
+
 BM-HypoSCs: 1%, mOct4
-
 BM-
MAPCs: 1 or 10%). Imaging was performed prior to (MRI) and following (MRI/BLI) stem cell injection (1 day and 5 days 
post stem cell injection for mMSC’s and mOct4
+
 BM-HypoSCs and 1 day after stem cell injection for mOct4
-
 BM-MAPCs) 
and after which GCV (50mg/kg) or PBS was administered for 14 consecutive days. At the end of treatment both MRI 
and BLI were performed to assess tumor response and mOct4
-
 BM-MAPC viability. Responding animals were defined as 
animals with tumors smaller than 5 mm
3
 at the end of GCV treatment. Some animals were followed up after the end of 
treatment for progression free survival analysis. 
Human glioma xenograft models (Hs683-U87-MG): Suicide gene therapy 
3 x 10
5
 U87-MG or 5 x 10
4
 Hs683 cells were stereotactically injected in the striatum of Hsd:athymic Nude-Foxn1
nu
 mice 
and allowed to grow for one (U87-MG) or two (Hs683) weeks prior to intratumoral stereotactical injection of 5 x 10
5
 
labeled and transduced hMultistem’s. All animals received tumor induction followed by the generation of three 
treatment groups at the time of stem cell injection. As such, SHAM operated animals, which received a PBS injection, 
PBS treated animals which received 5 x 10
5 
hMultistems and that were treated with PBS and GCV treated animals, 
which also received 5 x 10
5 
hMultistems but were treated with GCV, were distinguished. To reduce the blooming effect 
and the possible negative effects on stem cell behavior, only 1% labeled hMultistems were injected. Imaging was 
performed prior to (MRI) and following (MRI/BLI) hMultistem injection after which GCV (50mg/kg) or PBS was 
administered for 14 consecutive days. At the end of treatment both MRI and BLI were performed to assess tumor 
response and hMultistem viability. Responding animals were defined as animals with tumors smaller than 5 mm
3
 at the 
end of GCV treatment. For GL261 bearing animals treated with mOct4
-
 BM-MAPCs, some animals were followed up 
after the end of treatment for a progression free survival analysis. Two GCV treated animals were followed for 184 days 
without tumor regrowth after which, animals were sacrificed. A progression free survival curve analysis was performed 
using GraphPad PRISM (GraphPad Software PRISM, La Jolla, CA, USA). 
Imaging: 
Magnetic resonance imaging (MRI): Suicide gene therapy 
All MR images were acquired with a 9.4 T Biospec small animal MR scanner (Bruker Biospin, Ettlingen, GE) equipped 
with a horizontal bore magnet and an actively shielded gradient set of 600mT m
-1
 (117 mm inner diameter) using a 7cm 
linearly polarized resonator or a quatrature decoupled resonator for transmission and an actively decoupled 
dedicated mouse surface coil for receiving (Rapid Biomedical, Rimpar, Germany).  
For the GL261 model, MRI was performed after GL261 tumor induction, prior (=d14 post glioma injection) and following 
stem cell injection but before treatment initiation (=d16 post glioma injection) and at the end of the treatment (=d30 
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post glioma injection), whereas for the human glioma xenograft models MRI was performed before (d15/d7 post tumor 
injection) and after (d17/d9 post tumor injection) stem cell injection but before treatment initiation and at the end of 
treatment (d31/d24 post tumor injection) for Hs683/hU87 respectively. Mice were anaesthetized with 2% isoflurane in 
oxygen for induction prior to scanning and 1.5% isoflurane in oxygen for maintenance. Temperature and respiration 
were monitored throughout the experiment and maintained at 37°C and 100-120 breaths / minute. For in vivo tracking 
of the SMG
2
-mPEGSi labeled mOct4
-
 BM-MAPCs 3D T2*weighted MR images were acquired (parameters: 3D FLASH 
sequence, TR= 100ms, TE= 12 ms, flip angle= 20°, isotropic resolution: 78 µm3, field of view: 2.0 x 1.5 x 0.75 cm) and 
analyzed with the Image J software using a semi-automated method (National Institute of Health, Bethesda, Maryland, 
USA) to calculate the hypointense pixel volume. Furthermore, 2D T2 weighted axial (parameters: RARE sequence, 
TR=3157.6  ms, TE=48.8 ms, matrix size= 256 x 256, FOV= 2.5 x 2.5 cm, in plane resolution= 78 µm2, number of slices= 
24, slice thickness= 0.5 mm) and coronal MRI scans (parameters: RARE sequence, TR=3000 ms, TE=50.2 ms, matrix 
size=256 x 256, FOV= 2.5 x 2.5 cm, number of slices= 16, slice thickness= 0.5 mm, in plane resolution: 78 µm
2
) were 
acquired to follow-up the tumor size. The area of the lesion was determined by outlining it manually on all slices using 
the 5.1 Paravision software (Bruker, Biospin). The sum of the cross sectional area was used to determine the total 
tumor size. An ANOVA test (GraphPad PRISM, GraphPad Software, La Jolla, CA, USA) was used to determine significant 
differences with p < 0.05. To validate the integrity of the blood brain barrier, pre- and post-contrast (gadolinium 
(Dotarem®) (100µl / mouse of 0.05 mmol/ml, i.v.), Guerbet, Villepinte, France) T1 weighted MR images were acquired 
(RARE sequence, TR: 819ms, TE: 7.6ms, matrix size: 256 x 256, FOV: 2 x 2 cm, number of slices: 20, in plane resolution: 
78µm
2
). The relative signal intensity of the tumor region showing the strongest contrast enhancement (relative to 
surrounding brain tissue) was determined by placing a region of interest (ROI) over the area using the Paravision 5.1 
software. To avoid influences from strong tumor heterogeneity (necrosis), we only analyzed tumor regions with strong 
contrast enhancements by manual delineation. For statistical analysis of the BBB integrity, pre-contrast scans were 
subtracted from post-contrast scans after which the procentual increase following gadolinium injection was calculated 
for the contralateral hemisphere (negative control set to 100%), tumor tissue and extracranial muscle tissue (positive 
control) for each animal. Significant differences were determined by ANOVA testing (GraphPad PRISM, GraphPad 
Software, La Jolla, CA, USA) with p<0.05. 
Bioluminescence imaging (BLI) 
Mice were anesthetized with isoflurane (2% induction, 1.5% maintenance) and placed in the IVIS® 100 system (Perkin 
Elmer, Waltham, MA, USA) or an IVIS Spectrum (Hs683/U87-MG) (Perkin Elmer), maintaining the body temperature 
at 37°C. Subsequently, D-Luciferin (126mg/kg in PBS, Promega) or coelenterazin-h (15µg/mouse) were injected 
intravenously to assess stem cell or U87-MG tumor viability respectively. Subsequently, bioluminescent images were 
acquired. Data were analyzed (living image® 2.50.1 software, Perkin Elmer) for maximum intensity of the photon flux.  
Positron emission tomography (PET) 
Mice were anesthetized with isoflurane (2% induction, 1.5% maintenance) and placed in a Focus 220 microPET system 
(Siemens Medical Solutions USA) after which 300µCi activity was injected i.v. and an 80 min dynamic PET scan was 
performed. Images were reconstructed using an iterative maximum a posteriori probability algorithm with ordered 
subsets (MAP; 18 iterations, 9 subsets, fixed resolution: 1.5 mm) and analyzed in PMODv.3.1 (PMOD Inc, Zurich, 
Switzerland). Summed images of the 80-min acquisition time were used for the analysis. 
Humane endpoints 
Animals were sacrificed when symptoms reached grade 3 out of 4 (grade 0 for healthy mice, grade 1 for slight unilateral 
paralysis, grade 2 for moderate unilateral paralysis and/or beginning hunchback, grade 3 for severe unilateral or 
bilateral paralysis and pronounced hunchback, and grade 4 for moribund mice) according to [4].  
Histology 
Animals were sacrificed by an i.p. overdose of Nembutal (300µl, Ceva) and subsequently perfused with 4% ice-cold 
paraformaldehyde (PFA) solution (Sigma-Aldrich). After overnight post fixation in 4% PFA, the brain tissue was stored in 
a 0.1% sodium azide solution in PBS (Fluka, Sigma-Aldrich) at 4°C. 5 µm paraffin sections were sliced and a Masson 
trichrome staining, a Prussian blue staining (see Chapter 5) and an Iba 1 staining were performed. For the latter, 
sections were stained with an Iba1 antibody (1/250). Visualization was achieved by using the Dako EnVision + system-
HRP (DAB) kit (Dako, Glostrup, Denmark). 
Statistical analysis 
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Statistical analysis was performed using GraphPad Prism (GraphPad Software PRISM, La Jolla, CA, USA). Significant 
differences between GCV and PBS-treated animals regarding total tumor volumes (MRI:mm
3
) and cell viability (BLI: P/s) 
were determined by means of an ANOVA test with p < 0.05 regarded significant. Figures show means ± SEM. 
6.3 Results 
6.3.1 Bystander killing effect assessment in a mouse glioblastoma (GL261) model 
6.3.1.1 mMSC’s  
5 x 105  eGFP-fLuc-HSVTK transduced and SMG2-mPEGSi labeled (1%) mMSC’s were injected stereotactically 
in the striatum of GL261 tumor bearing C57BL6/j mice, after which PBS or GCV (50mg/kg) treatment was 
administered for 14 consecutive days. GL261 tumor sizes were comparable before mMSC injection as 
assessed by T2 weighted MRI. Furthermore, PBS treated animals (N = 4) (44.3 ± 14.3 mm3) and most GCV 
treated (N = 3) (48.7 ± 22.4 mm3) animals did not show a significant difference in tumor size by the end of 
treatment (week 5 post injection of GL261 cells) (Figure 37A). One GCV treated animal however showed a 
slight delay in tumor growth at the end of treatment (4.6 mm3). Furthermore, BLI was performed to assess 
stem cell viability, which showed a decreased viability for GCV treated animals but not for PBS control 
animals at the end of treatment (PBS: 2.1 x 107 ± 1.7 x 107, GCV: 7.7 x 104 ± 2.4 x 104), indicating mMSC 
response to GCV treatment (Figure 37B). Hypointense voxel volume determinations showed no statistical 
difference at any time point (prior/after mMSC injection, at the end of treatment) between PBS or GCV 
treated groups (Figure 37C). When comparing different time points, a statistical difference was found 
between prior to and after mMSC injection (2 weeks and 3 weeks post GL261 injection), indicating that 
labeling only 1% of the injected mMSC’s is sufficient for in vivo cell distribution follow-up (Figure 37D). 
Furthermore also the MRI and BLI images of one representative animal are shown for each group in Figure 
37E. 3D T2*W MR images show the distribution of the mMSC’s surrounding the tumor prior to treatment 
initiation. 
Furthermore, histological analysis was performed to assess tumor characteristics in vivo which revealed a 
high similarity between the tumors growing in mMSC-treated and untreated GL261 bearing animals.  
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Figure 37: Bystander killing effect assessment exerted by mMSC’s on the GL261 glioblastoma model.  
A. Anatomical T2 weighted MR images revealed no statistically significant difference in tumor size following 
treatment (week 5 post GL261 injection) between PBS (N= 4) and most GCV treated animals (N = 3). Only one 
GCV treated animal displayed a delayed tumor growth. 
B. BLI analysis showed a decrease in stem cell viability for GCV treated animals (N=4) compared to PBS control 
animals (N = 4).  
C. Hypointense voxel determinations from 3D T2* MR images showed no statistical difference beween PBS and 
GCV treated groups prior to (2 weeks post GL261 injection) or after stem cell injection (3 weeks post GL261 
injection) nor at the end of treatment (5 weeks post GL261 injection).  
D. Statistical analysis of the hypointense voxel volume on different time points showed that 1% labeled mMSC’s 
were sufficient for in vivo detection following injection (week 2 versus week 3 post GL261 injection) (N = 8 at 
each time point). 
E. MRI images (left) of animals from PBS and GCV treated groups show a comparable tumor growth prior to 
mMSC injection on T2 weighted coronal MR images (upper row for each group) whereas there is little 
hypointense contrast visible on 3D T2* MR images (lower row for each group). Stereotactically injected 
mMSC’s could be detected by 3D T2* MRI on day 4 after injection. When tumors grew larger, the hypointense 
voxels got more dispersed over time, whereas the mouse (outlier) that showed a delay in tumor growth still 
showed hypointense signal from the stem cells at the end of treatment (week 5 post GL261 injection). 
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6.3.1.2 mOct4+ BM-HypoSCs 
Subsequently, 5 x 105  eGFP-fLuc-HSVTK transduced and SMG2-mPEGSi labeled (1%) mOct4+ BM-HypoSCs 
were injected stereotactically in the striatum of GL261 tumor bearing C57BL6/j mice, after which PBS or GCV 
(50mg/kg) treatment was administered for 14 consecutive days. GL261 tumor sizes were also comparable 
prior to mOct4+ BM-HypoSC injection as assessed by T2 weighted MRI. Furthermore, PBS treated animals (N 
= 4) (44.5 ± 14.9 mm3) and GCV treated (N = 4) (30.3 ± 16.7 mm3) animals did not show a significant 
difference in tumor size by the end of treatment (week 5 post injection of GL261 cells) (Figure 38A). 
Furthermore, BLI was performed to assess stem cell viability, which showed a decreased viability for GCV 
treated animals but not for PBS control animals at the end of treatment (PBS: 2.2 x 108 ± 4.3 x 107, GCV: 7.1 x 
105 ± 5.3 x 105). Although mOct4+ BM-HypoSCs seem to be responding to GCV treatment, background level 
could not be reached (Figure 38B).  
Hypointense voxel volume determinations showed no statistical difference at any time point (prior/after 
mMSC injection, at the end of treatment) between PBS or GCV treated groups (Figure 38C).  
When comparing different time points, a statistical difference was found between prior to and after mOct4+ 
BM-HypoSC injection (2 weeks and 3 weeks post GL261 injection), indicating that labeling only 1% of the 
injected mOct4+ BM-HypoSCs is sufficient for in vivo cell distribution follow-up (Figure 38D). 
The MRI and BLI images of one representative animal per group are shown in Figure 38E. 3D T2*W MR 
images show the distribution of the mMSC’s surrounding the tumor prior to treatment initiation. BLI images 
show mOct4+ BM-HypoSC killing in the GCV but not in the PBS treated group, which was also apparent from 
histological analysis where Masson’s trichrome staining showed that PBS treated animals developed masses 
that consisted of both GL261 tumors and mOct4+ BM-HypoSC masses whereas GCV treated animals only 
showed evidence of GL261 tumor growth and not mOct4+ BM-HypoSC mass growth. 
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Figure 38: Bystander killing effect assessment exerted by mOct4
+
 BM-HypoSCs on the GL261 glioblastoma model.  
A. Anatomical T2 weighted MR image analysis revealed no statistically significant difference in tumor size 
following treatment (week 5 post GL261 injection) between PBS treated animals (N= 4) and GCV treated 
animals (N = 4).  
B. BLI analysis showed a decrease in stem cell viability for GCV treated animals compared to PBS control animals.  
C. Hypointense voxel determinations from 3D T2* MR images showed no statistical difference beween PBS and 
GCV treated groups prior to (2 weeks post GL261 injection) or after stem cell injection (3 weeks post GL261 
injection) nor at the end of treatment (5 weeks post GL261 injection).  
D. Statistical analysis of the hypointense voxel volume on different time points showed that 1% labeled m Pct4(+) 
BM-HypoSCs were sufficient for in vivo detection following injection (week 2 versus week 3 post GL261 
injection) (N = 8 at each time point). 
E. MRI (left) and BLI (middle) images of one representative animal from PBS and GCV treated groups show a 
comparable tumor growth prior to mMSC injection on T2 weighted coronal MR images (upper row for each 
group) whereas there is little hypointense contrast visible on 3D T2* MR images (lower row for each group). 
Stereotactically injected SMG
2
-mPEGSi labeled mMSC’s could be detected by 3D T2* MRI on day 4 after 
injection. When tumors grew larger, the hypointense voxels got more dispersed over time. Furhtermore 
Masson’s trichrome staining revealed tumor growth from both GL261 (1) and mOct4+ BM-HypoSCs (2) in the 
PBS treated group whereas only GL261 tumor growth could be detected in the GCV treated group. 
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6.3.1.3 mOct4- BM-MAPCs 
5 x 105 mOct4- BM-MAPCs were engrafted, of which only a fraction (1 or 10%) of the injected cells was 
labeled using SMG2-mPEGSi particles, as  
Subsequently, stereotactical injection of 5x105 mOct4- BM-MAPCs, of which only a fraction (1% or 10%) of 
the injected cells was labeled using SMG2-mPEGSi particles, as 3 x 105 cells already generated extensive 
hypointens contrast (Figure 26). Evaluation of the grafted cells by MRI showed that when 10% (Figure 39B), 
but not 1% (Figure 39A) of the stem cells were labeled with SMG2-mPEGSi particles, it was possible to follow 
them by MRI as indicated by the hypointense signal, with one representative animal shown in Figure 39C.  
Subsequently, 5 x 105 eGFP-Fluc-HSVtk expressing cells of which only a fraction (10%) was labeled using 
SMG2-mPEGSi particle (10%) were stereotactically injected into GL261 tumor bearing animals (= d15 post 
GL261 injection). The following day (= d16) MRI and BLI were performed to ascertain stem cell location in 
and surrounding the tumor. Using T2* weighted MR images, we were able to demonstrate for all animals 
receiving 10% labeled mOct4- BM-MAPCs, that the tumors contained and were surrounded by SMG2-mPEGSi 
labeled mOct4- BM-MAPCs from the first imaging time point post engraftment (= day 16 post injection).  
Subsequently, PBS or GCV (50mg/kg) administration was commenced for 14 consecutive days (i.e. until d30 
following GL261 tumor induction). At d30 post GL261 injection, sham operated animals and some PBS 
treated animals started to develop grade 3 symptoms that were related to tumor growth, and needed to be 
sacrificed. Analysis of MR images results showed that there was no statistically significant difference in 
tumor volume prior to (= d14) and following (= d16) steretactical injection of the mOct4- BM-MAPCs. At the 
end of treatment however smaller tumor sizes were observed in GCV treated animals compared to Sham 
operated and PBS treated animals (Figure 40A). Viability data from mOct4- BM-MAPCs indicated that GCV 
(N=18) administration resulted in a viability reduction of the mOct4- BM-MAPCs, which was not the case for 
the PBS-treated (N=12) and the Sham operated group (N=5) (Figure 40B) as assessed by BLI. During this 
analysis, a heterogenic respons was observed for GCV- and PBS treated animals. Therefore, additional sub-
analyses were performed to assess therapeutic respons.  
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Figure 39: Analysis of eGFP-fLuc-HSVTK (+), SMG
2
-mPEGSi labeled mOct4
-
 BM-MAPCs tracking in a mouse glioblastoma 
model (GL261).  
A. Hypointense signal volume determination (3D T2* MRI) on 1% labeled mOct4
-
 BM-MAPCs did not show 
statistically significant differences between stem cell injected animals (PBS/GCV) and sham operated animals 
one day after surgery (day 16). At the end of treatment (day 30), there was however a significant difference 
between sham operated animals and GCV-treated animals. due to the smaller tumor sizes in the GCV-treated 
group. In the sham operated and PBS-treated group, tumor formation was present which is accompanied with 
necrosis and bleedings when tumors grow over time. In contrast, the hypointense signal in the GCV-treated 
group, which did not develop tumors is mostly generated by remaining labeled mOct4
-
 BM-MAPCs. (green bar: 
mOct4
-
 BM-MAPC steretactical injection; red bar: treatment phase) 
B. Hypointense signal volume determination (3D T2* MRI) on 10% labeled mOct4
- 
BM-MAPCs showed statistically 
significant differences between stem cell injected animals (PBS/GCV) and sham operated animals one day after 
surgery (day 16). At the end of treatment (day 30), there was a statistically significant difference between 
sham operated and PBS-treated animals and between the PBS-treated and GCV-treated groups.  
 * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 
C. MR images of one representative animal stereotactically injected with 1% or 10% labeled mOct4
-
 BM-MAPCs 
showed that the hypointense contrast, delineated in red, generated by 10% labeled mOct4
-
 BM-MAPCs was 
more pronounced compared to 1% labeled cells. 
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Figure 40: In vivo suicide gene therapy using eGFP-fLuc-HSVTK (+), SMG
2
-mPEGSi labeled mOct4
-
 BM-MAPCs in a mouse 
glioblastoma model (GL261).  
A. Tumor volume determined for SHAM operated, PBS and GCV treated animals. No statistically significant 
differences could be found on day 14 and 16 between the different groups.  
B. Statistical analysis of the tumor volumes at the end of treatment (day 30) showed a statistically significant 
difference in tumor size between GCV-treated (N = 18) animals and SHAM operated (N = 5) / PBS treated 
animals (N = 12).  
C. mOct4
-
 BM-MAPC viability measurements showed a reduced cell viability for the GCV but not the PBS treated 
group. 
 
During the previous analysis, it was observed that while all sham operated animals (N=5) showed substantial 
tumor masses at the end of the treatment period (day 30), some of the PBS-treated animals showed a 
substantially smaller tumor size compared to the rest (N=4 out of N=12 PBS-treated animals, see Figure 41A 
and B). Among the GCV-treated animals, 11 responded to treatment while 7 animals did not respond to 
treatment (Figure 41A and B). MRI analysis showed that sham operated (N = 5), non-responding PBS-treated 
animals (N = 8) and GCV-treated, non-responding animals (N=7) developed tumors on day 30 after 
transplantation of the glioblastoma cells that were not statistically different in size (see Figure 41A and B). 
GCV-treated animals, that responded to therapy (N = 11); showed a statistically significant reduction in 
tumor volume (after 14 days of GCV treatment). For all GCV-treated animals, BLI signal intensity decreased 
significantly (see Figure 40 B and 41C). No difference in BLI signal intensity was seen between responding 
and non-responding animals (data not shown). Furthermore, a few animals injected with mOct4- BM-MAPCs 
and treated with PBS also displayed a reduced tumor size (N = 4) at the end of PBS administration (Figure 
41A and B), although the BLI signal from the mOct4- BM-MAPCs did not change over time (Figure 41C). 
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Figure 41: of In vivo suicide gene therapy using eGFP-fLuc-HSVTK (+), SMG
2
-mPEGSi labeled mOct4
-
 BM-MAPCs in a 
mouse glioblastoma model (GL261).  
A. Tumor volume determined for SHAM operated, PBS and GCV treated animals. No statistically significant 
differences could be found on day 14 and 16 between the different groups.  
B. Statistical analysis of the tumor volumes at the end of treatment (day 30) showed a statistically significant 
difference in tumor size between GCV responding (N = 11) animals and SHAM operated (N = 5) / PBS treated 
animals (N = 8). Furthermore, some GCV (N = 7) treated animals did not respond to therapy whereas some PBS 
treated (N = 4) animals also showed a reduced tumor size at the end of treatment. 
C. MR and BLI images of one representative animal for each group. 
C.
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A number of animals were observed long- term to determine progression free survival (Figure 42). 
Progression free survival curves generated for sham operated animals (N = 3) and PBS-treated (N = 6) 
animals were comparable. From the GCV-treated animals, some (N=3) did not respond to treatment and 
showed a similar survival to the sham operated and PBS-treated animals. However, some GCV (N = 4) and 
one animal treated with PBS displayed a longer progression free survival with two animals of the GCV-
treated group surviving long term (184 days) without any signs of tumor regrowth (Figure 42A). The median 
progression free survival of sham operated animals (35 days) was significantly lower compared to GCV 
responding animals (119.5 days) with p = 0.0101.  
Figure 42: Progression free survival analysis.  
A. A number of animals was observed for a progression free survival analysis. Sham operated animals (N = 3), 
PBS-treated (N = 6) and GCV (N = 3) unresponsive animals had comparable progression free survival curves 
whereas the animals that responded to GCV (N = 4) treatment and one animal treated with PBS but with a 
reduced tumor size after treatment displayed a prolonged progression free survival with two animals of the 
GCV-treated group surviving for 184 days without any sign of tumor regrowth. 
B. T2 weighted-MRI images showing tumor growth evolution in one representative animal for each of the three 
treatment groups. 
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Furthermore, histological analysis was performed to confirm the data obtained in vivo. Masson’s trichrome 
staining showed the presence of large blood vessels explaining the hypointense signal in large tumors. 
Prussian blue staining confirmed the presence of SMG2-mPEGSi particles in and around the tumor. In small 
tumors, iron staining was more concentrated to the injection site in comparison to large tumors. Finally also 
an Iba I staining for the presence of activated microglia was performed which showed remarkably few 
activated microglial cells inside the tumor, although microglial activation was more pronounced surrounding 
the tumor (Figure 43). 
Figure 43: Histological analysis of representative animals at the end of treatment.  
Several animals were sacrificed at the end of treatment for histological analysis. Massson’s Trichrome staining 
(upper left) of SHAM operated and PBS controlled animals showed very large tumors with a large amount of 
bleedings, corresponding to hypointense voxels on MRI. Prussian blue (upper right) staining was also 
performed which showed slight iron staining in PBS controlled animals. GCV treated responders showed high 
iron content as the cells remained more localized with smaller tumors. Finally, an Iba1 staining (bottem) was 
performed which showed microglial activation in the GCV treated responding group. Microglial activation was 
also very pronounced around the tumor in SHAM operated and PBS controlled animals. 
 
In order to gain further insights in tumor cell viability following suicide gene therapy, [18F] FET PET scan was 
acquired in addition to MR imaging. Statistical analysis (Figure 44A) showed that relatively large tumor sizes 
were required for detection by [18F] FET PET as displayed by the sham operated group (N = 2). No statistically 
significant distinction could be made between the PBS treated group (N = 2) and the GCV treated group (N = 
3) based on [18F] FET PET, although it was very clear on MRI that tumor sizes in the PBS treated group were 
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larger than in the GCV treated group. MR and PET images of one representative animal from each treatment 
group are shown in Figure 44B. These show clearly that although tumors in PBS and GCV control animals 
could be detected by [18F] FET PET, it was indeed very difficult to distinguish between both groups, which 
was much more clear on MR images. 
Figure 44: [
18
F] FET PET analyze on GL261 tumor bearing animals treated with mOct4
-
 BM-MAPCs.  
A. .Statistical analysis of sham operated (N = 2), PBS control (N = 2) and GCV treated (N = 3) groups showed that 
sham operated animals had significantly more tracer uptake in the tumor area compared to PBS and GCV 
treated animals. 
B.  Overview of MR and corresponding [
18
F] FET PET images of one animal from each treatment group.  
Top: T2W coronal MR images from one animal of each treatment group. 
Bottem: [
18
F] FET PET images from one animal of each treatment group. 
    Left: A relatively large tumor could be detected by [
18
F] FET PET in the sham operated group 
  Middle: The tumor of a PBS treated group could also be detected by [
18
F] FET PET but tracer uptake  
                was rather low. 
   Right: The tumor of a GCV treated animal could barely be detected by [
18
F] FET PET.  
SHAM PBS GCV
Data 6
C
o
n
tr
a
la
te
ra
l/
G
L
2
6
1
 r
a
ti
o
SHAM PBS GCV
0.0
0.5
1.0
1.5
2.0
SHAM
PBS
GCV
***
***
Min Max
A. B.
 
 Chapter 6:  
Multi-modal imaging of the bystander killing effect in malignant brain tumors  
126 
 
6.3.1 Bystander killing effect assessment in a human malignant glioma xenograft models (Hs683/U87-MG) 
6.3.1.1 hMultistem mediated suicide gene therapy in a human glioma xenograft model (Hs683) 
5 x 105 transduced and 1% SMG2-mPEGSi labeled hMultistem’s were injected stereotactically in the striatum 
of Hs683 tumor bearing Hsd:athymic Nude-Foxn1nu mice, after which PBS or GCV (50mg/kg) treatment was 
administered for 14 consecutive days. MRI data showed that hMultistem’s could be dectected in vivo 
following stereotactic injection (Figure 45A). BLI data showed that although expression of the fLuc gene was 
sufficiently high for detection of the hMultistem’s following injection, no statistically significant difference in 
viability could be obtained between GCV treated and PBS treated animals after initiation of treatment. Only 
a slight decrease was observed in the GCV, but not the PBS treated group when comparing the BLI signal 
intensity before and after treatment (Figure 45B). Concurrent with these results, no statistically significant 
differences in tumor volume were found between the sham operated (N = 3), PBS treated (N = 6) and GCV 
treated (N = 6) groups at the end of the treatment (day 31), nor in their subsequent progression of tumor 
growth (Figure 45C). Irrespective of the treatment group, developing tumors showed statistically significant 
tumor enhancing regions on T1 weighted pre- and post contrast MR images (Figure 45D).  
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Figure 45: In vivo suicide gene therapy using hMultistem as cellular vehicles in a human glioma xenograft (Hs683) 
model.  
A. Hypointense voxel volume quantification of SMG
2
-mPEGSi labeled eGFP-fLuc-HSVTK + hMultistem cells in the 
Hs683 model showed sufficient in vitro labeling for in vivo detection of 1% labeled cells in the tumor one day 
post hMultistem injection. (sham: N= 3, PBS treated: N = 6, GCV treated: N = 6).  
B. Bioluminescent imaging data showed that the stem cells were detectable through BLI but no statistically 
significant decrease in stem cell viability could be detected following treatment although there was a small 
decrease in the BLI signal from the GCV treated group compared to the beginning of treatment.  
C. Tumor volume measurements proved no statistical differences between sham operated, PBS treated or GCV 
treated animals. (green bar: hMultistem injection; red bar: duration of GCV/PBS treatment). 
D. T1 weighted MRI pre- and post contrast injection showed BBB integrity loss in the Hs683 tumor compared to 
the contralateral hemisphere and the extracranial muscle at all timepoints. (N = 15) 
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MRI and BLI images of one representative animal are shown for each group in Figure 46A. Histological 
analysis (Figure 46B) showed the presence of large bloodvessels, explaining some of the hypointense signal 
in large tumors. Furthermore, PB staining showed iron accumulation only in PBS and GCV treated animals, 
most likely arising from the SPIO labeled stem cells. Finally, Iba I staining for the presence of activated 
microglia was performed which showed remarkably few activated microglial cells inside the tumor in 
addition to more pronounced microglial cell activation surrounding the tumor. 
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Figure 46: In vivo suicide gene therapy using hMultistem as cellular vehicles in a human glioma xenograft (Hs683) 
model.  
A. MRI images (left) of one representative animal from sham, PBS and GCV treated groups show a comparable 
tumor growth prior to hMultistem injection on T2 weighted coronal MR images (upper row for each group) 
whereas there is little hypointense contrast visible on 3D T2* MR images (lower row for each group). 1% 
SMG
2
-mPEGSi labeled hMultistem’s could be detected by 3D T2* MRI on day 1 after injection. When tumors 
grew larger, the hypointense voxels got more dispersed over time. 
B. One week after the end of therapy, animals developed symptoms after which histological analysis was 
performed. Masson’s Trichrome staining (upper left) of all animals showed very large tumors with a large 
amount of bleedings, corresponding to hypointense voxels on MRI. Prussian blue (upper right) staining was 
also performed which showed iron staining in PBS and GCV treated animals. Finally, an Iba1 staining (bottem) 
was performed which showed a predominant absence of activated microglia in all treatment groups. Microglial 
activation was however more pronounced around the tumor.  
A.
B.
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6.3.1.2 hMultistem mediated suicide gene therapy in a human glioma xenograft model (U87-MG) 
Subsequently, 2.5 x 105 eGFP-fLuc-HSVTK expressing and SMG2-mPEGSi labeled (1%) hMultistem’s were 
stereotactically injected in the striatum of mCherry-rLuc expressing U87-MG tumor bearing Hsd:athymic 
Nude-Foxn1nu mice, after which PBS or GCV (50mg/kg) treatment was administered for 14 consecutive days. 
MRI data showed that hMultistem’s could be dectected in vivo following stereotactic injection (Figure 47A) 
when labeling only 1% of the injected cells. BLI data showed that expression of the fLuc gene was sufficient 
for detection of the hMultistem’s following injection and prior to treatment initiation. Both PBS treated and 
GCV treated groups displayed a decrease of the hMultistem viability by the end of treatment, indicating that 
the tumor environment induced cell death of the injected hMultistem’s (Figure 47B). The BLI signal of the 
rLuc-expressing tumor cells, using Coelenterazine-h as a substrate, was used as an indicator for tumor cell 
viability. An increase of the BLI signal for the sham operated group and the PBS treated group but not for the 
GCV treated group was observed when compared with the signal intensity before initiation of the treatment 
(Figure 47C). This slightly reduced increase in tumor cell viability does however not correlate with the tumor 
size after treatment as there were no statistically significant differences between the sham operated, PBS 
treated and GCV treated groups observed. This decreased viability might however reflect a slight increase in 
necrotic area size, which is difficult to assess on MRI due to the existence of bleedings and the iron oxide 
label present in the hMultistem’s. Developing tumors showed statistically significant tumor enhancing 
regions on T1 weighted pre- and post contrast MR images (Figure 47D). MRI and BLI images of one 
representative animal are shown for each group in Figure 48A. Two weeks after the end of treatment, all 
animals started to develop symptoms due to tumor growth, after which animals were sacrificed and 
histological analyisis was performed (Figure 48B). Trichrome staining confirmed the MRI data, which showed 
large and dense tumors. Furthermore, Prussian blue staining was performed which showed iron staining 
preferentially in PBS treated animals in comparison to sham operated and GCV treated animals. Iba 1 
staining was performed to assess the microglial activation status between groups, which showed no clear 
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differences between the different treatment groups. Although much less microglial activation surrounding 
the tumor was observed when compared to the Hs683 model. 
Figure 47: In vivo suicide gene therapy using hMultistem as cellular vehicles in a human glioma xenograft (U87-MG) 
model.  
A. Hypointense voxel volume quantification of SMG
2
-mPEGSi labeled eGFP-fLuc-HSVTK + hMultistem cells in the 
U87-MG model showed sufficient in vitro labeling for in vivo detection of 1% labeled cells in the tumor one day 
post hMultistem injection. (sham: N= 3, PBS treated: N = 5, GCV treated: N = 6).  
B. Bioluminescent imaging (fLuc) data showed that hMultistem’s displayed a decreased viability at the end of 
therapy irrespective of the treatment group.  
C. Bioluminescent imaging (rLuc) data showed an increase in tumor viability at the end of treatment for the sham 
operated and the PBS treated group but not the GCV treated group. 
D. Tumor volume measurements proved no statistical differences between sham operated, PBS treated or GCV 
treated animals. (green bar: hMultistem injection; red bar: duration of GCV/PBS treatment). 
E. T1 weighted MRI pre- and post contrast injection showed BBB integrity loss in the U87-MG tumor compared to 
the contralateral hemisphere and the extracranial muscle at all timepoints. (N = 11) 3DT2star hU87+hMulti
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Figure 48: In vivo suicide gene therapy using hMultistem as cellular vehicles in a human glioma xenograft (u87-MG) 
model.  
A. MRI images (left) of one representative animal from sham, PBS and GCV treated groups show a comparable 
tumor growth prior to hMultistem injection on T2 weighted coronal MR images (upper row for each group) 
whereas there is little hypointense contrast visible on 3D T2* MR images (lower row for each group). 1% 
SMG
2
-mPEGSi labeled hMultistem’s could be detected by 3D T2* MRI on day 1 after injection, which was still 
detectable at the end of treatment (day 22 post U87-MG injection). 
B. Two weeks after the end of therapy, animals developed symptoms after which histological analysis was 
performed. Masson’s Trichrome staining (upper left) of all animals showed large, dense tumors with very little 
bleedings. Prussian blue (upper right) staining was also performed which showed iron staining in PBS treated 
mice but much less in sham operated or GCV treated animals. Finally, an Iba1 staining (bottem) was performed 
which did not show much differences in activated microglial status between treatment groups.  
A.
B.
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6.4 Discussion 
Unfortunately, results obtained in clinical trials have been limited, mainly due to insufficient expression and 
poor intratumoral distribution of the viral vectors encoding for the suicide gene [199]. Therefore, HSV-TK 
expressing stem cells that are able to track tumor cells [82, 84, 150-152] have been considered as vehicle for 
suicide gene delivery with increasing emphasis on non-invasive follow-up of the fate of stem cells while 
performing these experiments in the preclinical phase [198, 200]. aiming for better translatability from 
mouse to man. Tumor size, viability and location can be validated with MRI, PET or BLI prior to stem cell 
injection, thus identifying outliers earlier [198, 200]. Furthermore, the location and viability of the stem cells 
prior to initiation of treatment is crucial as this will greatly influence the bystander suicide treatment 
response. Moreover, animals can be followed longitudinally, thus reducing the number of animals needed 
while additional information can be obtained to gain a better understanding of the dynamics of this 
experimental glioblastoma treatment and to exclude outliers that are based on experimental errors like 
failure of correct cell implantation.  
In this study, GL261 tumor bearing C57BL6/j mice received 5 x 105 syngeneic HSV-TK / fLuc expressing and 
SMG2-mPEGSi labeled mMSC’s (1%), mOct4+ BM-HypoSCs (1%) or mOct4- BM-MAPCs (1-10%) for 
longitudinal follow-up of suicide gene therapy in immunocompetent animals following in vitro and in vivo 
detection feasibility studies.  
mMSC treated GL261 tumor bearing animals did not show significant differences in tumor growth when 
comparing most GCV treated to PBS control animals. Only one mouse out of 4 animals in the GCV treated 
group showed a reduction in tumor size, which was probably related to experimental variation.  
In the mOct4+ BM-HypoSC treated GL261 tumor bearing animals, no statistical difference was found in terms 
of tumor size of GCV treated and PBS control animals, although a sligh growth delay was observed for both 
groups. Although GCV treatment reduced the BLI signal originating from the stem cells treated with GCV, 
background signal intensity levels were never reached, indicating that in the tumor environment, optimal 
stem cell killing can not be achieved. As mOct4+ BM-HypoSCs form masses themselves when injected in the 
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brain, endpoint tumors might consist of a combination of masses formed by GL261 and mOct4+ BM-
HypoSCs.  
Hypointense signal volume determination (3D T2* MRI) on 1% labeled mOct4- BM-MAPCs did not show 
statistically significant differences between stem cell injected animals (PBS/GCV) and sham operated animals 
one day after surgery (day 16). At the end of treatment (day 30), there was however a significant difference 
between sham operated animals and GCV-treated animals due to the smaller tumor sizes in the GCV-treated 
group. In the sham operated and PBS-treated group, tumor formation was present which is accompanied 
with necrosis and bleedings when tumors grow over time. In contrast, the hypointense signal in the GCV-
treated group, which did not develop tumors is mostly generated by remaining labeled mOct4- BM-MAPCs. 
Results showed that labeled mOct4- BM-MAPCs were located in and in close proximity to the tumor from 
one day post injection for all animals. Therefore, treatment was commenced on day one post injection 
following multi-modal imaging (MRI / BLI). In the majority of GCV, but not PBS-treated animals, a significant 
difference was found in mOct4- BM-MAPCs viability and tumor size at the end of treatment (Figure 40). 
However, not only the majority of GCV-treated animals but also some PBS-treated animals showed a 
significant decrease in tumor size compared to sham operated animals. One hypothesis in the suicide gene 
therapy field is that the initial, limited intratumoral cell killing caused by injection of the stem cells and the 
inhospitable tumor micro-environment, of both stem cells and tumor cells generates the release of 
immunostimulatory molecules resulting in the generation of a Th1 response [161-163], which helps to 
overcome immune suppression by the tumor.  
Our results show however that all PBS-treated animals displayed mOct4- BM-MAPCs survival during PBS 
administration as determined by BLI, indicating that the observed effect on tumor growth in the PBS-treated 
group is probably not majorly influenced by mOct4- BM-MAPC cell death. Another possible explanation for 
the reduction of tumor growth could be the immunomodulatory properties of MAPCs themselves and their 
capability to exert both immune suppression and immune stimulation [201], which might cause the immune 
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system to favor immune stimulation rather than immune suppression in the tumor setting and thus 
contribute to a therapeutic effect and a reduction in tumor size.  
This would however still need to be confirmed by additional studies. In any case, our studies demonstrate 
clearly that adding GCV treatment augments killing of the glioblastoma, which is likely the result of the 
typical bystander killing effect, and might be enhanced by the additional effect of the proposed Th1 
response system described earlier. Furthermore, histological analysis showed the presence of large blood 
vessels explaining the hypointense signal in large tumors (Masson’s Trichrome) and the presence of SMG2-
mPEGSi particles in and around the tumor (Prussian blue staining). In smaller tumors, iron staining was more 
concentrated to the injection site in comparison to large tumors. Activated microglial cells were identified 
mostly at the tumor border although areas of microglial activation within the tumor tissue were also found. 
No clear differences could be found however between sham operated, PBS controlled and GCV treated 
animals in microglial activation status.  
Furthermore, [18F] FET PET was performed in addition to MR imaging in order to gain further insights in 
tumor viability following suicide gene therapy. Large tumors present in the sham operated groups could be 
detected quite easily by [18F] FET PET whereas no statistical differences could be detected between the PBS 
treated group and the GCV treated group based on [18F] FET PET, which indicates a mismatch between the 
difference in tumor sizes between the PBS treated group (larger) and the GCV treated group (smaller) seen 
in MRI and the metabolic rate seen in PET. 
Subsequently, Hs683 or (mCherry rLuc expressing) U87-MG tumor bearing Hsd:athymic Nude-Foxn1nu mice 
were divided in a sham operated group, a PBS treated group and a GCV treated group (50mg/kg) of which 
the PBS and GCV treated group received treatment for 14 consecutive days. Labeled hMultistem’s were 
located in close proximity to the tumor (inside and around) already one day post injection. Therefore, 
treatment was commenced at day one post injection following multi-modal imaging (MRI / BLI). The 
hMultistem viability decreased in both the PBS and the GCV treated group in the U87-MG tumor bearing 
animals but not in the Hs683 tumor bearing animals as assessed by BLI using D-luciferin as a substrate for 
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fLuc, indicating stem cell killing probably due to the harsh U87-MG tumor microenvironment. No differences 
could be found in either tumor model concerning tumor size between animals that were sham operated or 
treated with PBS or GCV. However, there was a stagnation of the number of viable tumor U87-MG tumor 
cells of GCV treated animals after treatment. This was not the case in PBS treated or sham operated animals. 
All in all, stem cell mediated suicide gene therapy in human glioma xenograft models proved much less 
effective when comparing the results with the data generated in the GL261 glioblastoma mouse model.  
There are several plausible explanations for this failure of therapeutic response. First, developing tumors 
were generally larger in the U87-MG and Hs683 models compared to the GL261 model at the time of stem 
cell injection, which may mean that the injection of more stem cells might be necessary reach all tumor cells 
and hereby elicit a therapeutic response. Secondly, it is apparent that administration of 50mg/kg GCV is 
insufficient to efficiently kill all stem cells in vivo as indicated by the BLI experiments. Increasing the 
concentration of administered GCV was not feasible as this resulted in the development of side effects such 
as diarrhoea and weight loss. Increasing the HSV-TK expression in the stem cells would be another 
alternative but this might need a different approach for transgene insertion as application of higher 
concentrations lentiviral vector during transduction resulted in detrimental effects on cell propagation.  
Furthermore, the bystander killing effect is dependent on the existence of gap junctions between adjacent 
cells. It has been described in literature that high grade glioma display less cell-cell communication and thus 
fewer gap junctions which might result in decreased therapeutic response [202]. It has been reported that 
the bystander killing effect is also in part T cell mediated [161-163], which would explain why no effect can 
be seen in the human glioma xenograft mouse models, which uses immune-compromized animals that lack T 
cells. This theory is also supported by our observation that in some cases PBS treated GL261 tumor bearing 
animals, which received mOct4- BM-MAPCs, also showed a delayed tumor growth even when tumor growth 
comparable to sham operated controls was present at the time of stem cell injection.  
As no T cells are present in immunodeficient mice, brain sections were stained for activated microglia. In 
Hs683 tumor bearing animals, very few activated microglia could be seen inside the tumor area. In contrast, 
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activated microglial cells were abundantly present in the tissue surrounding the tumor. In the U87-MG 
tumor model, some activated microglial cells were present inside the tumor area although no differences in 
microglial activation could be seen between the different treatment groups.  
Finally, as the tumor has a doubling time of days rather than months, we would not be able to pick up 
marginal effects on tumor growth with only imaging before and after treatment. Additional scanning 
sessions might be beneficial although care should be taken with increasing the sedation sessions as this may 
result in profound weight loss as animals are already weakened due to tumor growth.  
Thus, we have shown that suicide gene therapy using mOct4- BM-MAPCs as cellular carriers, is effective in 
reducing the GL261 tumor size in the majority of the GCV-treated animals, resulting in a longer progression 
free survival compared to sham operated animals. We were however unable to show significant reduction in 
tumor size using hMultistem as cellular carriers in the human glioma xenograft models. 
These results indicate that although stem cell based suicide gene therapy is a promising approach; further 
investigations are required to understand possible mechanisms of action in different tumor environments 
and the role of different stem cell types.  
In conclusion, we have shown that suicide gene therapy using several stem cells in different malignant 
glioma models can be followed in vivo by MRI and BLI, where MRI can be used to ascertain stem cell location 
prior to treatment initation and follow-up of tumor size. BLI can be used to assess stem cell and/or tumor 
cell viability prior to and following treatment response. Thus, outliers can be detected earlier, GCV treatment 
can be initiated based on stem cell distribution rather than on empirical time points and a more thorough 
follow-up can be provided prior to and following treatment of these animals. Although, PET can provide 
valuable information on the tumor and/ or stem cell metabolic activity, it was less suitable for our mouse 
models due to its low spatial resolution. This will contribute to a rapid and efficient validation of stem cell 
based therapeutic approaches of glioma and hereby to a better understanding and optimization of a 
promising therapeutic approach for glioblastoma patients.  
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Chapter 7: General conclusions & future perspectives 
7.1 General conclusions 
Non-invasive imaging modalities such as MRI and PET are considered an essential tool in both the clinical and 
preclinical setting. Patients diagnosed with glioblastoma multiforme still face a dismal prognosis despite 
advances in general treatment regimes [3] and promising preclinical research on new treatment approaches. 
This discrepancy between preclinical and clinical efficacy for most experimental therapies is in part related to 
the tumor models used in preclinical research. A multitude of animal models exist ranging from models of 
spontaneously developing tumors, to syngeneic xenograft models which are usually mouse or rat models 
that do not entirely reflect human glioblastoma’s, or human glioma xenograft models which use human 
glioblastoma cells in immunodeficient mice. The latter use human tumor cells/cell lines but very limited 
information can be gained in regard to immune responses to the tumor, as they minimally lack T cells, which 
is a major contributor to treatment. None of the available xenograft models however truly recapitulate all 
aspects of glioblastoma in human patients. For instance, most cell-line based animal models have limited 
infiltrating tumor cells, which are the main cause for recurrence and subsequent mortality in human 
patients. All results deduced from these animal models should therefore be carefully considered prior to 
making assumptions for human applications. Promising therapeutic approaches should also be tested in 
human biopsy models in order to fully evaluate the therapeutic response on human GBM as these 
recapitulate the geno- and phenotype much better compared to cell-line based models [52, 53], although 
care should be taken with therapeutic approaches which require immune system involvement. In any case, 
glioblastoma multiforme is actually a very heterogenous population [203] of tumors which makes it difficult 
to postulate hypotheses for the entire population. Which type of tumor model is most suited therefore 
depends heavily on the specific experimental therapy under investigation. In this study, we have selected an 
orthothopic mouse glioblastoma model in which GL261 cells are stereotactically injected in the striatum of 
syngeneic C57BL6/J mice for reproducible tumor growth. Additionally, two human malignant glioma 
xenograft models in Hsd:athymic Nude-Foxn1nu mice were selected, namely the Hs683 oligodendroglioma 
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model which is perceived as a grade III or grade IV model and the U87MG cell line which is classified as a 
glioblastoma.  
One of the promising preclinical therapies with yet clinically rather dispappointing results is suicide gene 
therapy. One of the major causes for this is believed to be the poor distribution of the suicide gene inside 
and around the tumor [70]. Therefore, attention turned to stem cells carrying the suicide gene to the tumor 
cells in order to achieve more efficient tumor cell killing [82, 84, 150, 151]. It is however necessary to follow-
up animals longitudinally not only to assess initiation of therapy, therapeutic response, and possible side 
effects but also to track stem cell fate for safety purposes as stem cells are capable of longitudinal 
proliferation and differentiation into several cell types including such with unwanted side effects, such as 
mass formation. In both, clinical and preclinical settings, diagnosis and follow-up is usually mainly based on 
1H MRI although a number of difficulties remain including reliable grading [204] and pseudoprogression 
[205]. Additionally [18F] FET PET, which is also routinely used in some hospitals or 1H MR spectroscopy, can 
be performed to gain further information on metabolism in the tumor [196], thus further identifying regions 
to be biopsied and subsequently graded by a histopathologist. We opted to assess both approaches in the 
selected tumor models, complemented by stem cell viability information gained from BLI measurements.  
The overall problems in regard to diagnosis, treatment and follow-up of patients diagnosed with 
glioblastoma multiforme, was discussed in Chapter 1. Subsequently, the aims of this work were specified in 
Chapter 2 and included: 1. Label and transduce stem cells and glioma cells to obtain cells with therapeutic 
potential and which are traceable with non-invasive, multi-modal imaging (MRI, BLI, PET); 2. Characterize 
and optimize different glioma models; 3. Conduct in vivo multi-modal imaging proof-of-principle 
experiments on stem cells and glioma cells in order to generate a model for screening of stem cell mediated 
suicide gene therapy in different preclinical glioblastoma models; 4. Assess stem cell mediated suicide gene 
therapy in different preclinical glioblastoma models using multi-modal small animal imaging, including 
MRI/BLI/PET for follow-up of stem cell distribution and treatment response.  
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Suicide gene therapy using stem cells as cellular vehicles to deliver the suicide gene to the tumor area 
requires alteration of the stem cells in order to stabily express a therapeutic gene. Therefore, lentiviral 
vectors were designed and produced. In addition, reporter genes such as eGFP and fLuc were included to 
allow for multi-modal imaging follow-up. Initial experiments included optimization of the lentiviral vector 
promoter (CMV vs EF1α) for applications in stem cells, as we showed that the CMV promoter was unable to 
induce stable eGFP expression in rOct4+ BM-HypoSCs. Subsequent assessment of an EF1α promoter driven 
lentiviral vector encoding for eGFP however established stable eGFP expression in HEK 293T, mMSC, rOct4+ 
BM-HypoSCs and mOct4+ BM-HypoSCs after antibiotic selection. Next, the newly designed, multicistronic 
lentiviral vectors encoding for eGFP and fLuc or eGFP, fLuc and HSV-TK were produced and assessed in 
mMSC’s, mOct4+ BM-HypoSCs, mOct4- BM-MAPCs and hMultistem’s for fLuc and HSV-TK expression. Both 
transgenes were considered to be expressed sufficiently for in vivo experimentation.  
Furthermore, mMSC’s, mOct4+ BM-HypoSCs, mOct4- BM-MAPCs and hMultistem’s were labeled with SMG2-
mPEGSi particles for MRI-based in vivo tracking of the stem cells. ICP-OES and MRI on phantoms were 
performed to assess the amount of iron per cell and the hypointense contrast generation in vitro. Both 
confirmed efficient labeling in all cells, without significant differences in cell viability as assessed by BLI when 
compared to non-labeled eGFP-fLuc-HSVTK expressing controls. For mMSC’s and mOct4+ BM-HypoSCs, 
labeling of the cells with SMG2-mPEGSi particles was compared to labeling with the previously commercially 
available contrast agent Endorem® which showed better uptake of the particles in the cells which also 
corresponded to quicker relaxation in the MRI phantom when using SMG2-mPEGSi particles.  
Finally, when assessing therapeutic response, tumor size is not the most predictive and valuable parameter 
to be validated. Therefore, we attempted also to follow-up tumor growth by rLuc BLI. Therefore, rLuc 
expression was assessed in all tumor cell lines in vitro, namely the GL261, Hs683 and U87-MG cell line. BLI 
showed sufficiently high expression of rLuc in vitro for later in vivo assessment. 
In conclusion, the in vitro detection and treatment characteristics of different stem cells and glioma cell lines 
were assessed successfully in Chapter 3. 
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In Chapter 4, the eGFP-fLuc-HSVTK + and SMG2-mPEGSi labeled mMSC’s, mOct4+ BM-HypoSCs, mOct4- BM-
MAPCs and hMultistem’s generated in Chapter 3 were assessed in vivo for multi-modal imaging detectability 
and response to GCV. All the mentioned cells types could be well localized and monitored by BLI 
measurements. Initial safety studies indicated that most stem cells, including mMSC’s, mOct4- BM-MAPCs 
and hMultistem’s did not show any mass growth over time. MOct4+ BM-HypoSCs however did show mass 
formation and growth, which has already been described by Lo Nigro et al [145] for rOct4+ BM-HypoSCs. 
Most stem cell types responded very well to the GCV treatment with even no mass formation in mOct4+ BM-
HypoSCs following GCV treatment. hMultistem’s however did not respond well to GCV treatment. A 
plausible cause is that due to limited BBB integrity loss in the absence of mass formation in the brain, 
suboptimal levels of GCV reached the respective brain regions, as GCV does not efficiently cross the BBB 
[206]. These suboptimal GCV concentrations combined with a higher natural resistance to GCV killing, which 
was already apparent in the in vitro studies performed in Chapter 3. Higher concentrations of GCV were 
required to efficiently kill the hMultistem cells in vitro compared to the other stem cell types under 
investigation. Therefore, applying these stem cells in a malignant glioma model with BBB disruption might 
increase the attainable GCV levels in the brain and therefore result in more pronounced hMultistem killing. 
Furthermore, [18F] FHBG, which can be used as a tracer for HSV-tk detection [207], was evaluated in vivo. 
Hereby, eGFP-fLuc-HSVTK expressing HEK293T cells were injected as a xenograft, after which a 80 min 
dynamic PET scan was performed. Results showed that the cells could be observed in vivo. As [18F] FHBG 
does not easily passess the BBB [208], we chose to directly validate the PET contribution for in vivo 
assessment of the suicide gene therapy in a mouse glioblastoma (GL261) model. Hereby, mMSC’s, mOct4+ 
BM-HypoSCs mOct4- BM-MAPCs were injected in the GL261 tumor and [18F] FHBG PET was performed.  
Results showed that although there was some tracer uptake in the tumor area, this activity was rather low 
and mostly limited to the first half hour of scanning. This activity could be stem cell specific but due to the 
partial volume effect and the small tumor sizes in mice, no distinction could be made between stem cells, 
which are located on the tumor border and tumor cells, which should not have specific [18F] FHBG signal as 
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they do not express HSV-tk. In addition, this increased activity present in the first half hour of scanning might 
also be related to the multitude of blood vessels in the GL261 cells. Blood vessels in tumors are known for 
their contortunesniss and leakiness [209], which could be an alternative explanation for higher uptake in the 
tumor area. Based on our experiments we concluded that [18F] FHBG PET is not the most suitable method to 
follow-up stem cell based glioma therapy in our mouse models. [18F] FHBG PET imaging has been described 
both in a clinical [210] and preclinical [207] setting. Clinical reports have been limited so far and preclinical 
data usually reports very limited increases in signal intensity, which is concurrent with our findings. Follow-
up of 5 x 105 stem cells during suicide gene therapy proved too much of a challenge in our model. As signals 
were perceived to be to low for actual suicide gene therapy follow-up and stem cells were also positive for 
fLuc, we decided to use BLI rather than PET imaging for follow-up of stem cell viability in vivo. 
Subsequently, SPIO labeled stem cells were validated in vivo for their hypointense contrast generation 
potential. 3DT2*-weighted MR images showed that labeled mMSC’s and mOct4- BM-MAPCs could be 
detected easily for up to 8 days when injected into the mouse brain. One of the references for SPIO labeling 
of stem cells for in vivo cell tracking is Endorem®, which is no longer commercially available. Therefore, Dr 
Jesse Trekker developed in house fabricated SMG2-mPEGSi particles [143] which emulate and even exceed 
the results obtained for Endorem® labeling in the stem cells used for these studies. Cell labeling efficiencies 
can however differ greatly, depending on the cell type. It is therefore very important to optimize labeling 
strategies for each individual cell line [211].  
Finally, we also evaluated the detectability of the mCherry-rLuc transduced glioma cell lines in vivo by BLI 
using coelenterazin-h as a substrate. Results showed that only tumor growth in the human glioma xenograft 
U87-MG glioblastoma model could be followed over time, although in vitro and ex vivo BLI signals also 
showed rLuc expression in the GL261 and Hs683 models. A multitude of reasons for this failure of sensitive 
detectability for the GL261 and Hs683 cell lines exist. First, rLuc emits light at 480nm (blue light). At this 
wavelength, much more absorption occurs by the animal’s skin, skull, brain tissue and blood (albumin) 
compared to eGFP which emits at 560nm (green light). Therefore, less light reaches the surface for in vivo 
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detection. Furthermore, in Hs683 tumors, BBB disruption is incomplete (see Chapter 5), which might cause 
insufficient levels of GCV as it does not pass the BBB easily [206]. GL261 tumors do however display a BBB 
integrity loss (Chapter 5), so it does not explain the discrepancy between the in vitro and in vivo data for this 
cell line. Another reason could be the presence of efflux pumps, which are present on tumor cells [164]. 
Furthermore, the human glioma xenograft tumor models that we used are generated in Hsd:athymic Nude-
Foxn1nu mice. These mice do not synthetize melanin, which also absorbs light. The GL261 model however 
has a syngeneic host, namely C57BL6/j mice, which do produce melanin that can therefore further absorb 
the light coming from the brain. We would like to stress that a combination of all these factors may have 
contributed to the failure to detect GL261 and Hs683 tumor cells in vivo. 
In Chapter 5, the selected malignant glioma models were optimized and characterized in vivo. 2.5 x 105 
GL261, 5 x 104 Hs683 or 3 x 105 U87-MG cells were stereoactically injected and followed by MRI 
measurements. These tumor models generated grade 3 symptoms due to volume effects caused by tumor 
growth at 4 (U87-MG), 5 (GL261) and 6-8 weeks post injection (Hs683), respectively. GL261 grew 
homogenous with central necrosis and large bleedings developing over time as apparent on both MRI and 
histological analysis. Blood vessels were also observed both inside the tumor and on the tumor periphery 
which has been reported to be derived either from the host or caused by neo-angiogenesis [165]. The U87-
MG tumor model also grew quite homegenously but with far fewer and smaller blood vessels inside and 
surrounding the tumor. The Hs683 tumors grew exceptionally large and developed large fluid filled cysts 
which were apparent on MRI and histology. Histological analysis showed some main characteristics of 
malignant gliomas including infiltration, mitosis, nuclear atypia, the presence of blood vessels/bleedings. 
Central necrosis was apparent in the GL261 model but no distinctive regions of necrosis could be identified 
using histological assessment for the U87-MG and Hs683 models. The formation of connective tissue in the 
U87-MG tumors was very striking on Masson’s trichrome staining. GFAP staining proved negative for the 
Hs683 and GL261 model, which has been described previously for both models by Szatmari et al [155] and 
Belot et al [180], respectively.  
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Additionally, the BBB integrity was assessed by CE-T1W MRI and Evans blue injection in one mouse 
glioblastoma model (GL261) and two high-grade human glioma xenograft models (Hs683 and U87-MG). One 
of the hallmarks of high grade gliomas is neo-angiogenesis [178], which is correlated with tumor grade and 
malignancy [168]. It is therefore important to monitor the BBB status during therapy. Furthermore, some 
experimental brain tumor treatments, using for instance systemically injected stem cells or administration of 
large or hydrophilic therapeutic molecules, could be hampered by incomplete BBB disruption, which might 
result in less efficient treatment. It is therefore crucial to characterize tumors models very carefully before 
starting treatment regimes. BBB integrity loss was observed in all models using CE T1W MRI, although the 
Hs683 model proved to have a very heterogenous BBB integrity loss. The U87-MG and GL261 models 
displayed a more homogenous contrast enhancement, very soon in the tumor development (one week post 
injectiof for U87-MG tumors, two weeks post injection for GL261 tumors, respectively) with non-enhancing 
regions appearing over time when necrosis or bleedings occurred, which is concurrent with the data 
obtained by histology. Evans blue assessment was concurrent with these results for the GL261 tumors with 
enhancement starting from week 2 post injection. In contrast, this was not the case for Hs683 tumors were 
no positive Evans blue staining was observed at any time point. The BBB integrity loss demonstrated by both 
techniques for the GL261 model is concurrent with data obtained by Cha et al [35]. Although, loss of BBB 
integrity is a general characteristic of glioblastoma, little is known about the actual mechanisms involved in 
this BBB disruption [182]. The discrepancy between MRI data and Evans blue staining suggest incomplete 
BBB integrity loss in the Hs683 model as Evans blue binds to albumin and is therefore much larger compared 
to Dotarem.  
In Chapter 6, therapteutic stem cells were injected in the selected tumor models and treated with GCV for 
14 consecutive days. First, eGFP-fLuc-HSVTK expressing and SMG2-mPEGSi labeled mMSC’s, mOct4+ BM-
HypoSCs were evaluated in the GL261 model followed by hMultistem evaluation in the Hs683 and U87-MG 
models. All stem cells were detectable one day after injection by both MRI and BLI, indicating that SMG2-
mPEGSi labeling and transgene expression are sufficiently high, even for stem cell detection in a tumor 
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model where stem cells are dispersed over the entire tumor volume and beyond. Furthermore, we observed 
that stem cells are already located at the border of the tumor one day post stem cell injection. No 
subsequent stem cell re-location/migration was observed, indicating that stem cell treatment could be 
commenced at that time. This early initiation of treatment is beneficial as it was shown by Amano et al that 
for for treatment of rapidly growing tumors using HSV-TK gene therapy, early GCV administration is required 
for an effective tumoricidal effect [212].  
mMSC treated GL261 tumor bearing animals did not show significant differences in tumor growth when 
comparing most GCV treated to PBS control animals. Only one mouse out of 4 animals in the GCV treated 
group showed a reduction in tumor size, which was probably related to experimental variation.  
In the mOct4+ BM-HypoSC treated GL261 tumor bearing animals, no statistical difference could be found in 
tumor size of GCV treated and PBS control animals. Although a sligh growth delay was observed for both 
groups. Unfortunatly, although GCV treatment reduced the BLI signal originating from the stem cells treated 
with GCV, low background levels in BLI signal intensity were never reached, indicating that in the tumor 
environment, optimal stem cell killing can not be achieved using this cell line. As mOct4+ BM-HypoSCs form 
masses themselves when injected in the brain, endpoint tumors might consist of a combination of GL261 
and mOct4+ BM-HypoSCs masses.  
In the majority of GCV treated, but not PBS control, GL261 tumor bearing animals injected with mOct4- BM-
MAPCs, animals displayed a significant difference in mOct4- BM-MAPCs viability and tumor size at the end of 
treatment as assessed by MRI. Furthermore, O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography 
([18F] FET PET) was acquired in addition to MR imaging in order to gain further insights in tumor viability 
following suicide gene therapy. Large tumors present in the sham operated groups could be detected quite 
easily by [18F] FET PET whereas no statistical differences could be detected between the PBS treated group 
and the GCV treated group based on [18F] FET PET, although it was very obvious on MRI that tumor sizes in 
the PBS treated group were larger than in the GCV treated group. [18F] FET PET is used clinically for tumor 
grading as it is a measure for tumor metabolism. It is however generally accepted that mouse tumor models 
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not always fully encompass the full range of malignancy as in human tumors. It might be therefore possible 
that the metabolism in our model is not quite as high as observed in human tumor patients. Furthermore, 
the resolution of the µPET scanner is around 1.4 mm which makes it rather difficult to distinguish between 
different, relatively small tumors in the brain. 
Some PBS treated animals showed also a significant decrease in tumor size compared to sham operated 
animals and the majority of the PBS treated animals. One hypothesis in the suicide gene therapy field is that 
the initial, limited intratumoral cell killing generates immunostimulatory molecules, resulting in the 
generation of a Th1 response [161-163], which helps to overcome the immune suppression by the tumor 
[213]. Our results show however that all PBS treated animals displayed mOct4- BM-MAPCs survival during 
PBS administration as determined by BLI, indicating that the observed effect on tumor growth in the PBS 
treated group is not solely attributable to mOct4- BM-MAPC cell death. It is also described in literature that 
MAPCs themselves possess immunomodulatory properties, and are thus capable of both immune 
suppression and immune stimulation [201], which might cause the immune system to favor immune 
stimulation rather than immune suppression in the tumor setting, thus further contributing to a reduced 
tumor size. This would also explain the delay in tumor growth in the mOct4+ BM-MAPCs that was seen 
initially, irrespective of the treatment groups. Adding GCV treatment seems to augment this effect even 
further which could be related to the additional effect of the proposed Th1 response system described 
earlier. As some BLI signal remaind following GCV treatment in the mOct4+ BM-MAPCs treated animals, mass 
formation caused by mOct4+ BM-MAPCs explains the lack of difference in tumor size in these animals. 
Subsequently, Hs683 or (mCherry rLuc expressing) U87-MG tumor bearing Hsd:athymic Nude-Foxn1nu mice 
were stereotactically injected intratumorally with 5 x 105 or 2.5 x 105 eGFP-Fluc-HSVTK expressing and SPIO 
labeled (1%) hMultistem’s, respectively for longitudinal follow-up of suicide gene therapy. Three groups 
were distinguished for both malignant glioma models, including a sham operated group, a PBS treated group 
and a GCV treated group (50mg/kg) of which the PBS and GCV treated groups received treatment for 14 
consecutive days. Results showed that labeled hMultistem’s were also situated in close proximity to the 
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tumor already one day post injection, therefore warranting initiation of treatment. hMultistem viability 
decreased in both the PBS and the GCV treated group in the U87-MG tumor bearing animals but not in the 
Hs683 tumor bearing animals as assessed by BLI using D-luciferin as a substrate for fLuc. This indicates stem 
cell killing probably due to the harsh U87-MG tumor microenvironment. No differences could be found in 
either tumor model concerning tumor size between animals that were sham operated or treated with PBS or 
GCV. A stagnation of the tumor viability in U87-MG tumors of GCV treated animals was observed after 
treatment. This was not the case in PBS treated or sham operated animals. All in all, stem cell mediated 
suicide gene therapy in human glioma xenograft models proved much less effective when comparing the 
results with the data generated in the GL261 glioblastoma mouse model.  
There are several plausible explanations for this failure of therapeutic response. First, developing tumors 
were generally larger in the U87-MG and Hs683 models compared to the GL261 model at the time of stem 
cell injection, which may mean that the injection of more stem cells might be necessary to elicit a 
therapeutic response. Secondly, it is apparent that administration of 50mg/kg GCV is insufficient to elicit 
efficient stem cell killing in vivo. Increasing the concentration of administered GCV was not studied 
systematically as this resulted in the development of side effects such as diarrhoea and weight loss. Another 
method to increase the amount of GCV reaching the brain is to use a 1,4-dihydrotrigonelline modified GCV 
which crosses the BBB more easily and is subsequently trapped inside the brain [206]. Increasing the HSV-TK 
expression by the stem cells would be another alternative but this might need a different approach for 
transgene insertion as application of higher concentrations of lentiviral vectors during transduction resulted 
in detrimental effects on cell propagation. An alternative strategy to augment transgene expression is to use 
the CAG promoter in stead of the EF1α promoter to drive gene expression.  
Thirdly, it has been described in literature however that high grade glioma display less cell-cell 
communication and thus fewer gap junctions which might result in decreased therapeutic response [202, 
214].  
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More importantly, we have to use immune-compromized mice for the human glioma xenograft model. It 
was reported that the bystander killing effect is also in part T cell mediated [161-163] which would explain 
also why no effect can be seen in the human glioma xenograft mouse models which do not have T cells. This 
theory is also supported by our observation that in some cases PBS treated GL261 tumor bearing animals 
which received mOct4- BM-MAPCs also show a decreased tumor growth even when clear tumor growth was 
present at the time of stem cell injection.  
Brain sections were stained for activated microglia, which are normally activated by Th1 cells. In Hs683 
tumor bearing animals, very few activated microglia could be seen inside the tumor area, whereas activated 
microglial cells were abundantly present in the tissue surrounding the tumor. In the U87-MG tumor some 
activated microglial cells were present inside the tumor area although no differences in microglial activation 
could be seen between the different treatment groups. In GL261 tumor bearing animals however, microglial 
cells were also present in certain part of the tumor tissue in sham operated and PBS control animals. In GCV 
responding animals, many more microglial cells were present in and around the graft, indicating efficient 
microglial cell activation and clearing of the tumor.  
Finally, as the tumor has a doubling time of days rather than months, we would not be able to pick up 
marginal effects on tumor growth with only imaging before and after treatment. Additional scanning 
sessions might be beneficial although care should be taken with increasing the sedation sessions as this may 
result in profound weight loss as animals are already weakened due to tumor growth. Furthermore, the 
bystander killing effect is dependent on the existence of gap junctions between adjacent cells.  
These results indicate that although stem cell based suicide gene therapy is a promising approach; further 
investigations are required for possible mechanisms of action in different tumor environments, using a 
variety of stem cells to optimize therapeutic effects. With the development of the mentioned imaging 
techniques it is now possible to monitor these different stem cells, and other parameters longitudinally in 
vivo, which allows more rapid screening and optimization of malignant glioma models. 
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In conclusion, we have shown that suicide gene therapy using several stem cells in different malignant 
glioma models can be followed and guided in vivo by MRI and BLI. Hereby, MRI can be used to ascertain 
stem cell location prior to treatment initation and tumor growth follow-up. BLI can be used to assess stem 
cell viability prior to and following treatment response. Thus, outliers can be detected earlier, GCV treatment 
can be initiated based on stem cell distribution rather than on empirical time points and a more thorough 
follow-up can be provided prior to and following treatment of these animals.  
7.2 Future perspectives 
This work has shown that in vivo follow-up of suicide gene therapy mediated by stem cells delivering the 
suicide gene to the tumor site is feasible with multi-modal imaging. In our hands, MRI and BLI were best 
suited for this purpose in our preclinical setting. However, a more thorough understanding of tumor cell 
viability is also required for assessment of treatment efficacy. This information could be generated by BLI. 
However, rLuc was not successful in our models. Due to its low resolution in the mouse model, [18F] FET PET 
imaging conveyed little additional information with regard to tumor viability. For clinical relevance and 
translationability, it is however preferable to use PET in stead of BLI. Concurrent MRI and PET might result in 
more accurate quantification as co-registration becomes possible. Therefore, a transferable animal bed for 
MRI and PET purposes is required to obtain both images at the same time. Alternatively, multiple MRI/PET 
systems have become available which also aid this co-registration. Thus, the tumor area can be delineated 
on the MR images after which PET image analysis can be performed on the same region. In our study, PET 
data analysis was performed on the striatum derived from a mouse brain atlas. However, as described PET 
imaging was very challenging in a mouse model, ultimately, rat glioblastoma models could be more suitable 
for PET imaging as the rat brain is larger and a rat brain atlas is also available for striatal delineation.  
In this study, the use of mOct4- BM-MAPCs resulted in a delayed tumor growth in most of the GCV treated 
animals when compared to PBS control animals. However, 7 out of 18 animals did not show a response to 
GCV treatment, although stem cells were efficiently killed as shown by BLI. As we mentioned earlier, one 
underlying mechanism of action for the suicide gene therapy is possibly the generation of a Th1 response 
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which fortifies the tumor clearance. Treatments which enhance this Th1 response might further ameliorate 
the results obtained in this study. Therefore an approach combining suicide gene therapy with intralesional 
infusion, using for instance an ommaya reservoir adapted with an osmotic pump, of the Th1 promoting 
cytokine interleukin-12 (IL-12) [215] might ameliorate the evoked Th1 response and aid further clearance of 
residual tumor tissue. Further optimization is also required in HSV-TK expression levels as in our study, a 
dose of 50mg/kg GCV was used in order to reach sufficiently high levels for killing of the therapeutic stem 
cells in vivo. Further elevation of the GCV dose without exerting side effects proved to be challenging. 
Therefore, increasing the expression levels of HSV-TK might enable us to decrease the concentration of GCV 
required for generating an efficient therapeutic response and obtain higher response rates. This could, for 
example, be achieved by employing the CAG promoter to drive transgene expression. Furthermore, 
homogeneous GCV distribution might be hampered by the heterogenous nature of the studied malignant 
glioma models. A more optimized GCV distribution could be reached in the brain by using an adapted form 
of GCV, such as a liposomal formulation which crosses the BBB more easily and traps the GCV within the 
brain, resulting in higher homogenous GCV concentrations within the tumor and further increasing a 
therapeutic response [206].  
The current advancements in molecular multi-modal imaging have created a multitude of options for follow-
up of both stem cell fate and therapeutic efficacy when employing stem cell based suicide gene therapy. In 
this study, we have optimized protocols for stem cell tracking using MRI (distribution) and BLI (viability) 
during treatment of several malignant glioma models. The established imaging protocols to follow suicide 
gene therapy in different malignant glioma models using several different therapeutic stem cells enables 
researchers to screen a multitude of possible therapeutic stem cells in order to identify the most suitable 
stem cells and to gain further insights in the mechanisms involved in this therapeutic approach. This 
additional information might aid researchers in optimizing suicide gene therapy for clinical applications 
which might result in significant improvements regarding the poor prognosis faced by glioblastoma patients 
today.  
 References 
152 
 
References 
1. Dolecek, T.A., et al., CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors 
Diagnosed in the United States in 2005-2009. Neuro Oncol, 2012. 14 Suppl 5: p. v1-v49. 
2. Kagadis, G.C., et al., In vivo small animal imaging: current status and future prospects. Med Phys, 
2010. 37(12): p. 6421-42. 
3. Stupp, R., et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus 
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the 
EORTC-NCIC trial. Lancet Oncol, 2009. 10(5): p. 459-66. 
4. Aranguren, X.L., et al., Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J 
Clin Invest, 2008. 118(2): p. 505-14. 
5. Louis, D.N., et al., The 2007 WHO classification of tumours of the central nervous system. Acta 
Neuropathol, 2007. 114(2): p. 97-109. 
6. Walker, P.R., et al., T-cell immune responses in the brain and their relevance for cerebral 
malignancies. Brain Res Brain Res Rev, 2003. 42(2): p. 97-122. 
7. Cheng, L., et al., Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res 
Commun, 2011. 406(4): p. 643-8. 
8. Brustle, O., et al., Primitive neuroectodermal tumors after prophylactic central nervous system 
irradiation in children. Association with an activated K-ras gene. Cancer, 1992. 69(9): p. 2385-92. 
9. Bleeker, F.E., R.J. Molenaar, and S. Leenstra, Recent advances in the molecular understanding of 
glioblastoma. J Neurooncol, 2012. 108(1): p. 11-27. 
10. James, M.L. and S.S. Gambhir, A molecular imaging primer: modalities, imaging agents, and 
applications. Physiol Rev, 2011. 92(2): p. 897-965. 
11. Janowski, M., J.W. Bulte, and P. Walczak, Personalized nanomedicine advancements for stem cell 
tracking. Adv Drug Deliv Rev, 2012. 64(13): p. 1488-507. 
12. Contag, C.H., et al., Visualizing gene expression in living mammals using a bioluminescent reporter. 
Photochem Photobiol, 1997. 66(4): p. 523-31. 
13. Hilderbrand, S.A. and R. Weissleder, Near-infrared fluorescence: application to in vivo molecular 
imaging. Curr Opin Chem Biol, 2010. 14(1): p. 71-9. 
14. Dinca, E.B., R.V. Voicu, and A.V. Ciurea, Bioluminescence imaging of invasive intracranial xenografts: 
implications for translational research and targeted therapeutics of brain tumors. Neurosurg Rev, 
2010. 33(4): p. 385-94. 
15. Ozawa, T. and C.D. James, Establishing intracranial brain tumor xenografts with subsequent analysis 
of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp, 2010(41). 
16. Jost, S.C., et al., Measuring brain tumor growth: combined bioluminescence imaging-magnetic 
resonance imaging strategy. Mol Imaging, 2009. 8(5): p. 245-53. 
17. Badr, C.E. and B.A. Tannous, Bioluminescence imaging: progress and applications. Trends Biotechnol, 
2011. 29(12): p. 624-33. 
18. Zhao, S., et al., Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with 
regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med, 
2005. 46(4): p. 675-82. 
19. Di Chiro, G., et al., Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and 
positron emission tomography. Neurology, 1982. 32(12): p. 1323-9. 
20. Alavi, J.B., et al., Positron emission tomography in patients with glioma. A predictor of prognosis. 
Cancer, 1988. 62(6): p. 1074-8. 
21. Miyagawa, T., et al., "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood 
Flow Metab, 1998. 18(5): p. 500-9. 
22. Bergstrom, M., et al., Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-
(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol, 
1987. 28(3): p. 225-9. 
 References 
153 
 
23. Kracht, L.W., et al., Delineation of brain tumor extent with [11C]L-methionine positron emission 
tomography: local comparison with stereotactic histopathology. Clin Cancer Res, 2004. 10(21): p. 
7163-70. 
24. Grosu, A.L., et al., An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-
[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol 
Biol Phys, 2011. 81(4): p. 1049-58. 
25. Grosu, A.L., et al., An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-
[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol 
Biol Phys, 2010. 81(4): p. 1049-58. 
26. Ullrich, R.T., L.W. Kracht, and A.H. Jacobs, Neuroimaging in patients with gliomas. Semin Neurol, 
2008. 28(4): p. 484-94. 
27. Chen, X., et al., Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. 
Mol Imaging Biol, 2006. 8(1): p. 9-15. 
28. Wehrl, H.F., et al., Multimodal Elucidation of Choline Metabolism in a Murine Glioma Model Using 
Magnetic Resonance Spectroscopy and 11C-Choline Positron Emission Tomography. Cancer Res, 
2013. 73(5): p. 1470-1480. 
29. Collins, S.A., et al., PET imaging for gene & cell therapy. Curr Gene Ther, 2012. 12(1): p. 20-32. 
30. Penheiter, A.R., S.J. Russell, and S.K. Carlson, The sodium iodide symporter (NIS) as an imaging 
reporter for gene, viral, and cell-based therapies. Curr Gene Ther, 2012. 12(1): p. 33-47. 
31. Casteels, C., et al., Construction and evaluation of multitracer small-animal PET probabilistic atlases 
for voxel-based functional mapping of the rat brain. J Nucl Med, 2006. 47(11): p. 1858-66. 
32. Vande Velde, G., et al., Magnetic resonance imaging and spectroscopy methods for molecular 
imaging. Q J Nucl Med Mol Imaging, 2009. 53(6): p. 565-85. 
33. Choi, J.K., A. Dedeoglu, and B.G. Jenkins, Application of MRS to mouse models of neurodegenerative 
illness. NMR Biomed, 2007. 20(3): p. 216-37. 
34. Hoehn, M., et al., Application of magnetic resonance to animal models of cerebral ischemia. J Magn 
Reson Imaging, 2001. 14(5): p. 491-509. 
35. Cha, S., et al., Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with 
histopathology. Magn Reson Med, 2003. 49(5): p. 848-55. 
36. Doblas, S., et al., Glioma morphology and tumor-induced vascular alterations revealed in seven 
rodent glioma models by in vivo magnetic resonance imaging and angiography. J Magn Reson 
Imaging, 2010. 32(2): p. 267-75. 
37. Hoehn, M., et al., Cell tracking using magnetic resonance imaging. J Physiol, 2007. 584(Pt 1): p. 25-
30. 
38. Srinivas, M., et al., Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo 
imaging using 19F MRI and optical imaging. Biomaterials, 2010. 31(27): p. 7070-7. 
39. Schwarcz, A., et al., Localized proton MRS of cerebral metabolite profiles in different mouse strains. 
Magn Reson Med, 2003. 49(5): p. 822-7. 
40. He, Q., et al., Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer 
diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers, 
2003. 19(2-3): p. 69-94. 
41. Rosol, M., et al., Metabolism of orthotopic mouse brain tumor models. Mol Imaging, 2009. 8(4): p. 
199-208. 
42. Simoes, R.V., et al., Preliminary characterization of an experimental breast cancer cells brain 
metastasis mouse model by MRI/MRS. MAGMA, 2008. 21(4): p. 237-49. 
43. Nelson, S.J., Assessment of therapeutic response and treatment planning for brain tumors using 
metabolic and physiological MRI. NMR Biomed, 2011. 24(6): p. 734-49. 
44. Gerstner, E.R., et al., Advances in neuroimaging techniques for the evaluation of tumor growth, 
vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol, 2008. 21(6): p. 728-35. 
 References 
154 
 
45. Peet, A.C., et al., Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol, 2012. 
9(12): p. 700-11. 
46. Vrabec, M., et al., MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma 
treated with dendritic cell immunotherapy: a pilot study. Neuroradiology, 2011. 53(10): p. 721-31. 
47. Van Cauter, S., et al., Gliomas: diffusion kurtosis MR imaging in grading. Radiology, 2012. 263(2): p. 
492-501. 
48. Van Cauter, S., et al., Integrating diffusion kurtosis imaging, dynamic susceptibility-weighted 
contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas. Neuro 
Oncol, 2014. 
49. Assi, H., et al., Gene therapy for brain tumors: basic developments and clinical implementation. 
Neurosci Lett, 2012. 527(2): p. 71-7. 
50. Ardon, H., et al., Integration of autologous dendritic cell-based immunotherapy in the standard of 
care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II 
trial. Cancer Immunol Immunother, 2012. 61(11): p. 2033-44. 
51. Dietrich, J., A.D. Norden, and P.Y. Wen, Emerging antiangiogenic treatments for gliomas - efficacy 
and safety issues. Curr Opin Neurol, 2008. 21(6): p. 736-44. 
52. Lee, J., et al., Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely 
mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 
2006. 9(5): p. 391-403. 
53. Sakariassen, P.O., et al., Angiogenesis-independent tumor growth mediated by stem-like cancer cells. 
Proc Natl Acad Sci U S A, 2006. 103(44): p. 16466-71. 
54. Barth, R.F. and B. Kaur, Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, 
F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol, 2009. 94(3): p. 299-312. 
55. Kruse, C.A., et al., A rat glioma model, CNS-1, with invasive characteristics similar to those of human 
gliomas: a comparison to 9L gliosarcoma. J Neurooncol, 1994. 22(3): p. 191-200. 
56. Mathieu, D., et al., Standardization and detailed characterization of the syngeneic Fischer/F98 
glioma model. Can J Neurol Sci, 2007. 34(3): p. 296-306. 
57. Sibenaller, Z.A., et al., Genetic characterization of commonly used glioma cell lines in the rat animal 
model system. Neurosurg Focus, 2005. 19(4): p. E1. 
58. Tzeng, J.J., et al., Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from 
immunogenic and nonimmunogenic rat brain tumors. Cancer Res, 1991. 51(9): p. 2373-8. 
59. de Vries, N.A., J.H. Beijnen, and O. van Tellingen, High-grade glioma mouse models and their 
applicability for preclinical testing. Cancer Treat Rev, 2009. 35(8): p. 714-23. 
60. Ausman, J.I., W.R. Shapiro, and D.P. Rall, Studies on the chemotherapy of experimental brain tumors: 
development of an experimental model. Cancer Res, 1970. 30(9): p. 2394-400. 
61. Zimmerman, H.M., Hildegarde A., Experimental Brain Tumors I. Tumors Produced with 
Methylcholanthrene. Cancer res, 1941. 1(12): p. 20. 
62. Maes, W. and S.W. Van Gool, Experimental immunotherapy for malignant glioma: lessons from two 
decades of research in the GL261 model. Cancer Immunol Immunother. 
63. Candolfi, M., et al., Intracranial glioblastoma models in preclinical neuro-oncology: 
neuropathological characterization and tumor progression. J Neurooncol, 2007. 85(2): p. 133-48. 
64. Norden, A.D., J. Drappatz, and P.Y. Wen, Novel anti-angiogenic therapies for malignant gliomas. 
Lancet Neurol, 2008. 7(12): p. 1152-60. 
65. di Tomaso, E., et al., Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" 
revascularization as mode of escape. Cancer Res, 2011. 71(1): p. 19-28. 
66. Maes, W., et al., DC vaccination with anti-CD25 treatment leads to long-term immunity against 
experimental glioma. Neuro Oncol, 2009. 11(5): p. 529-42. 
67. Dey, M., I.V. Ulasov, and M.S. Lesniak, Virotherapy against malignant glioma stem cells. Cancer Lett, 
2010. 289(1): p. 1-10. 
 References 
155 
 
68. Holzmuller, R., et al., YB-1 dependent virotherapy in combination with temozolomide as a multimodal 
therapy approach to eradicate malignant glioma. Int J Cancer, 2011. 129(5): p. 1265-76. 
69. Kwiatkowska, A., et al., Strategies in gene therapy for glioblastoma. Cancers (Basel), 2013. 5(4): p. 
1271-305. 
70. Juratli, T.A., G. Schackert, and D. Krex, Current status of local therapy in malignant gliomas--a clinical 
review of three selected approaches. Pharmacol Ther, 2013. 139(3): p. 341-58. 
71. Bernardes, N., A.M. Chakrabarty, and A.M. Fialho, Engineering of bacterial strains and their products 
for cancer therapy. Appl Microbiol Biotechnol, 2013. 97(12): p. 5189-99. 
72. Germano, I.M., M. Uzzaman, and G. Keller, Gene delivery by embryonic stem cells for malignant 
glioma therapy: hype or hope? Cancer Biol Ther, 2008. 7(9): p. 1341-7. 
73. Duarte, S., et al., Suicide gene therapy in cancer: where do we stand now? Cancer Lett, 2012. 324(2): 
p. 160-70. 
74. Germano, I.M. and E. Binello, Gene therapy as an adjuvant treatment for malignant gliomas: from 
bench to bedside. J Neurooncol, 2009. 93(1): p. 79-87. 
75. Verfaillie, C.M., Adult stem cells: assessing the case for pluripotency. Trends Cell Biol, 2002. 12(11): p. 
502-8. 
76. Eckfeldt, C.E., E.M. Mendenhall, and C.M. Verfaillie, The molecular repertoire of the 'almighty' stem 
cell. Nat Rev Mol Cell Biol, 2005. 6(9): p. 726-37. 
77. Burns, T.C. and G.K. Steinberg, Stem cells and stroke: opportunities, challenges and strategies. Expert 
Opin Biol Ther, 2011. 11(4): p. 447-61. 
78. Bang, O.Y., et al., Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol, 
2005. 57(6): p. 874-82. 
79. Vaes, B., et al., Application of MultiStem((R)) Allogeneic Cells for Immunomodulatory Therapy: 
Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease. Front 
Immunol, 2012. 3: p. 345. 
80. Park, S.A., et al., CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells 
exhibit enhanced migratory capacity toward gliomas. Int J Oncol. 38(1): p. 97-103. 
81. Eskandary, H., et al., The role of stem cells in tumor targeting and growth suppression of gliomas. 
Biologics. 5: p. 61-70. 
82. Miletic, H., et al., Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating 
progenitor cells expressing a suicide gene. Mol Ther, 2007. 15(7): p. 1373-81. 
83. Alexander, D.B. and G.S. Goldberg, Transfer of biologically important molecules between cells 
through gap junction channels. Curr Med Chem, 2003. 10(19): p. 2045-58. 
84. Li, S., et al., Bystander effect-mediated gene therapy of gliomas using genetically engineered neural 
stem cells. Cancer Gene Ther, 2005. 12(7): p. 600-7. 
85. Matuskova, M., et al., HSV-tk expressing mesenchymal stem cells exert bystander effect on human 
glioblastoma cells. Cancer Lett. 290(1): p. 58-67. 
86. Egea, V., et al., TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes 
migration toward experimental glioma. Cell Death Differ. 
87. Paino, T., et al., Inhibition of ATP-sensitive potassium channels increases HSV-tk/GCV bystander effect 
in U373 human glioma cells by enhancing gap junctional intercellular communication. 
Neuropharmacology. 59(6): p. 480-91. 
88. Massoud, T.F. and S.S. Gambhir, Molecular imaging in living subjects: seeing fundamental biological 
processes in a new light. Genes Dev, 2003. 17(5): p. 545-80. 
89. Koul, D., et al., Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human 
glioblastoma. Neuro Oncol, 2010. 12(6): p. 559-69. 
90. Asanuma, T., et al., Diffusion tensor imaging and fiber tractography of C6 rat glioma. J Magn Reson 
Imaging, 2008. 28(3): p. 566-73. 
 References 
156 
 
91. Kharuzhyk, S.A., N.A. Petrovskaya, and M.A. Vosmitel, Diffusion-weighted magnetic resonance 
imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model. Exp 
Oncol, 2010. 32(2): p. 104-6. 
92. Tofts, P.S., et al., Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI 
of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging, 1999. 10(3): p. 
223-32. 
93. Zhao, Y., et al., Targeted suicide gene therapy for glioma using human embryonic stem cell-derived 
neural stem cells genetically modified by baculoviral vectors. Gene Ther, 2012. 19(2): p. 189-200. 
94. Zhang, K., et al., Comparison of cerebral blood flow acquired by simultaneous [(15)O]water positron 
emission tomography and arterial spin labeling magnetic resonance imaging. J Cereb Blood Flow 
Metab, 2014. 34(8): p. 1373-80. 
95. Brubaker, L.M., et al., Magnetic resonance angiography visualization of abnormal tumor vasculature 
in genetically engineered mice. Cancer Res, 2005. 65(18): p. 8218-23. 
96. Keunen, O., et al., Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in 
glioblastoma. Proc Natl Acad Sci U S A, 2011. 108(9): p. 3749-54. 
97. Spaeth, N., et al., Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-
deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging, 2006. 33(6): p. 673-82. 
98. Assadian, S., et al., FDG-PET imaging for the evaluation of antiglioma agents in a rat model. Neuro 
Oncol, 2008. 10(3): p. 292-9. 
99. Hekmatyar, S.K., et al., (1)H nuclear magnetic resonance spectroscopy characterisation of metabolic 
phenotypes in the medulloblastoma of the SMO transgenic mice. Br J Cancer, 2010. 103(8): p. 1297-
304. 
100. Park, I., et al., Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain 
tumors. Neuro Oncol, 2010. 12(2): p. 133-44. 
101. Lagae; U. Himmelreich, A.D.H.C.V.G.V.V.H.J.S.M.N.D.J.J.T.S.S.M.L. Gold nanostars as a theranostic 
agent for multimodal imaging and photothermal treatment of cancer. in 9th European Molecular 
Imaging Meeting. 2014. Antwerp (Belgium). 
102. Van de Broek, B., et al., Specific cell targeting with nanobody conjugated branched gold 
nanoparticles for photothermal therapy. ACS Nano, 2011. 5(6): p. 4319-28. 
103. Day, E.S., et al., Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for 
imaging and therapy of breast cancer. Int J Nanomedicine, 2010. 5: p. 445-54. 
104. Qian, X., et al., In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman 
nanoparticle tags. Nat Biotechnol, 2008. 26(1): p. 83-90. 
105. Yi, D.K., et al., Matrix metalloproteinase sensitive gold nanorod for simultaneous bioimaging and 
photothermal therapy of cancer. Bioconjug Chem, 2010. 21(12): p. 2173-7. 
106. Maes, W., et al., In vivo bioluminescence imaging in an experimental mouse model for dendritic cell 
based immunotherapy against malignant glioma. J Neurooncol, 2009. 91(2): p. 127-39. 
107. Jang, S.J., et al., Application of bioluminescence imaging to therapeutic intervention of herpes simplex 
virus type I - Thymidine kinase/ganciclovir in glioma. Cancer Lett, 2010. 297(1): p. 84-90. 
108. Winkler, F., et al., Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and 
peritumoral angiogenesis. Glia, 2009. 57(12): p. 1306-15. 
109. Himmelreich, U. and T. Dresselaers, Cell labeling and tracking for experimental models using 
magnetic resonance imaging. Methods, 2009. 48(2): p. 112-24. 
110. Tavare, R., et al., Monitoring of in vivo function of superparamagnetic iron oxide labelled murine 
dendritic cells during anti-tumour vaccination. PLoS One, 2011. 6(5): p. e19662. 
111. Miyagawa, T., et al., Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, 
[18F]FFEAU, and other imaging probes. J Nucl Med, 2008. 49(4): p. 637-48. 
112. Johnson, M., et al., Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-
FHBG PET imaging in a prostate tumor. J Nucl Med, 2009. 50(5): p. 757-64. 
 References 
157 
 
113. Zhou, J., et al., Differentiation between glioma and radiation necrosis using molecular magnetic 
resonance imaging of endogenous proteins and peptides. Nat Med, 2011. 17(1): p. 130-4. 
114. Spaeth, N., et al., Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute 
cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor 
recurrence. J Nucl Med, 2004. 45(11): p. 1931-8. 
115. Jarzabek, M.A., et al., In Vivo Bioluminescence Imaging Validation of a Human Biopsy-derived 
Orthotopic Mouse Model of Glioblastoma Multiforme. Mol Imaging, 2012. 12(3): p. 161-72. 
116. Corroyer-Dulmont, A., et al., Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-
imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma. Biol 
Chem, 2013. 394(4): p. 529-39. 
117. Corroyer-Dulmont, A., et al., Detection of glioblastoma response to temozolomide combined with 
bevacizumab based on muMRI and muPET imaging reveals [18F]-fluoro-L-thymidine as an early and 
robust predictive marker for treatment efficacy. Neuro Oncol, 2013. 15(1): p. 41-56. 
118. Cronin, M., et al., High resolution in vivo bioluminescent imaging for the study of bacterial tumour 
targeting. PLoS One, 2012. 7(1): p. e30940. 
119. Chu, S.H., et al., In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles. 
Neuro Oncol, 2013. 
120. Bach, P., et al., Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. 
Cancer Res, 2013. 73(2): p. 865-74. 
121. Llaguno-Munive, M., et al., Mifepristone improves chemo-radiation response in glioblastoma 
xenografts. Cancer Cell Int, 2013. 13(1): p. 29. 
122. Cen, L., et al., Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM 
xenograft models. Neuro Oncol, 2013. 
123. Viel, T., et al., Analysis of the growth dynamics of angiogenesis-dependent and -independent 
experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med, 2012. 53(7): p. 
1135-45. 
124. Schwartz, D.L., et al., HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor 
radiation resistance. Mol Cancer Res, 2011. 9(3): p. 259-70. 
125. Baumann, B.C., et al., An integrated method for reproducible and accurate image-guided stereotactic 
cranial irradiation of brain tumors using the small animal radiation research platform. Transl Oncol, 
2012. 5(4): p. 230-7. 
126. Zhou, H., et al., Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial 
glioma of athymic mice. PLoS One, 2009. 4(11): p. e8051. 
127. Dorsey, J.F., et al., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel 
have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther, 2009. 8(12): 
p. 3285-95. 
128. Wei, L.H., et al., Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase 
inhibition by rapamycin in glioblastoma. Clin Cancer Res, 2008. 14(11): p. 3416-26. 
129. Vrabec, M., et al., MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma 
treated with dendritic cell immunotherapy: a pilot study. Neuroradiology. 
130. Law, M., et al., Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging 
and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J 
Neuroradiol, 2003. 24(10): p. 1989-98. 
131. Gursel, D.B., N. Berry, and J.A. Boockvar, Therapeutic stem cells encapsulated in a synthetic 
extracellular matrix selectively kill tumor cells, delay tumor growth, and increase survival in a mouse 
resection model of malignant glioma. Neurosurgery, 2012. 70(6): p. N17-9. 
132. Ulloa-Montoya, F., et al., Comparative transcriptome analysis of embryonic and adult stem cells with 
extended and limited differentiation capacity. Genome Biol, 2007. 8(8): p. R163. 
 References 
158 
 
133. Roobrouck, V.D., et al., Differentiation potential of human postnatal mesenchymal stem cells, 
mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially 
influenced by the culture conditions. Stem Cells, 2011. 29(5): p. 871-82. 
134. Verfaillie, C.M., Multipotent adult progenitor cells: an update. Novartis Found Symp, 2005. 265: p. 
55-61; discussion 61-5, 92-7. 
135. Breyer, A., et al., Multipotent adult progenitor cell isolation and culture procedures. Exp Hematol, 
2006. 34(11): p. 1596-601. 
136. Branle, F., et al., Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human 
glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the 
evaluation of surgery combined with chemotherapy. Cancer, 2002. 95(3): p. 641-55. 
137. Ibrahimi, A., et al., Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum 
Gene Ther, 2009. 20(8): p. 845-60. 
138. Subramanian, K., et al., Isolation procedure and characterization of multipotent adult progenitor cells 
from rat bone marrow. Methods Mol Biol, 2010. 636: p. 55-78. 
139. Trekker, J., Jans K., Damm H., Mertens D., Nuytten T., Vanacken J., Moshchalkov V., D'Haen J., 
Stakenborg T., Van Roy W., Himmelreich U. , Synthesis of PEGylated magnetic nanoparticles with 
different core sizes. IEEE Trans Magn, 2013(49): p. 219-226. 
140. Trekker, J., et al., Sensitive in vivo cell detection using size-optimized superparamagnetic 
nanoparticles. Biomaterials, 2013. 35(5): p. 1627-35. 
141. Struys, T., et al., Magnetic resonance imaging of human dental pulp stem cells in vitro and in vivo. 
Cell Transplant, 2013. 22(10): p. 1813-29. 
142. Rosland, G.V., et al., Long-term cultures of bone marrow-derived human mesenchymal stem cells 
frequently undergo spontaneous malignant transformation. Cancer Res, 2009. 69(13): p. 5331-9. 
143. Trekker, J., et al., Sensitive in vivo cell detection using size-optimized superparamagnetic 
nanoparticles. Biomaterials, 2013. 
144. Cunningham, J.J., et al., Lessons from human teratomas to guide development of safe stem cell 
therapies. Nat Biotechnol, 2012. 30(9): p. 849-57. 
145. Lo Nigro, A., et al., MAPC culture conditions support the derivation of cells with nascent hypoblast 
features from bone marrow and blastocysts. J Mol Cell Biol, 2012. 4(6): p. 423-6. 
146. Chien, L.Y., et al., In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and 
therapeutic impact of human mesenchymal stem cells in a murine glioma model. Biomaterials, 2011. 
32(12): p. 3275-84. 
147. Sun, N., A. Lee, and J.C. Wu, Long term non-invasive imaging of embryonic stem cells using reporter 
genes. Nat Protoc, 2009. 4(8): p. 1192-201. 
148. Wolfs, E., et al., Optimization of multimodal imaging of mesenchymal stem cells using the human 
sodium iodide symporter for PET and Cerenkov luminescence imaging. PLoS One, 2014. 9(4): p. 
e94833. 
149. Wang, N., et al., Comparison of transduction efficiency among various lentiviruses containing GFP 
reporter in bone marrow hematopoietic stem cell transplantation. Exp Hematol, 2013. 41(11): p. 934-
43. 
150. Jacobs, A.H., et al., Improved herpes simplex virus type 1 amplicon vectors for proportional 
coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther, 2003. 
14(3): p. 277-97. 
151. Kucerova, L., et al., Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer 
gene therapy. Cancer Res, 2007. 67(13): p. 6304-13. 
152. Miletic, H., et al., Normal brain cells contribute to the bystander effect in suicide gene therapy of 
malignant glioma. Clin Cancer Res, 2007. 13(22 Pt 1): p. 6761-8. 
153. Barth, R.F., Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), 
RT-2 and CNS-1 gliomas. J Neurooncol, 1998. 36(1): p. 91-102. 
 References 
159 
 
154. Kovacsovics-Bankowski, M., et al., Pre-clinical safety testing supporting clinical use of allogeneic 
multipotent adult progenitor cells. Cytotherapy, 2008. 10(7): p. 730-42. 
155. Szatmari, T., et al., Detailed characterization of the mouse glioma 261 tumor model for experimental 
glioblastoma therapy. Cancer Sci, 2006. 97(6): p. 546-53. 
156. Leten, C., et al., In vivo and ex vivo assessment of the blood brain barrier integrity in different 
glioblastoma animal models. J Neurooncol, 2014. 
157. Jacobs, A.H., et al., Imaging-guided gene therapy of experimental gliomas. Cancer Res, 2007. 67(4): 
p. 1706-15. 
158. Le Mercier, M., et al., Knocking down galectin 1 in human hs683 glioblastoma cells impairs both 
angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol, 2008. 67(5): p. 
456-69. 
159. Nichols, J., et al., Formation of pluripotent stem cells in the mammalian embryo depends on the POU 
transcription factor Oct4. Cell, 1998. 95(3): p. 379-91. 
160. Fillat, C., et al., Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase 
gene/Ganciclovir system: fifteen years of application. Curr Gene Ther, 2003. 3(1): p. 13-26. 
161. Vile, R.G., et al., Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-
mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of 
cytokines in the tumour cells. Biochem Soc Trans, 1997. 25(2): p. 717-22. 
162. Vile, R.G., et al., Generation of an anti-tumour immune response in a non-immunogenic tumour: 
HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural 
cytokine expression. Int J Cancer, 1997. 71(2): p. 267-74. 
163. Braumuller, H., et al., T-helper-1-cell cytokines drive cancer into senescence. Nature, 2013. 
494(7437): p. 361-5. 
164. Perek, N. and D. Denoyer, The multidrug resistance mechanisms and their interactions with the 
radiopharmaceutical probes used for an in vivo detection. Curr Drug Metab, 2002. 3(1): p. 97-113. 
165. Zagzag, D., et al., Vascular apoptosis and involution in gliomas precede neovascularization: a novel 
concept for glioma growth and angiogenesis. Lab Invest, 2000. 80(6): p. 837-49. 
166. Wesseling, P., D.J. Ruiter, and P.C. Burger, Angiogenesis in brain tumors; pathobiological and clinical 
aspects. J Neurooncol, 1997. 32(3): p. 253-65. 
167. Kaya, M. and B. Ahishali, Assessment of permeability in barrier type of endothelium in brain using 
tracers: Evans blue, sodium fluorescein, and horseradish peroxidase. Methods Mol Biol, 2011. 763: p. 
369-82. 
168. Roberts, H.C., et al., Quantitative estimation of microvascular permeability in human brain tumors: 
correlation of dynamic Gd-DTPA-enhanced MR imaging with histopathologic grading. Acad Radiol, 
2002. 9 Suppl 1: p. S151-5. 
169. Just, M., et al., MRI-assisted radiation therapy planning of brain tumors--clinical experiences in 17 
patients. Magn Reson Imaging, 1991. 9(2): p. 173-7. 
170. Roberts, H.C., et al., Dynamic, contrast-enhanced CT of human brain tumors: quantitative 
assessment of blood volume, blood flow, and microvascular permeability: report of two cases. AJNR 
Am J Neuroradiol, 2002. 23(5): p. 828-32. 
171. Nomura, T., T. Inamura, and K.L. Black, Intracarotid infusion of bradykinin selectively increases blood-
tumor permeability in 9L and C6 brain tumors. Brain Res, 1994. 659(1-2): p. 62-6. 
172. Preston, E. and J. Webster, Differential passage of [14C]sucrose and [3H]inulin across rat blood-brain 
barrier after cerebral ischemia. Acta Neuropathol, 2002. 103(3): p. 237-42. 
173. Loveless, M.E., et al., A quantitative comparison of the influence of individual versus population-
derived vascular input functions on dynamic contrast enhanced-MRI in small animals. Magn Reson 
Med, 2011. 67(1): p. 226-36. 
174. Matuskova, M., et al., HSV-tk expressing mesenchymal stem cells exert bystander effect on human 
glioblastoma cells. Cancer Lett, 2009. 290(1): p. 58-67. 
 References 
160 
 
175. Hata, N., et al., Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem 
cells for malignant gliomas. Neurosurgery, 2010. 66(1): p. 144-56; discussion 156-7. 
176. Pardridge, W.M., Drug targeting to the brain. Pharm Res, 2007. 24(9): p. 1733-44. 
177. Vandeputte, C., et al., Characterization of the inflammatory response in a photothrombotic stroke 
model by MRI: implications for stem cell transplantation. Mol Imaging Biol. 13(4): p. 663-71. 
178. Jain, R.K., et al., Angiogenesis in brain tumours. Nat Rev Neurosci, 2007. 8(8): p. 610-22. 
179. Lee, S.W., et al., Blood-brain barrier interfaces and brain tumors. Arch Pharm Res, 2006. 29(4): p. 
265-75. 
180. Belot, N., et al., Molecular characterization of cell substratum attachments in human glial tumors 
relates to prognostic features. Glia, 2001. 36(3): p. 375-90. 
181. Lamoral-Theys, D., et al., Long-term temozolomide treatment induces marked amino metabolism 
modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia, 2010. 
12(1): p. 69-79. 
182. Wolburg, H., et al., The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med, 
2012. 33(5-6): p. 579-89. 
183. Mathieu, V., et al., Combining bevacizumab with temozolomide increases the antitumor efficacy of 
temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia, 2008. 10(12): p. 
1383-92. 
184. Sturm, D., et al., Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological 
subgroups of glioblastoma. Cancer Cell, 2012. 22(4): p. 425-37. 
185. Szerlip, N.J., et al., Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA 
amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl 
Acad Sci U S A, 2011. 109(8): p. 3041-6. 
186. Barajas, R.F., Jr., et al., Regional variation in histopathologic features of tumor specimens from 
treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol, 
2012. 14(7): p. 942-54. 
187. Kremer, S., et al., Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. 
Neurology, 2013. 81(3): p. 206-10. 
188. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl 
J Med, 2005. 352(10): p. 987-96. 
189. Chiocca, E.A., et al., Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral 
therapies in neuro-oncology. J Neurooncol, 2004. 69(1-3): p. 101-17. 
190. Zu, C. and J. Wang, Tumor-colonizing bacteria: a potential tumor targeting therapy. Crit Rev 
Microbiol, 2014. 40(3): p. 225-35. 
191. Binello, E. and I.M. Germano, Stem cells as therapeutic vehicles for the treatment of high-grade 
gliomas. Neuro Oncol, 2012. 14(3): p. 256-65. 
192. Namba, H., et al., Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-
mediated gene therapy is influenced by the expression of connexin43 in the target cells. Cancer Gene 
Ther, 2001. 8(6): p. 414-20. 
193. Mesnil, M., et al., Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is 
mediated by connexins. Proc Natl Acad Sci U S A, 1996. 93(5): p. 1831-5. 
194. Mori, K., et al., Bystander killing effect of tymidine kinase gene-transduced adult bone marrow 
stromal cells with ganciclovir on malignant glioma cells. Neurol Med Chir (Tokyo), 2010. 50(7): p. 
545-53. 
195. Cha, S., Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol, 2006. 
27(3): p. 475-87. 
196. Heiss, W.D., P. Raab, and H. Lanfermann, Multimodality assessment of brain tumors and tumor 
recurrence. J Nucl Med, 2011. 52(10): p. 1585-600. 
197. Deroose, C.M., et al., Noninvasive monitoring of long-term lentiviral vector-mediated gene 
expression in rodent brain with bioluminescence imaging. Mol Ther, 2006. 14(3): p. 423-31. 
 References 
161 
 
198. Waerzeggers, Y., et al., Multimodal imaging of neural progenitor cell fate in rodents. Mol Imaging, 
2008. 7(2): p. 77-91. 
199. Chiocca, E.A., et al., A phase I open-label, dose-escalation, multi-institutional trial of injection with an 
E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, 
in the adjuvant setting. Mol Ther, 2004. 10(5): p. 958-66. 
200. Winkeler, A., et al., Switching on the lights for gene therapy. PLoS One, 2007. 2(6): p. e528. 
201. Luyckx, A., et al., Mouse MAPC-mediated immunomodulation: Cell-line dependent variation. Exp 
Hematol, 2010. 38(1): p. 1-2. 
202. Huang, R.P., et al., Reduced connexin43 expression in high-grade human brain glioma cells. J Surg 
Oncol, 1999. 70(1): p. 21-4. 
203. Mischel, P.S., S.F. Nelson, and T.F. Cloughesy, Molecular analysis of glioblastoma: pathway profiling 
and its implications for patient therapy. Cancer Biol Ther, 2003. 2(3): p. 242-7. 
204. Scott, J.N., et al., How often are nonenhancing supratentorial gliomas malignant? A population 
study. Neurology, 2002. 59(6): p. 947-9. 
205. Fink, J., D. Born, and M.C. Chamberlain, Pseudoprogression: relevance with respect to treatment of 
high-grade gliomas. Curr Treat Options Oncol, 2011. 12(3): p. 240-52. 
206. Bodor, N. and P. Buchwald, Recent advances in the brain targeting of neuropharmaceuticals by 
chemical delivery systems. Adv Drug Deliv Rev, 1999. 36(2-3): p. 229-254. 
207. Min, J.J., M. Iyer, and S.S. Gambhir, Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk 
reporter gene expression: adenoviral infection vs stable transfection. Eur J Nucl Med Mol Imaging, 
2003. 30(11): p. 1547-60. 
208. Slutsky, E.D., Modeling of [18F]-FHBG in tumor and normal tissue, in Department of Nuclear Science 
and Engineering. 2007, Massachusetts institute of technology: Massachusetts. p. 40. 
209. Goldman, C.K., et al., Epidermal growth factor stimulates vascular endothelial growth factor 
production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. 
Mol Biol Cell, 1993. 4(1): p. 121-33. 
210. Yaghoubi, S.S., et al., Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a 
patient with glioma. Nat Clin Pract Oncol, 2009. 6(1): p. 53-8. 
211. Ketkar-Atre, A.S., T.  Soenen, S. Lambrichts, I. Verfaillie, C. De Cuyper, M. Himmelreich, U., Viability in 
contrast agent uptake by different but similar stem cell types. International Journal of Nanomedicine, 
2013(8): p. 4577-4591. 
212. Amano, S., et al., Timing of ganciclovir administration in glioma gene therapy using HSVtk gene-
transduced mesenchymal stem cells. Cancer Genomics Proteomics, 2011. 8(5): p. 245-50. 
213. Gomez, G.G. and C.A. Kruse, Mechanisms of malignant glioma immune resistance and sources of 
immunosuppression. Gene Ther Mol Biol, 2006. 10(A): p. 133-146. 
214. Bertram, J.S., The molecular biology of cancer. Mol Aspects Med, 2000. 21(6): p. 167-223. 
215. Athie-Morales, V., et al., Sustained IL-12 signaling is required for Th1 development. J Immunol, 2004. 
172(1): p. 61-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Conference abstracts 
162 
 
Curriculum Vitae 
Personalia: 
Name: Cindy Leten 
Address: Haspengouwstraat 3, 3560 Lummen 
email: cindy.leten@med.kuleuven.be 
Mobile no: 0032 497205837 
Date of Birth: 18/03/1986 
Nationality: Belgian 
Education 
2007-2009: Master in Biomedical Sciences (KU Leuven) 
2004-2007: Bachelor in Biomedical Sciences (KU Leuven) 
Work experience: 
2009-2014: Doctoral research on Multi-modal small animal imaging for brain tumor therapy assessment in 
the lab of Biomedical MRI of Prof. U Himmelreic at KU Leuven, Belgium and BIL of Prof. Annemie Van Der 
Linden at University of Antwerp, Belgium. 
2014-present: Global data manager for Valesta at Janssen Pharmaceutica, Belgium. 
List of publications 
1. Leten C., Roobrouck VD., Struys T., Dresselaers T., Vande Velde G., Santermans J., Lo Nigro A., Ibrahimi A.,  
     Gijsbers R., Eggermont K., Lambrichts I., Verfaillie CM., Himmelreich U. , Controlling and monitoring stem  
     cell safety in vivo in an experimental rodent model. Stem cell, 2014. 
2. Leten C., Struys T., Dresselaers T., Himmelreich U., In vivo and ex vivo assessment of the blood brain  
     barrier integrity in different glioblastoma  animal models. J Neurooncol, 2014. 119(2): p. 297-306. 
3. Leten C., Trekker J., Struys T., Dresselaers T., Gijsbers R., Vande Velde G., Lambrichts I., Van der Linden  
     A., Verfaillie C., Himmelreich U. Assessment of bystander killing mediated therapy of malignant brain  
     tumors using a multi-modal imaging approach. (Submitted to Stem cell research & therapy) 
5. Trekker J., Leten C., Struys T., Lazenka VV., Argibay B., Micholt, L., Lambrichts I., Van Roy W., Lagae L.,  
     Himmelreich U., Sensitive in vivo cell detection using size-optimized superparamagnetic nanoparticles.  
    Biomaterials, 2013. 
6. Nemethova, A., Leten, C., Gomez Pinilla PJ., van Bree SH., van Heijningen, C., Cailotto, C., Himmelreich, U.,  
    Depoortere, I., Matteoli, G., Boeckxstaens G., Effect of ghrelin administered before or after surgery in a  
    mouse model of postoperative ileus. (Submitted to PLOS ONE) 
 Conference abstracts 
163 
 
4. Struys T., Ketkar-Atre A., Gervois P., Leten C., Hilkens P., Martens W., Bronckaers A., Dresselaers T.,  
     Politis C., Lambrichts I., Himmelreich U., Magnetic resonance imaging of human dental pulp stem cells in  
    vitro and in vivo. Cell Transplant, 2012. 22(10): p. 1813-29. 
Conference abstracts 
1. Leten C., Trekker J., Struys T., Gijsbers R., Debyser Z., Lambrichts I., Verfaillie C., Himmelreich  
  U. (2013) Proof of principle: imaging of suicide gene therapy for glioblastoma. World  
  Molecular Imaging Congress (WMIC), Savannah, Georgia, USA (oral presentation). 
2. Leten C., Struys T., Verfaillie C., Himmelreich U. (2013) Monitoring safety of sem cells in vivo. 
  Belgian Molecular Imaging Congress (BMIC), Leuven, Belgium (oral presentation). 
3. Leten C., Struys T., Verfaillie C., Himmelreich U. (2013) Monitoring safety of sem cells in vivo.  
  European Molecular Imaging Meeting (EMIM), Torino, Italy (poster presentation). 
4. Leten C., Trekker J., Struys T., Maris M., Gijsbers R., Debyser Z., Himmelreich U. (2012) Multi- 
  modal imaging of therapeutic HSV-tk expressing stem cells for glioma treatment. World  
  Molecular Imaging Congress (WMIC), Dublin, Ireland (poster presentation). 
5. Leten C., Maris M., Debyser Z., Himmelreich U. (2010) Multi-modal validation of stem cell  
  based tumor therapy. Young Belgian Magnetic Resonance Scientists (YBMRS),  
  Blankenbergen, Belgium (poster presentation). 
 
 
 
